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Abstract
The International Commission on Radiological Protection (ICRP) publishes biokinetic models that relate measurements of radioactive material in the body and excreta (bioassay) to the amount of the material taken into the body (intake). Given
the intake and the biokinetic model, radiation dose to organs and tissues can be
calculated. The ICRP approximates the biokinetics of radioactive materials in the
body with compartmental models expressed mathematically as a system of ordinary
differential equations, for which they provide point estimates of the rate constants.
Inaccurate estimates of intake and radiation dose can result in cases where the biokinetics of an individual differ from the ICRP model (i.e., model misspecification), and
currently there is no disciplined way to correct for this problem. In addition, the
ICRP models don’t allow for the estimation of realistic uncertainties in the intakes
and radiation doses. To address these limitations, proper probability distributions
must be assigned to the rate constants. In this dissertation a proof-of-principle example is given showing how the ICRP 134 zirconium model can be calibrated with
bioassay data from an experimental study and Bayesian hierarchical methods, which
give the desired probability distributions for the rate constants. Once the ICRP 134
zirconium biokinetic model is calibrated, its posterior distributions are expressed as
probability distributions that are used as “canned” priors in subsequent Bayesian evaluations of bioassay data from other individuals. Examples of canned prior Bayesian
calculations are given and compared to the results obtained by 3 other methods:
standard regression method, add-one-in Bayesian analysis, and MAP analysis of the
canned prior Bayesian model. Both Bayesian analyses gave intake estimates with
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higher accuracy and more realistic uncertainties than the standard method, but the
canned prior Bayesian analysis was approximately 60 times faster than the add-one-in
Bayesian analysis. In addition, the canned priors are concise and can be provided
along with the biokinetic model in ICRP publications. The MAP analysis gave some
of the benefits of the Bayesian analysis with the speed of the standard method, and
automatically comes along with the canned Bayesian analysis.
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years. My ultimate goal was to offer innovative, practical solutions to some of the
problems we face in internal dosimetry. Thus, the researchers who develop and use
the biokinetic models in internal dosimetry are my target audience. This means that
I have an interdisciplinary audience consisting of internal dosimetrists and statisticians, so I have provided ample background material for both. The final product you
see here is probably a bit longer than it needed to be, but only represents a small
fraction of what I have learned since 2006.
Thomas LaBone
Aiken, South Carolina
November 22, 2021
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Figure I.11 Fits on a log-log scale to more clearly show the urine bioassay
results: standard method top row, add-one-in Bayesian analysis
middle row, and canned prior Bayesian analysis bottom row.
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Subject Zr0101102 (left top) and Zr0102004 (right top) and
from MVN canned prior analysis for Subject Zr0101102 (left
bottom) and Zr0102004 (right bottom). The error bars denote
the 95% credible intervals on the posterior predictive distribution. 176
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Chapter 1
Introduction
1.1

Internal Dosimetry

Radioactive materials spontaneously emit ionizing radiation, which makes them very
useful for many industrial and medical applications. However, this property also
makes them carcinogenic. To limit the risk of detrimental health effects in individuals, federal and state governments in the United States set regulatory limits on the
quantity of radioactive materials that can be taken into the body as a result of occupational exposures, and the concentrations of radioactive materials in the air and
water that the public can access, which is intended to limit the quantity of radioactive
material a member of the public takes into the body.
The quantity of material taken into the body that is the subject of these regulations is referred to as the intake. Intakes can occur through various pathways such
as inhalation, ingestion, absorption through intact skin, and through wounds (which
includes intravenous injections). An inhalation intake is defined to be the quantity
of radioactive material that passes through the nares and an ingestion intake the
quantity of material that passes through the mouth. It is not possible in practice to
measure an intake directly. Instead, for occupationally exposed individuals the magnitude of the intake is inferred from measurements of the quantity of the radioactive
material present in various regions of the body or excreta (e.g., urine and feces) at
various times after the intake. Such measurements are referred to as radiobioassay or
just bioassay for short. Once an intake is calculated, the time-integrated retention of
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the radioactive material is determined for all significant organs and tissues. Given the
time integrated retention and factors that describe the transport of radiation between
the organs that contain the radioactive material and the organs of interest, we can
calculate the radiation dose to the organ of interest. Radiation dose is the amount
of ionizing radiation absorbed in tissues and organs and is used as an index of harm
(e.g., the risk of developing cancer).

1.2

Biokinetic Models

The process of using bioassay to calculate an intake and using this intake to calculate radiation dose is called internal dosimetry 1 , and it requires an appropriate
biokinetic model. A biokinetic model is an idealized mathematical representation of
how a material is deposited in the body, subsequently translocated to various organs
and tissues, and ultimately excreted ((Boecker, 1998); Harrison, 2009). Thus, the
biokinetic model provides a useful mathematical relationship between the intake and
the bioassay data, and between the intake and the radiation dose delivered to the
organs and tissues of the body by the intake.
The term kinetic model has it origins in physiological and biomedical research
where a radioactive or relatively rare stable isotope of an element is used to trace
the metabolic pathways in living organisms (Robertson, 1983, Chapter 1). When
applied to occupational internal dosimetry, kinetic models are usually referred to as
biokinetic models. Although the applications differ, biokinetic models are basically
the same as pharmacokinetic models used in the development of drugs (Bonate, 2011)
and toxicokinetic models used to assess the risk from intakes of toxic chemicals (Hubal
et al., 2019).
1

See Li (2018) for a detailed review of internal dosimetry.
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Figure 1.1 Riggs iodine compartmental model.
Biokinetic models for use in occupational internal dosimetry are issued in International Commission on Radiological Protection (ICRP)2 publications that are
subsequently used by regulatory agencies to derive limits for workers and the public.
Biokinetic models are represented by a system of compartments between which the
transfer of material is described by first order differential equations. For example, the
Riggs iodine biokinetic model for an injection intake of iodine into the bloodstream
was first proposed in the early 1950’s (Riggs, 1952). This model, which is shown in
Figure 1.1, was used with minor modifications in the ICRP Publication 30 (ICRP,
1979) and ICRP Publication 68 (ICRP, 1995), only recently being superseded by the
more complex Leggett iodine model in ICRP Publication 137 (ICRP, 2017).
The compartments in a biokinetic model are mathematical constructs used to
describe the retention of material in the body and do not necessarily match up with
2

The International Commission on Radiological Protection is an independent organization chartered in 1928 that has developed, maintained, and elaborated the International System of Radiological Protection used world-wide as the common basis for radiological protection standards,
legislation, guidelines, programs, and practice. The Commission has published over 100 reports (see
www.icrp.org).
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specific tissues and organs in the body. In the iodine biokinetic model blood represents
the pool of inorganic iodine in the body, thyroid represents the pool of organic iodine
(thyroid hormones) in the overall thyroid, other represents the pool of organic iodine
in the body other than the thyroid, urine represents excretion to the urine, and feces
represents excretion to the feces. Physiologically based biokinetic models (PBBK)
incorporate realistic physiological information like blood flow through organs and
tissues (Leggett and Williams, 1995), which allows for more accurate modeling of
biokinetics across individuals, populations, and species.

1.3

Forward and Inverse Problems

Compartment models are used to solve two different types of problems: the Forward
Problem and the Inverse Problem (Jacquez, 1985, Sections 1 & 3) shown in Figure
1.2. In the Forward Problem we are given the compartmental structure of the model
and its rate constants that are used to solve the system of ODE for the content qx (t)
of each compartment x at time t after intake. For example, given measurements of
iodine in the thyroid qthy (t) at various times the quantity of iodine initially injected
into the blood can be calculated, or given the quantity of iodine injected into the blood
the content of the thyroid at any later time can be predicted. The internal dosimetry
practitioner uses the ICRP biokinetic models to solve the Forward Problem, i.e., to
evaluate bioassay measurements from individuals who were occupationally exposed
to radioactive materials (Skrable, Chabot, et al., 1988).
In the Inverse Problem the compartment structure and its transfer rate constants
are treated as unknown parameters to be estimated from the measurements of the
contents of the compartments and prior knowledge. The modeler solves the Inverse
Problem, developing the biokinetic models that are eventually adopted by the ICRP
and used by the practitioner. Thus, the modeler takes available data and biological
knowledge, applies simplifying assumptions, and develops an idealized compartmental
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Figure 1.2 Forward Problem (left) and Inverse Problem (right).
model that is adequate for the task at hand 3 . This is a complicated process that
requires considerable expertise and judgment.

1.4

Problems with the Forward Problem

At first glance Forward Problem appears to be a relatively simple math problem, but
there are issues that complicate the task. First of all, frequently the predictions of
the compartment contents made with the ICRP biokinetic models don’t agree with
the observed bioassay measurements. Such disagreements can be the result of measurement error, but often the biokinetic model is not a good approximation to the
biokinetics of the individual, i.e., there is model misspecification. This is a consequence of ICRP biokinetic models being deterministic, with all model parameters
provided as exact point values (Paquet, Bailey, et al., 2016). Thus, the models don’t
account for uncertainty in the model structure or parameters, and can’t accommodate variability between people. When confronted with this lack-of-fit problem, the
practitioner can do one of three things, only the last of which is of interest here: (i)
just continue on, stating that the conclusions of the analysis are valid despite the
3

To paraphrase G. E. P. Box, all biokinetic models are wrong but some are useful (Box, 1979)
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Figure 1.3 Combination of Forward and Inverse Problems.
poor agreement between the predicted and observed measurements (most common
in regulatory programs); (ii) use some sort of maximizing technique that will give an
overestimate of the intake and dose (most common in compensation programs); (iii)
tweak parameters in the biokinetic model to get a better fit to the data.
Model parameters are tweaked in an effort to reduce the misspecification error in
the biokinetic model, thus improving the agreement between the predictions of the
model and the observed bioassay measurements. This is the Inverse Problem, and
attempts to tweak a model must be exercised with caution because: we really don’t
know which parameters to tweak and by how much – a good fit to the data does
not necessarily mean good choices have been made; parameters are correlated, so we
can’t just change one without the risk of creating an unrealistic biokinetic model; we
risk over fitting, i.e., changing parameters in the model to fit noise in the observed
measurements.
A disciplined mechanism is needed for creating acceptable agreement between the
observed and predicted bioassay measurements while at the same time not making
unrealistic changes to the biokinetic model (Figure 1.3).
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Closely related to the problem of model misspecification is the desire to estimate
and report the uncertainty in assigned intakes and doses. For example, the NCRP4
(NCRP, 2010) stated that
“... it is scientifically and ethically necessary to assess the possibility that persons
with assigned estimates of internal dose did not in fact receive much larger doses.
This is the reason to evaluate the uncertainties in assigned dose.”
A motivating question behind this dissertation is how exactly does one go about
making a realistic estimate of the uncertainty for an internal dose? This is a complicated question (Paquet, Bailey, et al., 2016) that the NCRP did not fully address.
In summary, in this dissertation I will focus on how to reduce the inaccuracy
of internal dose estimates caused by standard ICRP biokinetic models that do not
adequately describe the kinetics of an individual, and estimate of uncertainty in intake
and radiation dose caused by variability in the parameters in the biokinetic model at
the level of the population and at the level of the individual. The uncertainties in
internal dose associated with the transport of radiation within and between organs
are not addressed (Fairlie, 2005).

1.5

Path Forward

To deal with the lack-of-fit problem while at the same time assessing the uncertainties
in estimated intakes the modeler has to provide more informative biokinetic models.
More specifically, realistic probability distributions that describe the uncertainty and
variability in the rate constants are needed in place of the point estimates. In addition,
the practitioner needs more advanced computational methods that can use these
informative biokinetic models.
4

The National Council on Radiation Protection and Measurements (NCRP) was chartered by the
U.S. Congress in 1964 to develop basic concepts about radiation quantities, units and measurements,
about the application of these concepts, and about radiation protection.
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The practitioner and modeler both face some significant challenges. However, a
lot of work has been done in the last 30 years in the field of setting chemical exposure limits for populations and evaluating individual chemical exposures using PBBK
biokinetic models and Bayesian population modeling (for example, see Hack (2006),
Allen, Hack, and Clewell (2007), Bois et al. (1996)). To illustrate the methodology,
let’s assume that the modeler wants to create a more informative version of the Riggs
iodine model. The modeler will:
• Assemble measurements of iodine kinetics in a number of human subjects (e.g.,
thyroid bioassay, urine bioassay).
• Propose distributions for all rate constants based on all prior knowledge (e.g.,
previous human and animal studies, SWAGs5 , etc.).
• Update the prior knowledge with the observed measurements using Bayes Rule
to create posterior distributions of the rate constants. This is referred to as a
Bayesian calibration of the biokinetic model ((Kennedy and O’Hagan, 2002);
Hack, 2006).
• Summarize and publish the posterior distributions for the iodine model in a
form that is usable by the practitioner.
This is a fairly complex process, but it produces an iodine model that accounts for
variability between individuals and lack of knowledge about the biokinetics of iodine
– it has all the properties we need. Once the practitioner has access to the new informative iodine model, it becomes the prior information for the Bayesian analysis of the
iodine bioassay data from an out-of-study individual. Such an evaluation allows the
individual’s bioassay data to influence the estimates of rate constants in the biokinetic
model while ensuring that the model is identifiable and physiologically realistic (see
5
“Scientific wild-ass guess (SWAG) is an American English slang term meaning a rough estimate
made by an expert in the field, based on experience and intuition.” -Wikipedia.
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Section A). In addition, the posterior distributions of the rate constants calculated
for the individual can be used to estimate the uncertainty in the individual’s iodine
intake and organ doses.
The objective of this dissertation is to flesh out the details of how one might
implement the procedure discussed in the previous paragraph. A proof-of-principle
analysis will be performed with measurements of zirconium6 in the blood plasma and
urine of human subjects after injection intakes. Methods that allow us to generate
informative distributions for rate constants are proposed in Aim 1 of this dissertation:
1. Assemble an appropriate zirconium bioassay dataset and perform populationlevel Bayesian calibration of ICRP 134 zirconium biokinetic model (Chapter
3).
Methods that allow us to use the informative posterior distributions from are given
in Aim 2:
2. Fit distributions to the population-level posteriors and use them as priors in
the evaluation of out-of-study datasets (Chapter 4).
Aim 3 is to fully document the computational routines and provide simulated bioassay
datasets that allow interested individuals to reproduce the calculations in Aims 1 and
2:
3. Create a vignette demonstrating how to calibrate the zirconium model and use
the resulting informative priors to evaluate the bioassay data from an individual
and make it available on GitHub (Chapter 5).
This is an interdisciplinary study, using Bayesian statistical methods to attack applied
problems in biokinetic modeling. The meat of this dissertation lies in Chapters 3 and
6

Zirconium (Zr) is a metal with an atomic number of 40 whose radioisotopes are common around
nuclear power reactors.
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4, which will be submitted for publication. Out of necessity those chapters jump right
into the details with little background exposition, so to ease statisticians and internal
dosimetrists into the discussion some background material on statistical methods and
biokinetic modeling is given in Chapter 2. Supporting information that expands on
topics discussed in the main chapters of the dissertation are given in the appendix.
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Chapter 2
Primer on Biokinetic Modeling
2.1

Biokinetic Models

The Riggs iodine biokinetic model (Riggs, 1952) shown in Figure 1.1 is typical of all
ICRP biokinetic models, consisting of compartments between which the movement of
material is described by a system of first-order linear ordinary differential equations
(ODE). The system of ODE can be solved to give the content of each compartment
(and hence any combination of compartments) at any time after the intake. The
Riggs iodine model that describes the rate of change in each compartment can be
represented as the following system of ODE
dq1 (t)
= −k11 q1 (t) + k21 q2 (t) + k31 q3 (t) + k41 q4 (t) + k51 q5 (t)
dt
dq2 (t)
= k12 q1 (t) − k22 q2 (t) + k32 q3 (t) + k42 q4 (t) + k52 q5 (t)
dt
dq3 (t)
= k13 q1 (t) + k23 q2 (t) − k33 q3 (t) + k43 q4 (t) + k53 q5 (t)
dt
dq4 (t)
= k14 q1 (t) + k24 q2 (t) + k34 q3 (t) − k44 q4 (t) + k54 q5 (t)
dt
dq5 (t)
= k15 q1 (t) + k25 q2 (t) + k35 q3 (t) + k45 q4 (t) − k55 q5 (t).
dt

(2.1)

For example, q1 (t) describes the quantity of iodine in compartment 1 (the blood)
at time t after injection of the iodine and

dq1 (t)
dt

describes the instantaneous rate of

change of iodine the blood at that time. A rate constant like k12 describes the instantaneous rate at which iodine moves from compartment 1 (the blood) to compartment
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2 (the thyroid). Note that rate constants are 0 between compartments with no connections. For example, k51 = 0 because according to the model there is no transfer of
iodine from the urine back to the blood. Rate constants on the diagonal of the rate
matrix describe the removal of iodine from the compartment by all pathways. For
example, k11 describes the rate at which stable iodine moves from the blood to the
thyroid and from the blood to the urine.
The rate constants for the Riggs iodine model are given in Table 2.1. Riggs derived
the rate constants by looking at the mass balance of iodine in a compartment system
that was in equilibrium, i.e., when the rate at which iodine enters the system equals
the rate at which it leaves. Such analyses are possible for essential elements like iodine
where the material is present in the food we eat. To get a better idea of how this is
done let’s look at the process in more detail. Riggs assumed that there is 150 µg/day
of inorganic iodine that comes into the blood from outside sources (the intake) and
150 µg/day leaves by the urinary and fecal pathways. Of the 150 µg/day of iodine
that enters the blood, 70 µg/day is taken up by the thyroid and 70 µg/day leaves the
thyroid since the system is in equilibrium. The metabolic pool of organic iodine in
the thyroid under these conditions is 8000 µg, which gives a transfer rate constant of
k23 =

70 µg/day
= 0.008736 day −1 .
8000 µg

(2.2)

Since 70 µg/day leaves the thyroid, 70 µg/day also enters and leaves the other compartment, which has a 1200 µg iodine pool. The total removal rate constant for other
is thus
k33 = k31 + k34 =

70 µg/day
= 0.05833 day −1 .
1200 µg

(2.3)

Of the 70 µg/day leaving Other, 6 µg/day goes to feces and 64 µg/day is recycled
back to the blood. This gives a fraction going to feces ff of
ff =

6 µg/day
= 0.08571.
70 µg/day
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(2.4)

The rate constants for Other to feces and Other to blood are




k34 = ff 0.058272 day −1 = 0.004995 day −1 ,


(2.5)



k31 = (1 − ff ) 0.058272 day −1 = 0.05328 day −1 .

(2.6)

Finally, if there is 6 µg/day going to feces then under equilibrium conditions there
must be 144 µg/day going to the urine, which gives a transfer rate constant for blood
to urine of
k15 =

144 µg/day
= 1.92 day −1 .
75 µg

(2.7)

The system of ODE in (2.1) can be presented in the following matrix notation
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(2.8)

where nc = 5 is the number of compartments in the iodine model. An even more
concise expression is q̇ = kq, where k is referred to as the rate matrix. The goal is
to solve this system of ODE for the quantity of iodine qi (t) in each compartment i
at time t.
There are a number of different ways to solve this system of linear first-order differential equations, including Laplace transforms (Jacquez, 1985, App 3), Runge–Kutta
family of methods (Spiegel, 1981, Ch 9), eigenvalue/eigenvector method (Jacquez,
1985, App 2), and the matrix exponential (Polig, 2001).
Laplace transforms are tedious to use for all but the simplest models, e.g., one can
use this method to solve the iodine model but it is not a pleasant experience because of
the algebra involved. The other three methods are numerical, so the primary factor in
choosing one is the availability of suitable routines that implement the method. The
software used in this dissertation for the Bayesian calculations (Stan) implements the
13

Table 2.1 Rate constants for Riggs iodine model. Rate constants on the diagonal of
the rate matrix (e.g., k22 ) are the sum of all rate constants for material leaving that
compartment.

From
blood
blood
other
other
thyroid
other
blood
urine
feces
thyroid

To
thyroid
urine
feces
blood
other

k12
k15
k34
k31
k23
k33
k11
k55
k44
k22

Rate Constant
(1/d)
0.9336
1.92
0.004992
0.05328
0.008736
0.058272
2.8536
0
0
0.008736

Half Life
(days)
0.7424
0.3610
138.8516
13.0095
79.3438
11.8950
0.2429

79.3438

Runge–Kutta methods and the matrix exponential. The matrix exponential method
is used here per the recommendations of the software developers (Stan Development
Team, 2021b, pg 181) and it has been found to be an efficient method for solving
systems of ODE like those associated with biokinetic models. The matrix exponential
solution to the system of ODE is
qt = exp (kt) q0 ,

(2.9)

where q0 is the quantity of iodine in each compartment at t = 0 and exp (kt) is
defined by the Taylor series expansion
exp (kt) =

(kt)j
.
j=0 j!
∞
X

(2.10)

Although (2.10) defines the matrix exponential it is not calculated directly using a
truncated version (2.10) because of numerical instability of this method (especially
when j is large). There are a variety of numerical methods used to solve the matrix
exponential (Moler and Van Loan, 2003) but the exact method used in Stan is not
specified in its reference documentation.
As mentioned previously, the compartments in a biokinetic model are mathematical constructs that do not necessarily correspond directly to the organs and tissues in
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the body or excreta. To improve the agreement between the predictions of the biokinetic model and what is actually observed in bioassay, a collection of compartments
in the biokinetic model can considered as a group. This collection of compartments
in the biokinetics model that are considered to correspond to what was measured
in bioassay is referred to a reference bioassay function m (t) (Paquet, Leggett, et
al., 2016). For example, if we want to predict the quantity of iodine in the thyroid
(compartment 2) the reference bioassay function is
mthy (t) = q2 (t) ,

(2.11)

if we are interested in predicting the quantity of iodine in the total body, noting q4 (t)
and q5 (t) are not in the body, the reference bioassay function is
mtot (t) = q1 (t) + q2 (t) + q3 (t) ,

(2.12)

and if we are interested in predicting the cumulative quantity of iodine excreted in
the cumulative urine the reference bioassay function is
murn (t) = q5 (t) .

(2.13)

Note that m (t) is also a function of k and q 0 , but they are suppressed here to make
the notation more concise. The reference bioassay function is defined for a specific
mode of administration. For example, the reference bioassay functions for iodine
discussed thus far are for intravenous injection of iodine. Other common modes of
administration are inhalation and ingestion. By convention, in a reference bioassay
function a unit quantity of material is administered so that the initial contents q 0 of
all the compartments sum to 1. Thus, the reference bioassay function for an injection
of iodine assumes that the initial content of the blood compartment is 1 and the
contents of all other compartments are 0.
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2.2

The Forward Problem

Predicting the quantity of iodine in the compartments of the iodine biokinetic model
given the reference bioassay functions is an example of what is referred to as the
Forward Problem. Because the reference bioassay function assumes a unit injection
of iodine, if we are interested in predicting the quantity of iodine in the thyroid after
injecting 2 units of iodine the desired result is 2mthy (t). The multiplier of 2 scales a
reference bioassay function to accommodate cases where the administered quantity
of iodine is equal to 2. This multiplier that represents the quantity of material
administered is referred to as the intake β.
An applied problem of interest is to calculate the intake given the the reference
bioassay functions and the quantity M of material actually measured in specific organs
and tissues or excreta. For example, given a single measurement Mthy (10) of iodine
in the thyroid at t = 10 days after an injection of iodine, the estimated intake β̂ is
β̂ =

Mthy (10)
mthy (10)

(2.14)

and the predicted quantity of iodine in the thyroid is
M̂thy (10) = β̂mthy (10)

(2.15)

Such calculations make the implicit assumption that the biokinetics of the individual
in whom we measured Mthy (10) are identical to the biokinetics of specified by the
Riggs biokinetic model.
If there are n > 1 thyroid bioassay measurements from a single individual following
a single intake at t = 0 we have to calculate the intake that gives the “best” agreement
between the observed and predicted bioassay. One way to do this is to define the sum
of the squares of the differences between the observed and predicted values (the
residual sum of squares)
RSS =

n
X

[Mthy (ti ) − βmthy (ti )]2

i=1
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(2.16)

and select the value of β that minimizes the sum. This is a regression of M on m
through the origin, the formal equation of which is
M (ti ) = β · m (ti ) + ε,

i = 1...,n

(2.17)

where the intake β is the slope of the line and ε is the homoscedastic regression
error. Bioassay measurement errors are usually heteroscedastic, so a refinement is
to perform a weighted regression, minimizing the weighted residual sum of squares
(Claudio Cobelli, Foster, and Toffolo, 2007, Chapter 10; Skrable, Chabot, et al., 1994)
W RSS =

n
X

wi [Mthy (ti ) − βmthy (ti )]2 ,

(2.18)

i=1

where wi are the weighting factors. Commonly used weighting factors are analytical
measurement uncertainties u (LaBone, 2010) or functions of the observed or predicted
bioassay measurements (Skrable, French, et al., 2002; Wakefield, 1996; Wakefield,
Aarons, and Racine-Poon, 1999).
Compartmental models like the Riggs iodine model are referred to as models of
systems (DiStefano and Landaw, 1984; Carson, Finkelstein, and C. Cobelli, 1983, pg
39). In system models the form of the regression given in (2.17) is dictated by the
biokinetic model. Arbitrary regression functions fit to bioassay measurements are
referred to as models of data. Relatively simple data models can provide answers
based on the observed data. For example, measurements of the thyroid content alone
over time can’t be used to estimate the content of the Other compartment or the
content of the thyroid compartment at times past the last measurement. On the
other hand, system models can be used to incorporate all available knowledge into
a single model that can give answers to questions concerning compartments under
conditions not directly observed. For example, following an injection of radioactive
iodine we might want to know the radiation dose to organs and tissues other than
the thyroid, i.e., the combination of the blood and Other compartments, based on
measurements of iodine in the thyroid. To do this requires a system model (the Riggs
17

iodine model) that relates the quantity of iodine in the thyroid to the quantity of
iodine in other compartments as a function of time.
As an example, reference bioassay functions were calculated for the thyroid by
solving the Riggs iodine model and the intake of iodine calculated from measurements
of iodine in the thyroid using weighted least squares regression for two individuals.
In the regression the weights were equal to wi = 1/u2i , where ui is the measurement
uncertainty. The results for Subject 4 and Subject 10 are shown in Figure 2.1 (a)
and (b), respectively. The results of the weighted least squares regressions are given
in Table 2.2. The plot for Subject 4 exhibits lack of fit, indicating that biokinetics of
Subject 4 are not adequately approximated by the Riggs biokinetic model.
These linear regressions are examples of the Forward Problem where a proportionality constant (the intake) is estimated. Note that when we perform regression to
estimate the intake it is assumed that we have the “correct” biokinetic model and well
behaved bioassay data. In this case the data points will lie neatly around a straight
line on a plot of observed bioassay data versus reference bioassay functions. To obtain a better fit to the bioassay data like those from Subject 4 we have to adjust the
parameters in the Riggs iodine model based on the bioassay results of the individual
while performing the regression. Maximum likelihood methods like those discussed
in the next section are better suited to such tasks than is linear regression.

2.3

Maximum Likelihood

Assume that the errors for the regression are independent, homoscedastic, and normally distributed. Given this, the sampling distribution of the data M is
M ∼ N (βm, Σ) ,

(2.19)

Σ = σ 2 I,

(2.20)
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Figure 2.1 Scatter plots of observed thyroid burden versus thyroid reference bioassay function for Subject 10 (a) and Subject 4 (b). These fits were calculated using
weighted least squares estimates of the intakes (the errors bars are 2σ measurement
uncertainties). The fits obtained for Subject 4 using unrestricted maximum likelihood
(c), restricted maximum likelihood (d), MAP (e), and Bayesian (f) estimates of intake
and the rate matrix. In plot (f) the error bars are the 95% credible intervals for each
measurement and the intake is the geometric mean (see Appendix D for definition)
of the intake posterior distribution.
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Table 2.2 The results of weighted least squares (WLS), unrestricted maximum likelihood (MLU), restricted maximum likelihood (MLR), and maximum a posteriori
(MAP) estimates of intake and the rate constants (all except WLS, which estimates
intake only). The values in red are problematic because they are either physiologically
improbable or physically impossible.
WLS
MLU
MLR
MAP
WLS
MLU
MLR
MAP

Sub Intake
4
1132
4
1502
4
1500
4
1582
10
1620
10
418
10
956
10
1667

k[bld,thy] k[bld,urn] k[oth,fec] k[oth,bld] k[thy,oth]
0.9336
0.0087
0.0533
0.0050
1.9200
0.9408
0.0106
-1.7086
146.202
2.1100
0.9418
0.0106
0.6862
146.576
2.1092
0.9512
0.0144
0.0486
0.0049
2.1905
0.9336
0.0087
0.0533
0.0050
1.9200
1.4234
0.0322
1023.57
692.644
-0.3293
0.4900
0.0120
909.23
413.286
0.3799
0.9347
0.0092
0.0483
0.0048
1.9566

where σ is the standard deviation of the regression error and I is an n × n identity
matrix. The likelihood L (β) of the intake given the data, its covariance matrix, and
the reference bioassay functions is
L (β) =

n
Y

f (M (ti ) , βm (ti ) , Σi,i )

(2.21)

i=1

where f (·) is the normal pdf with conditional mean βm (ti ) and variance Σi,i for observed bioassay result M (ti ). As discussed in Appendix G the likelihood is frequently
expressed as pβ (M |m, β) = L (β). The maximum likelihood estimator (MLE) for the
intake β is that value of β that maximizes the likelihood function, i.e., it is the value
of β that makes the observed data the most likely to have been observed
β̂ = arg max L (β) .

(2.22)

Numerically, it is more convenient to work with the log of the likelihood function
L (β) = log (L (β)) ,

(2.23)

which has the same maximum as L (β) because the maximum of a function is invariant
under a monotonic transformation like the log.
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Finding the MLE of single parameter like β is straightforward (it can be accomplished by hand), but more sophisticated optimizers are required for the multidimensional optimizations discussed in the next section. Note that the MLE of β is
the same as the weighted least squares estimate because of the assumption of normally
distributed regression errors.
Errors in the parameter estimates (β in this case) are based on quadratic approximation to the curvature of the log likelihood function evaluated at the maximum
likelihood estimate (Pawitan, 2001, page 31), i.e., the observed Fisher information
 

I β̂

 

I β̂ = −

d2
L (β).
dβ 2

(2.24)

A high curvature in the likelihood function results in a narrow likelihood function
that is well defined and has a small estimated standard error. A quadratic curvature
corresponds to a normal distribution, but this approximation is not accurate if the log
likelihood function is not quadratic. The normal approximations of standard errors
in the parameters are typically given in the output of optimization routines from the
bbmle library (Bolker, 2020) and can be used to construct normal Wald confidence
intervals for the uncertainty in the parameters (Pawitan, 2001, pg 42).
Heterscedasticity in bioassay measurement errors is addressed with a covariance
matrix Σ that contains the squared measurement uncertainties u2 on its diagonal
and zeros elsewhere (i.e. the analytical uncertainties in the measurements are uncorrelated):
Σi=i = u2i ,

2.4

Σi̸=j = 0.

(2.25)

The Inverse Problem

Fits of the bioassay data to reference bioassay functions often show excessive lack
of fit like that seen for Subject 4 because the standard biokinetic model does not
adequately describe the biokinetics of the individual. As a remedy we can attempt to
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estimate the reference bioassay functions and the intake using maximum likelihood.
To accomplish this the reference bioassay function in the likelihood must be expressed
as an explicit function of the rate matrix
pβ (M |m, β) = L (β, k) =

n
Y

f (M (ti ) , βm (ti , k) , Σi,i ) .

(2.26)

i=1

Note that the intake β is a physical quantity that could conceivable be known, but
the rate constants k are latent variables that are not directly observable.
In theory, the maxima of the likelihood in (2.26) with respect to β and k give the
maximum likelihood estimators of (β, k). However, there are significant problems
encountered if we try to do this because the ML estimates may be physiologically
unrealistic, e.g., negative rate constants or intakes may be obtained if no restrictions are imposed on the estimated values of the parameters (unrestricted maximum
likelihood). The plot for Subject 4 shown in Figure 2.1(c) and looks quite reasonable. However, inspection of the results (rows 3 and 4 of Table 2.2) shows physiologically unrealistic values for koth,f ec and koth,bld , including negative rate constants
that are not physically possible. The likelihood function can be constrained to produce positive parameter estimates, but physiologically unrealistic rate constants like
koth,f ec = 909.2 day −1 in Table 2.2 are still possible. Such problems can’t be identified
by examination of the fit of the model predictions to the data. For example, the extreme restricted likelihood estimates in rows 5 and 6 of Table 2.2 appear to fit the data
well in Figure 2.1(d). The problem is that the Riggs iodine biokinetic model is not
identifiable given only thyroid bioassay data. In a non-identifiable biokinetic model
there are multiple sets (perhaps infinite number) of rate constants that are solutions
to the model. In other words, a non-identifiable biokinetic model has a likelihood
function that is essentially flat for many combinations of parameters. As discussed
in Appendix A, non-identifiability can occur even if we have an infinite amount of
error-free data, and ICRP biokinetic models should be assumed to be non-identifiable
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in all practical applications where there are limited quantities and types of bioassay
data.

2.4.1

Maximum A Posteriori Estimates

One way to constrain parameter estimates to physiologically realistic values and ensure that the model is identifiable is to bring additional information about the parameters into the calculation — information that is not derived from the current dataset.
This prior information is expressed as probability distributions for the parameters
that are referred to as prior probability distributions. For example, based on previous
knowledge a multivariate lognormal prior p (k) can be assigned to the rate matrix k
where the log means of the distribution are the logs of the Riggs rate constants, the
log standard deviations of the distribution are are log(1.25), and the rate constants
are not correlated. Further, based on knowledge of the incident that caused the intake
of iodine, a lognormal distribution is assigned to the prior for the intake p (β) where
the log mean is log(1600) and the log standard deviation log(3). The maxima of the
resulting product L (β, k) p (k) p (β) are the a posteriori maximum likelihood (MAP)
estimates of the parameters, which are given in rows 7 and 8 of Table 2.2. The fit to
the data using the MAP parameter estimates is shown in Figure 2.1(e).

2.5

Bayesian Methods

All the methods discussed thus far to solve the Inverse Problem provide point estimates of the model parameters and estimates of the uncertainty in those point
estimates by treating the data as random and the parameters fixed. This paradigm
can be referred to as frequentist statistics. In a reversal of paradigm, we can treat
the data as fixed and the parameters as random, which is referred to as Bayesian
statistics. A brief introduction to Bayesian analysis is given here, but there is a large
body of literature discussing the theory and application of Bayes Law. In order of
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increasing complexity, I recommend Lambert (2018), McElreath (2018), and Gelman,
Carlin, et al. (2013) to those unfamiliar with Bayesian methods. The application of
Bayesian methods to biokinetic models is discussed in Bonate (2011, Ch 10).
If we express the likelihood as p (M |k, β) the laws of conditional probability tell
us that the joint distribution p (k, β, M ) of the parameters and the data is

p (k, β, M ) = p (k, β|M ) p (M ) = p (M |k, β) p (k) p (β) ,

(2.27)

where p (M ) is the marginal probability density of the bioassay data and p (k, β|M )
is the probability of observing the parameters given the data, which is called the
posterior distribution. A minor rearrangement of (2.28) gives the immensely useful
Bayes Law
p (k, β|M ) =

p (M |k, β) p (k) p (β)
.
p (M )

(2.28)

In Bayesian methods the posterior distribution contains all that is presently known
about the parameters, combining what the data are telling us with our prior knowledge. All inferences about the fate of iodine in this system are calculated with the
posterior distributions. Like MAP methods, Bayesian methods make the parameters
in biokinetic models identifiable through the incorporation of prior knowledge about
the biokinetic model and its parameters. Unlike MAP methods, Bayesian methods
provide estimates of the probability distribution of parameters that are interpreted
as the uncertainty in the parameters of the biokinetic model.
The marginal probability density of the data p (M ) is a normalization constant
that ensures the posterior distribution is a proper probability distribution and is
ˆ ˆ
p (M ) =

p (M |k, β) p (k) p (β) dkdβ.

(2.29)

This integration is intractable in most real-life problems so it is side stepped by
using a simulation that takes correlated random samples directly from the posterior
distribution. This type of sampling is referred to as Markov Chain Monte Carlo
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(MCMC) to help differentiate it from regular Monte Carlo sampling where the samples
are independent of each other. The MCMC samples are used to estimate the posterior
distributions and their summary statistics.
The results of a Bayesian analysis are expressed as the posterior distributions
of the parameters. For example, the data for Subject 4 were analyzed using the
lognormal prior distributions on the rate constants and the intake discussed above.
The posterior distributions of the rate constants are shown in Figure 2.2(a) and
the posterior distribution of the intake in 2.2(b) . The rate constant for kthy,oth is
noticeably more precisely than the other rate constants (i.e., it has a narrower peak)
because of the large influence the thyroid data had on its posterior. The geometric
mean (gm) and geometric standard deviation (gsd) are used to as summary statistics
for the intake. The posterior distributions are proper probability density functions
and it is appropriate to make statements like there is a 95% probability that the true
iodine intake by Subject 4 is in the credible interval of (1271, 2691), which is denoted
by the vertical dashes lines in Figure 2.2(b). The confidence intervals on parameters
generated by the other methods like maximum likelihood can not be interpreted in
this way (Lambert, 2018).
The fit to the bioassay data using Bayesian methods is shown in Figure 2.1(f).
The error bars are pointwise 95% credible intervals on the predicted quantity of iodine
in the thyroid, i.e., on the regression line. Note that the error bars in the other plots
in Figure 2.1 are 95% coverage intervals on the measurements and should not be
compared directly to the credible intervals.

2.6

Summary

The Inverse Problem in biokinetic modeling, which is the estimation of parameters
in the biokinetic model based on observed bioassay data, was discussed in this chapter. This process is referred to as calibrating the biokinetic model. The relatively
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Figure 2.2 Marginal posterior distributions for rate constants (left) and intake
(right) for Subject 4.
simple Riggs iodine biokinetic model was used to introduce the nomenclature and
mathematics of biokinetic models and to illustrate several statistical methods used
to calibrate the biokinetic model with observed bioassay data. The Bayes method
for calibrating a biokinetic model was shown to have the advantages of allowing us
to incorporate prior knowledge, which makes the biokinetic model identifiable, and
expressing results as probability distributions, which allows us to properly assess the
uncertainty in the results. The general workflow of a Bayesian analysis is often referred to as “Turning the Bayesian Crank” because a similar workflow is used in all
Bayesian problems. Adapted from Kruschke (2015, pg 25), the Bayesian Crank used
in this dissertation can be described as follows:
1. Identify the bioassay data.
2. Identify the biokinetic model.
3. Specify prior distributions for all the parameters in the biokinetic model.
4. Use Bayesian inference to meld the data and prior distributions of the parameters into the posterior distributions of the parameters.
5. Check to see whether the predictions of the biokinetic model using the posterior
distributions agrees with the observed bioassay data.
26

The primary difficulties associated with turning the crank are Step 3, fabricating
prior distributions that are realistic and informative, and Step 4, dealing with the
integral in (2.29). These problems are discussed in more detail in the next chapter
where the more complex zirconium biokinetic model is calibrated.
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Chapter 3
Population Zirconium Biokinetic Model
3.1

Introduction

Radioactive materials spontaneously emit radiation, which makes them very useful
for many industrial and medical applications. However, this property also makes
them potentially carcinogenic (National Research Council, 1988). In order to limit
the risk of detrimental health effects in individuals, limits are set on the quantity
of radioactive materials that can be taken into the body as a result of occupational
exposures. The quantity of material taken into the body that is the subject of these
limits is referred to as the intake. Intakes can occur through various pathways such
as inhalation, ingestion, absorption through intact skin, and through wounds. In
practice it is not possible to measure an intake directly. Instead, for occupationally
exposed individuals the magnitude of the intake is inferred from measurements of the
quantity of the radioactive material present in regions of the body or excreta (e.g.,
urine and feces) at various times after the intake occurred. Such measurements are
referred to as radiobioassay or just bioassay for short.
Using bioassay to calculate an intake requires an appropriate biokinetic model.
A biokinetic model is an idealized mathematical representation of how a material is
deposited in the body, subsequently translocated to various organs and tissues, and
ultimately excreted (Boecker, 1998; Harrison, 2009). The biokinetic model provides
a useful mathematical relationship between the intake and the bioassay data, and
between the intake and the radiation dose delivered to the various organs and tissues
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of the body. Radiation dose is the amount of ionizing radiation absorbed in tissues and
organs and is used as an index of harm, relating the intake to the risk of developing
cancer, and is calculated by applying factors that describe the transport of radiation
between organs to the time-integrated retention of the radioactive material in the
organs.
The International Commission on Radiological Protection (ICRP) publishes biokinetic models for all radionuclides of practical concern. These models are the international standard, being used to calculate intakes from bioassay data and to calculate
permissible concentrations of radionuclides in air and water (Clarke and Valentin,
2009). Two problems with the application of these models are: (i) the ICRP biokinetic model may not adequately describing the biokinetics of a particular individual,
and (ii) ICRP models don’t give a straightforward way to estimate the uncertainty
in estimated intakes and radiation doses. Practical methods for dealing with these
two problems are the main focus of this dissertation
My exposition will revolve around the biokinetics of zirconium (Zr), which is a
metallic element whose radioisotopes like Zr95 are commonly associated with nuclear
power reactors. The ICRP defined the compartmental structure of the ICRP 134
zirconium biokinetic model (Paquet, Leggett, et al., 2016) shown in Figure 3.2 and
provided point values of the rate constants in the system of ordinary differential
equations (ODE) that define the biokinetics of zirconium in the human body.
Greiter et al. (2011) presented data from a zirconium stable isotope study (discussed further in Section 3.2) that were used to construct a zirconium biokinetic
model that will be referred to as the Helmholtz Zentrum Center for Radiation Research (HMGU) model. Bayesian model comparison methods were used by Schmidl
et al. (2012) to show that the HMGU model had better predictive power than the
ICRP Publication 56 zirconium biokinetic model (ICRP, 1990), which was the predecessor for the ICRP 134 zirconium model. Schmidl et al. (2012) also discussed the
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use of Bayesian methods to estimate credible intervals on radiation doses assigned
to an individual. Finally, Schmidl’s work is referenced in the discussion in Section
3.4.4 on prior selection. Li, Greiter, et al. (2011a) performed an uncertainty analysis
of the HMGU zirconium biokinetic model and Li, Greiter, et al. (2011b) performed
a sensitivity analysis of the model using Monte Carlo methods. These studies were
concerned with selecting an optimal compartmental structure (i.e., the number of
compartments and their interconnections) for a zirconium biokinetic model and comparing it to the ICRP biokinetic model that was in use at the time.
In the calculations performed in this dissertation, the system of ODE must be
solved for each MCMC iteration, which is extremely computationally intensive. Schmidl
et al. (2012) used the matrix exponential to solve the system of ODE as was done here
(see Section 3.3). This is an expensive calculation that can be avoided by generating
a large number of candidate combinations of rate constants, solving the systems of
ODE once, and storing the solutions in a look-up table (Miller, 2008; Miller, 2017;
Poudel et al., 2018; NCRP 2010, Section 5.3.2.3). Another option for this computationally intensive task is weighted likelihood Monte Carlo sampling (WELMOS)
(Puncher, Birchall, and Bull, 2012; Puncher, Birchall, and Bull, 2014; Puncher and
Riddell, 2016; NCRP 2010, Section 5.5.2). In WELMOS, random draws are taken
from prior distributions for the the parameters in the biokinetic rate matrix and a
likelihood calculated for a discretized intake prior. The likelihoods are summed to
give an approximation to the posterior distribution of the intake. This is not a true
Bayesian approach because it samples from the prior rather than the posterior distribution, but if the data are not highly informative it will give results very similar
to a true Bayesian approach (NCRP, 2010, pg 169).
The goals of this dissertation are fundamentally different the works cited above.
In this chapter a Bayesian calibration (Hack, 2006) is performed on the ICRP 134
biokinetic model using bioassay data from the Greiter stable isotope study. This
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calibration incorporates the prior distributions of the model parameters and results
in posterior probability distributions of the rate constants in the model given the
observed data. This stochastic biokinetic model is designed to achieve the best agreement between the observations and the model predictions. A hierarchical Bayesian
calibration is performed, which accounts for parameter variability in an individual
and between individuals in the study group. In principle, knowledge of the posterior probability distributions of the model rate constants allows one to calculate the
uncertainty in all quantities derived from the biokinetic model. For example, it can
provide estimates and credible intervals for the intake of zirconium and the radiation
doses to organs and tissues. This population-level Bayesian calibration is a proofof-principle exercise that shows how researchers who develop biokinetic models for
the ICRP can provide probability distributions for the parameters in their models
that are consistent with observed bioassay and prior knowledge. In an actual model
development, prior information from multiple experimental studies and accidental exposures can be combined with expert elicitation (i.e., high quality SWAGs) to create
highly informative models that encapsulate all prior knowledge.
In the following Section we give a presentation of the Greiter zirconium data
followed by a summary of the ICRP 134 zirconium biokinetic model in Section 3.3.
Then, in Section 3.3.1 reference bioassay functions and intakes are defined in terms
of the biokinetic model. At this point population and individual Bayesian statistical
models are defined in Section 3.4, which include the specification of the likelihood
and prior distributions. The chapter concludes with the presentation of the results
in Section 3.5 and the discussion of results in Section 3.6.
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3.2

Data

The data from the Greiter study were provided by Dr. Augusto Giussani1 of the
German Bundesamt fur Strahlenschutz. The studies were originally performed at
the German Helmholtz Zentrum Center for Radiation Research (HMGU). The data
from the N = 16 study subjects used in previous studies (Greiter, 2008; Greiter
et al., 2011) and data from 2 additional out-of-study subjects were provided. Bioassay measurements consisted of the concentration of zirconium in the blood plasma
and the quantity of zirconium in incremental urine samples at various times after
intravenous administration of a known quantity of stable zirconium. The individuals
in the study each have nj bioassay measurements, j = 1, 2, . . . N . Each individual
has np measurements of the concentration of zirconium in the blood plasma and nu
measurements of the zirconium in incremental urine samples, with nj = nuj + npj .
For the j th individual, the response variable M j is a nj × 1 vector of the bioassay
measurements that consists of npj plasma measurements stacked on top of nuj urine
measurements. These measurements were made at times tj (a nj × 1 vector) after
injection of the zirconium. Urine samples are collected over a nuj × 1 vector of time
increments denoted by ∆tj . Urine samples tend to have a ∆t equal to either 12 or
24 hours.
The combined standard uncertainty u of the measurement calculated according
to guidance given in the ISO Guide to the Expression of Uncertainty in Measurement
(GUM) (ISO, 2008) was provided for each measurement. To facilitate comparison of
data from different individuals in the study, all bioassay measurements and associated measurement uncertainties were normalized by dividing them by the quantity
of zirconium injected. Thus, in the original dataset the units of the blood plasma
bioassay are fraction of injected zirconium per kg of blood plasma and the units of the
1

Personal communication on 4/14/2020.
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Figure 3.1 Urine and blood plasma data for 16 subjects from the Greiter zirconium
study used in the population model and 2 subjects (in red) that were not used in the
model. These two out-of-sample individuals are discussed in Chapter 4.
incremental urine bioassay are fraction of injected zirconium excreted per hour. Some
bioassay results were declared to be below the detection level (BDL) of the analytical
method and were not used in previous studies. The values of BDL measurements
and their associated uncertainties are available and are used in this analysis, i.e., no
data are excluded. Plots of the urine and blood plasma data are shown in Figure 3.1.
The urine data have more scatter that the blood plasma data because there is more
zirconium in the blood plasma than in the urine and because the urine samples can
have different collection intervals.

3.3

Zirconium Biokinetic Model

The biokinetic model for zirconium shown in Figure 3.2 is given in ICRP Publication
134 (Paquet, Leggett, et al., 2016, Page 273). This model consist of compartments
between which the movement of material is described by a system of first-order ODE.
The system of ODE can be solved to give the fraction of a unit intake2 (an injection in
2

In pharmacokinetics literature the dose is the amount of material delivered to an individual,
which is referred to as an intake here to be consistent with the internal dosimetry literature and to
avoid confusion with radiation dose.
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Figure 3.2 ICRP 134 biokinetic model for zirconium.
this case) of the zirconium that is present in each compartment, or any combination
of compartments at any time after the intake.
The nc = 16 compartment ICRP zirconium model that describes the rate of
change in each compartment can be represented by the following system of nc ODE
dq1 (t)
= q˙1 (t) = − k11 q1 (t) + k21 q2 (t) + · · · + knc 1 qnc (t)
dt
dq2 (t)
= q˙2 (t) =k12 q1 (t) − k22 q2 (t) + · · · + knc 2 qnc (t)
dt
..
.

(3.1)

dqnc (t)
= qn˙ c (t) =k1nc q1 (t) + k2nc q2 (t) + · · · − knc nc qnc (t),
dt
where qi (t) describes the content of compartment i at time t,

dqi (t)
dt

describes the rate

of change in compartment i at time t, and kij describes the instantaneous rate at
which zirconium is transferred from compartment i to compartment j. Note that
rate constants for compartments with no connections are 0. For example, k43 = 0
because there is no transfer of zirconium from the liver-1 compartment to the liver-0
compartment according to the biokinetic model (see Figure 3.2). In fact, for the
zirconium model only nr = 27 of the possible 256 of rate constants are non-zero. The
rate constants for the ICRP 134 zirconium model are given in Table 3.1.
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The rate of change of the ith compartment can be expressed as
q˙i (t) =

X

kji qj (t) − kii qi (t) ,

(3.2)

j̸=i

where kii is the sum of all the rate constants that govern the transfer of material out
of compartment i by all routes, and is given by
kii = λ +

X

(3.3)

kij ,

j̸=i

where the constant λ is added to account for removal by radioactive decay (Turner,
Downing, and Bogard, 2012, page 15; Claudio Cobelli, Foster, and Toffolo, 2007,
Section 2.3). For the stable isotopes of zirconium like those used in the Greiter study
λ = 0.
The ODEs in (3.1) can be presented concisely in matrix notation as
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(3.4)

or q̇ = kq, where k is referred to as the rate matrix. The goal is to solve this system of
ODE for the quantity of zirconium qi (t) of each compartment i at time t. For example,
q1 (t) describes how much zirconium is in the blood-1 compartment at time t. There
are a number of different ways to accomplish this, including Runge–Kutta methods,
eigenvalue decomposition, and the matrix exponential (Jacquez, 1985; Polig, 2001;
Stan Development Team, 2021b, Chapter 13). Here we will use the matrix exponential
which is a computationally simple and fast method for solving linear systems of ODE
that is available in the MCMC computational software (Stan Development Team,
2021b, pg 181). The matrix exponential solution to the system of ODE is
qt = exp (kt) q0 ,
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(3.5)

where q0 is the initial content of the compartments at t = 0, i.e., the initial conditions
needed to solve the ODE. Here exp (kt) can be expressed using the Taylor series
expansion
exp (kt) =

(kt)j
.
j=0 j!
∞
X

(3.6)

To calculate (3.6) we use a truncated version that has been shown to be an accurate
approximation that avoids numerical instability of raising kt to high powers (Moler
and Van Loan, 2003). The initial quantities q0 of zirconium in the compartments are
1 for blood plasma-1 and 0 for the other compartments because we are assuming an
intravenous injection of a unit quantity of zirconium into blood plasma-1. Thus, for
this model the initial content of the blood plasma-1 compartment is the intake.

3.3.1

Reference Bioassay Functions and Intake

In this section, we relate the compartment-specific content qt at time t to the observed
blood and urine data discussed in Section 3.2. To this end, we assume the observed
bioassay data M j for the jth subject is represented as
M j = β · mj + εj ,

(3.7)

where εj is the nj × 1 vector of heteroscedastic regression error with E (εj ) = 0.
The reference bioassay function mj = E(M j |β = 1) is a function of the qt ’s and
relates the measured bioassay to the compartment specific contents predicted by the
biokinetic model (discussed more below) and β represents the quantity of zirconium
injected into the individual (the intake), which is of interest in practice. The estimate
of the intake β can be made using the weighted residual sums of squares.
The collection of compartments in the biokinetic model that corresponds to what
was measured in a bioassay is referred to a reference bioassay function mj = m(tj )
at times tj (Paquet, Leggett, et al., 2016). For blood plasma, the reference bioassay
function will be the sum of blood-1 and blood-2 compartments (see Figure 3.2). In
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practice, mj,p must account for the volume of the blood plasma compartment, which
is incorporated for the subject via








q1 tpj + q2 tpj



mj,p ≡ mp tpj , vj =

vj



(3.8)

,

where tj is a vector of time points and vj is the volume of blood plasma, respectively,
for the jth subject (see Appendix B for more details on the calculation of blood
volume). Note that mj,p and mj,u are also a function of the rate matrix k and the
initial quantities q 0 but these parameters are suppressed for the moment to make the
notation more concise. The quantity of zirconium in an incremental urine sample has
the reference bioassay function












mj,u ≡ mu tuj , ∆tj = q12 tuj − q12 tuj − ∆tuj ,

(3.9)

where tuj is the time at which the collection of urine ended and ∆tuj is the time
interval over which the urine was collected. In practice, an individual collects an
incremental urine sample by completely voiding his bladder at time t1 . All subsequent
urine voids are collected until a later time t2 , when the individual completely voids his
bladder one last time, completing the incremental urine sample. By convention, in the
incremental urine reference bioassay function the time of the sample tj = t2 and the
collection interval ∆tuj = t2 − t1 . Collection intervals used in the Greiter zirconium




study were either 12 hours or 24 hours. The quantity variable mj = mpj , muj is a
nj × 1 vector that consists of the npj plasma reference bioassay functions stacked on
top of nuj urine reference bioassay functions.

3.4

Bayesian Models

The analysis described in the last section becomes more complicated when there exists
heterogeneity in the individual level biokinetic models, which results in them not
accurately describe the biokinetics of zirconium on an individual. In this section, we
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define a Bayesian population model that, with the data from the zirconium study, is
used to calibrate the zirconium biokinetic model. This calibration results in estimated
posterior distributions for the rate constants in the ICRP 134 zirconium model. Let’s
begin by looking at the Bayesian approach to modeling data from an individual, after
which the population model will be presented.

3.4.1

Individual-level Model

By Bayes Rule, the joint posterior distribution p (β, k, v|M ) of β, k, and v given the
bioassay data M is
p (β, k, v|M ) =

p (M |β, k, v) p (β, k, v)
,
p (M )

(3.10)

(Bernillon and Bois, 2000; Bonate, 2011, Chapter 10) where: p (M ) is the marginal
density of the bioassay data M ; k is the rate matrix; β is the intake; v is the volume of
blood plasma; p (β, k, v) is the joint prior distribution of β, k, and v; and p (M |β, k, v)
is the likelihood of the data. Thus, the likelihood is
p (M |β, k, v) =

n
Y

f (Mj , β · m (tj , k, v) , Σj,j ) ,

(3.11)

j=1

where f (·) is the pdf for a scaled and shifted Student’s t distribution with location
parameter β · m (tj , k, v), scale parameter Σj,j , and ν degrees of freedom. Assuming
that β, k, and v are independent of each other, the posterior distribution of the
parameters given the observed data is
p (β, k, v|M ) =

p (M |β, k, v) p (β) p (k) p (v)
.
p (M )

(3.12)

The normalization constant for the posterior, i.e., the constant that makes the posterior a proper probability density function is
ˆ ˆ ˆ
p (M ) =
p (M |β, k, v) p (β) p (k) p (v) ∂β∂k∂v.

(3.13)

All inferences concerning the unknown parameters are derived from their posterior
distributions given by (3.12). For example, from the posterior distribution of β a
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Figure 3.3 Bayesian model for an individual viewed from the perspective of the
distributions of the priors (pink shaded nodes), the likelihood (unshaded node), the
deterministic calculations (solid rectangle), and the fixed data (dashed rectangles).
point estimate of the intake and its associated uncertainty can be calculated (Hack,
2006, page 243).
In practice the integral given in (3.13) is intractable using conventional numerical
and analytical methods and requires specialized methods like Markov Chain Monte
Carlo (MCMC) to evaluate. We discuss this further in Section 3.4.5. The Bayes
model for an individual has a simple hierarchical structure, which means that the
values of some parameters depend on the values of higher-level parameters (see Figure
3.3). In the next section this hierarchical structure will be expanded to accommodate
variability between subjects.

3.4.2

Population Level Model

The individual Bayes model can be extended to describe a population of individuals
by adding hyperprior distributions, from which the parameters for the priors for an
individual are drawn. This is a population biokinetic model (Bois, 2001; Wakefield,
Aarons, and Racine-Poon, 1999), which allows us to model and account for hetero-
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geneity between individuals in a population. The population model can be concisely
expressed as
p (ψ|M ) =

p (M |ψ) p (ψ)
,
p (M )

(3.14)

where the the parameter vector ψ is
ψ = {k, θ, Π, Ω, τ, v}

(3.15)

p (ψ) = p (k|θ, Π) × p (θ) × p (Π|Ω, τ ) p (Ω) p (τ ) × p (v)

(3.16)

and the prior

The constant of proportionality is the marginal probability density of the data M
ˆ
p (M ) =

p (M |ψ) p (ψ) dψ.

(3.17)

The likelihood, prior, and hyperprior distributions for the population-level model
shown in Figure 3.4 are discussed in the following sections.

3.4.3

Likelihood

The residuals in the regression of M on m in (3.7) often show more dispersion than
expected from the normal distribution. This results in measurements frequently being
viewed as outliers that skew the fit to the data. The regression errors can be modeled
with a Student’s t distribution with a low number of degrees of freedom ν, resulting
in a regression that is more robust to outliers than a normal distribution (Kruschke,
2015, page 458). A Student’s t distribution with ν = 4 has been recommended as a
default for robust regression for cases where ν is not estimated from the data (Lange,
Little, and Taylor, 1989, pg 883). The sampling distribution given at the bottom
of Figure 3.4 is a scaled and shifted Student’s t distribution with ν = 4 degrees of
freedom
M j ∼ t (4, βj , mj , Σj ) ,
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(3.18)

Figure 3.4 Bayesian population model for evaluating cases with the intent of estimating the posterior distributions of the hyperpriors in the blue shaded nodes. The
nodes for parameter distributions are denoted by ellipses, computed parameters by
rectangles, and data by dashed rectangles.. Note that β = 1 is a known constant for
all subjects in the study and precise point estimates of their blood plasma volume
are available.
where Σj is a nj × nj matrix of squared measurement uncertainties associated with
the j th individual’s bioassay. For this error model only the main diagonal of Σj is nonzero, consisting of the nj squared measurement uncertainties u2j . The measurement
uncertainty is only part of the overall uncertainty in bioassay measurements, and
a covariance matrix consisting of only the measurement uncertainties is considered
to have the smallest possible variance. One approach to inflating the variances to
account for the additional uncertainty is to multiply the covariance matrix Σ times
a proportionality constant σ 2 ≥ 1 that is an unknown parameter to be estimated
(Gelman, Carlin, et al., 2013, pg 372; Kutner, 2005, pg 424). This approach was
not implemented here in order to have all the variation in excess of measurement
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uncertainty to be propagated to the posterior distributions of the rate constants. The
likelihood function for a robust regression with heteroscedastic Student’s-t distributed
errors is

p (M |β, k) = L (β, k) =

nj
Y

f (4, Mi , βmi , Σi,i )

(3.19)

i=1

3.4.4

Prior Specifications

Three types of priors discussed by Banner, Irvine, and Rodhouse (2020, page 883)
are
• vague: A prior that is used to reflect that not much is known about the parameter of interest but is well justified.
• weakly informative: A prior that is used to reflect a diluted (or scaled back)
amount of knowledge about the parameters.
• informative: A prior that is carefully designed to reflect the current knowledge
(and uncertainty) of the parameter.
Vague priors let the data “speak for themselves”, allowing one to gauge how much of
an influence the prior is having on the posterior distribution. However, vague priors
have limited use in this application because they give a posterior that is (more or
less) equivalent to a maximum likelihood solution, which is problematic (see Section
2.4). Priors need to be informative enough to make the biokinetic model identifiable
and the system of differential equations solvable.
Informative or weakly informative priors are the logical choice simply because we
have a lot of prior knowledge about the biokinetics of zirconium. The prior knowledge
concerning the biokinetics of zirconium summarized in ICRP 134 (Paquet, Leggett, et
al., 2016, pg 269) is based on animal and human studies with zirconium, the biokinetics of its chemical analog niobium, and expert opinion. The compartmental structure
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of the ICRP 134 zirconium biokinetic model and its associated rate constants are
considered to embody the best available prior information on the biokinetics of zirconium. However, ICRP 134 only provides point estimates of the rate constants, so
some generalizations concerning the prior distributions are required.
Priors in biokinetic models are generally assumed to follow normal or lognormal
distributions (Davidian, 2006, pg 18). Here we primarily use lognormal priors because the true values of the parameters of interest (e.g., rate matrix, intake, blood
plasma volume) are physically constrained to be non-negative. In addition, the multivariate normal (lognormal) distribution is often preferred for modeling multivariate
priors because of its somewhat unique properties (e.g., the marginal distributions
of a multivariate normal are all normally distributed). In this discussion lognormal
distributions are often specified in terms of the geometric mean (gm) and geometric
standard deviation (gsd). Specific values reported in the literature for rate constants
include: gsd of 2 or 3 for lognormally distributed rate constants and coefficient of
variation of 0.3 for normally distributed rate constants (Schmidl et al., 2012, Supplement, pg 8); mean gsd of ∼ 1.9 (calculated from 99% confidence intervals for Zr rate
constants given in Li, Greiter, et al. (2011a, Table 3)).
The time required to calculate the posterior distribution is a functions of the gsd
used in the lognormal priors – the more diffuse the prior the more parameter space
that must be searched. The default gsd used for rate constant priors is important
because it is approximately the gsd that will be observed in the posterior for rate
constants that are not identifiable. Therefore, a default gsd = 1.5 is used to limit
computer run times (that are already measured in weeks) while not greatly overstating
our degree of knowledge concerning these parameters.
Referring to Figure 3.4, the plasma volume vj for the j th individual has a lognormal
prior
vj ∼ LN (µv , σv ) ,
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(3.20)

with the scale parameter σv = log (1.1) is assumed to be constant for all individuals.
The location parameter is µv = log (Vj ), where Vj was determined by non-linear
regressions of the zirconium plasma concentrations for each individual (see Appendix
B). The rate matrix kj for the j th individual has a multivariate lognormal prior
for non-zero rate constants. That is, the log of the rate constant is modeled as a
multivariate normal distribution
log (kj ) ∼ M V N (log (θ j ) , Πj ) ,

(3.21)

where log (θ j ) is a nr × nr matrix of population level mean of the rates, and Πj
is a nr × nr covariance matrix that describes the dispersion of the rate parameters
from the population level means. The population-level location parameters θ j have
a MVLN hyperprior for non-zero rate constants
log (θ j ) ∼ M V N (µθ , σθ ) ,

(3.22)

where µθ is a nr long vector of location parameters and σθ is a nr × nr covariance
matrix populated only on the main diagonal. The logs of the ICRP 134 zirconium
model rate constants will populate µθ whereas σθ = log (1.5) as discussed above.
The covariance matrix Πj in the prior for kj is decomposed (Barnard, McCulloch,
and Meng, 2000) into the log of the geometric standard deviation τ and a nr × nr
correlation matrix Ω
Πj = diag (log (τ )) ·Ω ·diag (log (τ ))

(3.23)

which is equivalent to
h

i

Πj = log (τ )2 Ω

(3.24)

since a single value of τ is used. The decomposition of Π into τ and Ω allows us to
focus our attention on the geometric standard deviations, for which we might have
some intuition, and apply a simplified distribution to the correlations, for which we
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probably do not. As a result, Ω is modeled with a Lewandowski–Kurowicka–Joe
(LKJ) distribution (Lewandowski, Kurowicka, and Joe, 2009),
Ω ∼ LKJ (η) ,

(3.25)

where η is a scalar parameter that controls the dispersion of the off-diagonal elements
of Ω. Population model runs were made with η being a parameter to estimate, but
it was found that the posterior distribution of this parameter tends to be pretty
much the same as the prior distribution and estimating this parameter significantly
increases the time required to perform the calculations. As a result, a fixed value of
η = 10 was used to allow for an appropriate distribution of the correlations given the
sensitivity of the proposed model (see Appendix E). Finally, the log of the geometric
standard deviation τ is modeled with a normal distribution truncated at 0
log (τ ) ∼ T N (µτ , στ , 0) ,

(3.26)

which precludes the generation of a negative dispersion parameter. The log mean µτ =
log (1.55) and the log standard deviation στ = log (1.1) were selected using subject
matter knowledge. When estimating the zirconium biokinetic model parameters from
the 16 subjects, β = 1 for each because we know the quantity of zirconium that was
injected and the data were subsequently normalized to 1. When β is unknown it is a
parameter to be estimated.
One way to assess the suitability of the priors is to consider “are observations
drawn from the prior distributions plausible given our knowledge of the field?” Gelman, Simpson, and Betancourt (2017, page 9) explored this idea in detail, stating:
“The guiding principle for prior specification we have emphasized here can be
encapsulated in the question: could this prior generate the type of data we expect
to see? This is in accordance with the Jaynesian idea that a prior should reflect the
known constraints on the system. Rather than looking for hard constraints that are
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Figure 3.5 Simulations of bioassay data from the prior predictive distribution of the
Bayes population model compared the the observed data for two subjects (Zr0501112
on left and Zr0602615 on right). The observed bioassay data are plotted against the
mean of the respective reference bioassay function distribution.
difficult to elicit for complex models, however, we instead focus on ensuring that most
of the prior mass is in parts of the parameter space that correspond to reasonable
data generating processes.”
If we have observed bioassay data M , p (M ) in (3.17) is a normalization constant,
a number that makes the posterior a proper probability distribution. If the data have
yet to be observed, (3.13) is function of the data, the prior predictive distribution, that
gives the probability of observing a given set of bioassay data. The prior predictive
distribution is useful for judging the plausibility of the priors in complex models as
discussed by Wesner and Pomeranz (2020), Gelman, Simpson, and Betancourt (2017),
and McElreath (2018).
The prior predictive distributions in the Bayes population model for zirconium
were compared to the observed bioassay results for the 16 subjects. The examples in
Figure 3.5 show that bioassay data simulated from the prior distributions are plausible
and not excessively diffuse.
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3.4.5

Computational Details

The posterior distributions of the parameters given the data as described by (3.14)
reflect all the information contained in the data given the prior distributions. All
inferences are made with the posterior distributions of the parameters. In particular,
the mean of each posterior distribution is commonly used as the point estimate of the
parameter and the width of the posterior distribution is a measure of the uncertainty
in the parameter estimate (Hack, 2006, pg 245). The statistical model for zirconium is
too complex to obtain analytical solutions to the posterior distributions, so estimates
are by drawing samples directly from the posterior distributions using Markov Chain
Monte Carlo (MCMC) and analyzing these samples (Gelman, Carlin, et al., 2013).
The “No U-Turn Sampler” (NUTS) variant of Hamiltonian Monte Carlo (Lambert
2018, Ch 15; Monnahan, Thorson, and Branch, 2017; Kruschke 2015, Ch 14) as implemented in the the computer code Stan (Carpenter et al., 2017) is used to generate
the samples from the posterior distributions. NUTS is essentially the MetropolisHastings sampler where the proposal step incorporates information about the local
geometry of the log posterior distribution based on the motion of a particle on the
surface of the log posterior. This information allows NUTS to make good proposals
with a high acceptance rate, which results in efficient exploration of the complex parameter space. As far as MCMC samplers go, NUTS is somewhat unique in that it
provides feedback on whether the sampler is working properly, which is discussed in
the next section.
As a particular implementation of NUTS, Stan has the advantages that: (i) the
performance of Stan/NUTS is often superior to the more traditional Metropolis or
Gibbs MCMC samplers for high-dimensional models with correlated parameters like
the zirconium population model (Hoffman and Gelman, 2014); (ii) an efficient matrix exponential ODE solver is part of the Stan language; (iii) the Stan language
is compiled rather than interpreted, which makes it faster; (iv) the syntax of Stan
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resembles C++ with a pinch of R, which makes it familiar.; (v) Stan is under active
development by a team of expert statisticians and programmers.; (vi) Stan has an
active support community, which includes direct access to developers.
The Stan MCMC calculations discussed in this dissertation were performed with
cmdstan 27.1 interface using the codes and bash scripts discussed in Chapter 5. The
computers used were an Intel Core i7-7820X CPU and an Intel Core i9-10900X, both
with 128 GB of memory running the Linux Mint 20.2 operating system, and the
Hyperion computer cluster at the University of South Carolina3 . Calculations were
performed with one chain per core. A total of 11 chains were run, with each chain
started with 3000 iterations for warm up (to tune sampling parameters of NUTS) and
10000 iterations for sampling (total of 110, 000 sampling iterations). The calculations
took approximately 20–25 days to complete.

3.4.6

Checking for Convergence of MCMC

Determining whether the Markov chain has converged and the posterior samples are
from stationary chains is imperative. If so, we can proceed to the evaluation of the
biokinetic model. Adequacy of the MCMC sampling of the posterior is a necessary
prerequisite for assessing adequacy of the model.
The No-U-Turn Sampler is somewhat unique among MCMC samplers in that
it provides diagnostics that give an indication of whether the process of sampling
has been successful (Stan Development Team, 2021b, Ch 17). Perhaps the most
useful of these diagnostics is the divergent transition, the occurrence of which is an
indication that the sampler is not accurately following the contours of the log posterior
distribution. No divergent transitions were reported with the Stan MCMC runs used
in this analysis.
3

I would like to acknowledge that the Research Computing program under the Division of
Information Technology at the University of South Carolina contributed to the results in this research
by providing High Performance Computing resources and expertise.
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A properly constructed MCMC sampler is guaranteed to converge to the correct
stationary distributions and generate useful samples from the posterior distributions
only if it is run for an infinite length of time. There is no way to determine with
certainty whether the samples from truncated chains (i.e., run for a finite length
of time) are indeed from stationary chains and therefore useful. However, there
are diagnostics that can be used to identify MCMC chains that are not stationary.
Note that absence of proof is not proof of absence – just because no convergence
problems were detected with the diagnostics does not prove that convergence to
stationary chains was attained. Statistics used to judge convergence of the MCMC
calculations are (Vehtari et al., 2021): potential scale reduction statistic R̂, which
gives an indication whether the sampling has adequately explored the parameter
space of the posterior distribution; effective sample size ESS, which tells us whether
we have enough samples of the posterior distributions to calculate stable estimates
of the uncertainty in the parameter estimates; Monte Carlo standard error (mcse),
which is the uncertainty in the mean of a given parameter estimate. Simply put,
we are asking whether the MCMC sampling “worked”. If it did, do we have enough
information to calculate a stable estimate of the uncertainty in the parameters? If
we do, what is the uncertainty and is it small enough to be useful?
Autocorrelation can reduce the amount of information given by Markov chain
samples of the posterior distribution, making the number of MCMC samples equivalent to a smaller number of independent samples. The effective sample size is an
indication of the degree to which the MCMC samples autocorrelated, giving an an
estimate of the number of independent draws from the posterior distribution that
give the same amount of information as the dependent draws. The ESS for the tails
of a posterior distribution can be different than the center of the distribution, which
motivated Vehtari et al. (2021) to propose a bulk ESS for the center of a distribution
and a tail ESS for the tails (see lhs plot in Figure 3.6). They recommended that an
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ESS greater than 400 is desirable to get a stable estimate of the posterior distribution. The potential scale reduction statistic R̂ is an indication of the mixing of the
chain, i.e., the degree to which the chain has explored parameter space and achieved
stationarity. R̂ compares within chain variance to between chain variance, and if all
chains are at equilibrium these variances will be the same with R̂ = 1. Historically,
an R̂ > 1.1 was taken to indicate poor mixing, but more recent research has suggested
that a threshold of R̂ > 1.01 using a rank-normalized and folded version of R̂ is more
appropriate (Vehtari et al., 2021).
The mcse is the the standard error of the mean of the posterior draws divided by
the mean. What constitutes an acceptable mcse is a domain specific decision, but
a reasonable cutoff for this application is a relative mcse that is less than 10%, i.e.,
a relative mcse of ≤ 0.1. The plot on the lhs of Figure 3.7 shows the relative mcse
for all parameters. The correlation matrix Ω and the covariance matrix Π can have
mean values that are essentially equal to 0, which limits the usefulness of the relative
mcse for those parameters. The plot on the rhs of Figure 3.7 omits the correlation
matrix and the covariance matrix.
The trace plots can be useful for visualizing chains that are of interest for some
other reason, e.g., low ESS. However, they are not of much use as a first-line diagnostic
tool, especially if there are a large number of parameters as with the zirconium
population model and a large number of iterations as with these Stan runs 4 .

4
Note that Markov chains having negative correlation on odd lags (antithetic chains) can have an
ESS that is greater than the actual sample size. This result was observed for a number of parameters
in this analysis.
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Figure 3.6 Tail ESS versus Bulk ESS (left) and Bulk ESS versus R̂ (right).

Figure 3.7 Relative Monte Carlo standard error of the mean versus the absolute
value of the mean for all parameters (left), and the same plot without the correlation
matrix Π and covariance matrix Ω (right).
3.5

Results of Data Analysis

The plots of bulk ESS versus R̂ and tail ESS versus R̂ shown in Figure 3.6 show
that R̂ calculated in this Stan MCMC run meet the R̂ > 1.01 criterion and ESS
meets the > 400 criterion for all parameters in the zirconium population model. As
shown in Figure 3.7, the relative Monte Carlo standard error is < 0.1 for essentially
all parameters once the parameters with extremely small means are excluded. Trace
plots were examined if the ESS or R̂ diagnostics indicated a problem. Finally, Stan
did not report any divergences. Thus, there are no indications that the MCMC runs
did not converge.

51

Next, we can explore whether the zirconium population model adequately describes the observed data. A good way to do this is to ask are observations generated
using the posterior distributions of the parameters consistent with the observed data?




The posterior predictive distribution p M̃ |M is used to answer this question
ˆ 



(3.27)
p M̃ |M = p M̃ |ψ p (ψ|M ) dψ,




(Gelman, Carlin, et al., 2013, pg 7) where p M̃ |ψ is the sampling distribution of
future data M̃ given the posteriors ψ of the model parameters, i.e., the likelihood,
and p (ψ|M ) is the distribution of the parameters given the observed data M , i.e.,
the posterior distribution. In practice, the observations from the posterior predictive
distribution are generated during the the MCMC by using the values of the posterior distributions in a given iteration of the sampling distribution to generate a
corresponding set of predicted observations. Examples of posterior predictive distributions obtained for 4 representative subjects are given in Figure 3.8. These plots
clearly contrast the measurement uncertainty in the bioassay and the estimate of the
total uncertainty that includes biological variability.
The posterior distributions of θ and τ (the parameters in blue colored nodes in
Figure 3.4) are of particular interest because the canned priors discussed in Chapter
4 will be derived from them. The posterior distributions of the blood plasma volumes
for each individual are of interest because they are used to help define blood plasma
volume priors for out-of-sample subjects.
Marginal density plots of the posterior density of the population level rate constants θ appeared to be lognormally distributed. The medians and 95% credible
intervals for the marginal posteriors of these parameters are given in Table 3.1 where
they are compared to the default ICRP 134 rate constants. In Figure 3.9 a plot of the
gsd for each parameter is presented along with a plot of the median of the parameter
versus the default ICRP 134 value. The mean residence time for the urinary bladder,
which is the mean length of time a zirconium atom resides there, is shown in Figure
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Figure 3.8 Posterior predictive distribution for 4 of the 16 subjects given as an
example of posterior predictive distributions. The red error bars are the 95% credible
interval of the posterior predictive distribution and the black error bars are the 95%
coverage interval for the measurement uncertainty.
3.10. The residence times were calculated as discussed by Claudio Cobelli, Foster,
and Toffolo (2007, pg 94) from the individual rate matrix k in each MCMC iteration. The correlation plot for θ in Figure 3.11 shows that many of the rate constants
involving the urine and blood plasma are correlated. Posterior distributions of log
blood plasma volumes are summarized in a plot in Figure 3.12 of the gm versus the
gsd of the 16 blood plasma posterior distributions for the study group.

3.6

Discussion

In this chapter we took the ICRP 134 zirconium biokinetics model shown in Figure 3.2,
defined priors and hyperpriors for the hierarchical Bayesian statistical model shown
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Table 3.1 Transfer rate constants in units of day −1 for the ICRP 134 zirconium compartmental model (Paquet, Leggett, et al., 2016, page 274), where the rate constant
k13,1 was calculated with fA = 0.002. The median and 95% credible interval of the
marginal posterior distributions the parameters parameter are given in the last three
columns. Complete names of the compartments are given in Appendix F.
Posterior
ICRP 134

Rate Constants

Index

From

Comp

To

Comp

Rate Constants

2.5%

median

97.5%

1

bld1

1

bld2

2

2

2.283

3.283

4.633

2

bld1

1

liv0

3

0.075

0.03349

0.06964

0.1658

3

bld1

1

kid

5

0.0125

0.005859

0.01119

0.02139

4

bld1

1

ST0

6

2

1.892

2.573

3.472

5

bld1

1

ST1

7

0.0375

0.01675

0.03363

0.07349

6

bld1

1

ubc

12

0.1

0.05179

0.07543

0.1089

7

bld1

1

SI

13

0.025

0.01176

0.02223

0.04182

8

bld1

1

ts

8

0.375

0.1583

0.331

0.577

9

bld1

1

cs

10

0.375

0.13

0.2302

0.3821

10

bld2

2

bld1

1

0.462

0.5729

0.8335

1.216

11

liv0

3

SI

13

0.116

0.05678

0.1104

0.2158

12

liv0

3

bld1

1

0.116

0.06112

0.1207

0.2356

13

liv0

3

liv1

4

0.462

0.2347

0.4638

0.9136

14

liv1

4

bld1

1

0.01

0.005075

0.009721

0.01901

15

kid

5

bld1

1

0.01

0.004999

0.009736

0.01926

16

ST0

6

bld1

1

0.462

0.3429

0.5373

0.8349

17

ST1

7

bld1

1

0.02

0.01012

0.02029

0.04056

18

ts

8

bld1

1

0.000493

0.0003595

0.001015

0.001818

19

ts

8

tv

9

0.000247

0.0001229

0.0002368

0.0004588

20

tv

9

bld1

1

0.000493

0.0002536

0.0004932

0.0009616

21

cs

10

bld1

1

8.21E-05

4.106e-05

7.841e-05

0.0001494

22

cs

10

cv

11

4.11E-05

2.117e-05

4.119e-05

8.06e-05

23

cv

11

bld1

1

8.21E-05

4.213e-05

8.218e-05

0.0001602

24

ubc

12

urn

15

12

1.292

2.01

3.237

25

SI

13

col

14

1.5

0.7701

1.502

2.92

26

col

14

fec

16

1.5

0.777

1.506

2.957

27

SI

13

bld1

1

0.0030

0.001546

0.003004

0.005858
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Figure 3.9 Plot of geometric standard deviations of posterior distributions of rate
constants θ (top). For reference, the priors for these parameters had a gsd = 1.5. Plot
of median of posterior rate constants θ versus the default ICRP 134 rate constants
(bottom). The points in red on both plots have a gsd < 1.4 or a gsd > 1.6.
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Figure 3.10 Mean residence time of zirconium atoms in the urinary bladder calculated with the standard ICRP 134 zirconium biokinetic model (black dashed line at
0.083 days) and the population model (black curve). The red dashed lines denote
the 95% confidence interval of mean residence times calculated with the population
model, which has a median of 0.547 days.
in Figure 3.4, and calibrated the biokinetic model with the urine and blood plasma
bioassay data shown in Figure 3.1 from 16 subjects with known injection intakes of
zirconium. MCMC run with Stan was used to generate samples from the posterior
distributions of the parameters that can be used to estimate the mean, uncertainty
and 95% credible intervals. These uncertainties incorporate measurement error as well
as inherent heterogeneity between individuals in the population. The specification of
physiologically realistic and informative priors is crucial because a large number of
parameters are not identifiable. The plausibility of priors and hyperpriors defined for
use in the population model was checked using prior predictive distribution plots like
the ones in Figure 3.5, taking advantage of the generative property of the Bayesian
model. The MCMC calculations took ∼ 4 weeks, and with such calculations nonconvergence of the MCMC calculations is always a concern. The diagnostics used
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Figure 3.11 Correlation plot for samples from the posterior distribution of θ.

Figure 3.12 Plot of blood plasma geometric mean versus geometric standard deviation for 16 subjects.
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to check for convergence problems included the ESS versus R̂ plots in Figure 3.6
and relative Monte Carlo standard error plots in Figure 3.7. The information given
in these figures along with the absence of any divergences (as reported by Stan)
gives some assurance that the calculations converged and the number of samples
from the posterior distributions of all parameters is adequate to define the posterior
distributions with sufficient accuracy. Posterior predictive distribution plots like those
in Figure 3.8 were used to check the plausibility of the posterior distributions by
comparing simulated bioassay results generated from the population model with the
observed bioassay results. This comparison gives us a good picture of the uncertainty
in the predicted bioassay and is the only reality check available.
The parameters of primary interest are the population-level mean rate matrix θ
and the dispersion parameter τ . The posterior distribution of the dispersion parameter τ is well described by a lognormal distribution with a gm ≃ 2 and a gsd ≃ 1.1.
The marginal medians and 95% credible intervals of θ are tabulated in Table 3.1
where they are compared to the ICRP 134 values of the rate constants. The most
significant differences between the posterior distribution of θ and the ICRP 134 rate
constants can be seen Figure 3.9 where the gsd of each θ is plotted versus its identity
in the top plot and the median of each θ is plotted against the ICRP 134 rate constant
in the bottom plot. The prior distribution for θ had a gsd = 1.5 and the most significant changes in gsd were observed in 9 rate constants involving the blood plasma
and urine. The same 9 rate constants had the greatest change in their median values
compared to the ICRP 134 values. The posteriors of the other 18 rate constants did
not have gm or gsd significantly different than the default values because they don’t
involve the urine or blood plasma. This is expected because these rate constants are
most likely to be influenced by the bioassay data through the likelihood. To improve
the estimates of these rate constants we would have to provide information about the
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associated compartments in the form of more informative priors derived from previous
studies or additional types of bioassay data that involved those compartments.
Of particular interest is the rate constant for the ubc -> urn pathway, which
was reduced from the ICRP default of 12 d−1 to marginal posterior median of 2 d−1 .
The consequences of this change can be readily grasped by comparing the mean
residence time of zirconium atoms in the urinary bladder calculated with the ICRP
134 zirconium biokinetic model with the residence times calculated with the zirconium
population model as shown in Figure 3.10. The distribution of mean residence times
for the population model does not agree with the residence time obtained from the
standard ICRP 134 model. This can in part be attributed to the ICRP urinary
bladder model not providing a distribution for the k[ubc, urn] rate constant and the
model not being intended for the evaluation of urine bioassay (see Appendix J). This
result is nevertheless interesting because the informative prior on k[ubc, urn] was
overwhelmed by the data, suggesting that there is something non-trivial occurring.
For example, the structure of the ICRP 134 zirconium biokinetic model shown in
Figure 3.2 has a single excretion pathway from the blood to the urinary bladder,
bypassing the kidney. This structure, combined with observed bioassay on either side
of the urinary bladder, may be causing the large shift in k[ubc, urn]. This is will be
a subject of future research.
Most correlations between posterior values of θ are in range of approximately −0.4
to 0.4 (see Figure 3.11), which is consistent with the LKJ (η = 10) prior distribution
on the correlation matrix for θ (see Appendix E). The physical interpretation of
these correlations is complex. Consider there is a given amount of zirconium in the
blood plasma and urine at a given time. If, for example, the k[ts, bld1] rate constant
increases, the k[bld1, liv0] rate constant needs to decrease for the predicted content
of these compartments to match the observed contents (i.e., they are negatively cor-
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related). Expand this process to all the rate constants and one can see how it might
be difficult to give a more detailed physical interpretation of the correlation matrix.
The plot of gm versus gsd of the posterior distributions of the blood plasma
volumes for the 16 subjects shown in Figure 3.12 shows that there is not much intersubject variability in the geometric mean volume except for Subject 16, who has a
somewhat implausible blood plasma volume of excess of 10 liters. This volume is
consistent with that estimated by other means and is not an anomaly in the Bayesian
calculation. In contrast, the intrasubject variability in the estimate of the blood
plasma volume as indicated by the geometric standard deviation of the posterior is
quite small, ranging from 1.02 to 1.07. Schmidl et al. (2012) appear to have treated
the blood plasma volume as a known constant in their Bayesian modeling rather than
a parameter to estimate as was done here. The blood plasma volume has a significant
influence on the reference bioassay function for blood plasma, so properly accounting
for its uncertainty can provide more accurate estimates the uncertainties in the intake
and radiation dose.
A population-level Bayesian analysis like the one discussed in this chapter has
two primary practical applications in radiation protection. First, the calculation of
radiation dose can easily be incorporated into the Stan code. The resulting posterior
distribution of the radiation dose for members of the population can be used to establish population exposure limits for radioactive isotopes of zirconium that reflect
sensitive members of the population (Bois et al., 1996, pg 1409; USEPA, 2006). Second, the knowledge gained from the population-level calibration can be incorporated
into the individual-level evaluation of bioassay data from a new, out-of-study subject.
This application is of primary interest in this dissertation. The idea of incorporating
knowledge gained from previous studies into the current study is a strength of the
Bayesian approach, and in the context of this dissertation there are two main ways
of doing this: (i) add the data from the new subject to the data from the 16 study
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subjects and repeat the population-level Bayesian analysis, and (ii) approximate the
posterior distributions of θ and τ from the controlled study in closed form, and use
them as priors in the individual-level analysis of the new subject. These approaches
will be compared in Chapter 4 using the population-level model developed here.
Ultimately, the population-level analysis in this chapter is a proof-of-principle
exercise that shows how researchers who develop biokinetic models for the ICRP can
go about can go about it in a way that provides realistic probability distributions that
incorporate all prior knowledge. In an actual biokinetic model development, prior
information from experimental studies and accidental exposures can be combined
with expert elicitation (high quality SWAGs) to create a highly informative model.
Thus, the goal of this chapter, i.e., to provide a example of a how the ICRP can
create more informative an useful biokinetic models, is fundamentally different than
that of the researchers at HMGU, LANL, and HPE. HMGU (Schmidl et al., 2012) was
concerned with developing new and improved compartmental models for zirconium
using data from controlled experimental studies. LANL (Poudel et al., 2018) and HPE
(Puncher and Riddell, 2016) were concerned with incorporating Bayesian analyses
into production environments, evaluating a large number of subjects with Bayesian
models. Li was primarily concerned with sensitivity and uncertainty analysis of the
zirconium biokinetic model (Li, Greiter, et al., 2011a) and the cesium biokinetic model
(Li, Klein, et al., 2015). The uncertainty analysis of the cesium biokinetic model is
notable because it gives an excellent example of how one might go about generating
informative prior distributions for the parameters in the biokinetic model.
While the work in this chapter has many strengths, there are a number of weaknesses that warrant further work. First and foremost is the complexity of the calculations and the length of time required to perform them. This issue is ameliorated
to some extent because the population level models are designed and evaluated by
expert modelers, which means that the typical end user is not exposed to the full
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complexity of the process. The time required to perform MCMC calculations can
be reduced by optimizing the ODE solvers (e.g., use eigensystems) and to profile the
codes to find and eliminate pinch points. In addition, Stan allows for the use of multiple cores for each chain, which would allow full exploitation of the modern multi-core
processors and high performance computer clusters. The level of complexity end users
are exposed to can be reduced by making MAP calculations available and creating
user friendly wrappers for the Stan code a la those given in the brms R package by
Burkner (2017). Second, to make this work of greater practical use methods need to
be presented for coupling the systemic models like the one in Figure 3.2 to models
for the respiratory tract and GI tract that feed the systemic compartments. This is
a topic of ongoing research.
At the end of the day, all we know for certain about ICRP 134 zirconium biokinetic model is that it is only an approximation to the real world. For example, here
we assume that the kinetics of zirconium in the body can be described by the compartmental analysis, the ICRP model has the correct compartmental structure, and
that movement of material between compartments is governed by first order processes that are independent of time. In a system as complex as the human body
these assumptions are unlikely to hold exactly.
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Chapter 4
Development and Use of Canned Priors
4.1

Introduction

If a worker is inadvertently exposed to a radioactive material in the workplace it is
often necessary to estimate the quantity of material taken into the body, the intake,
from quantities of radioactive material measured in the body or excreta, the bioassay.
Intake, denoted by β, can be estimated with the standard method which uses linear
regression of the observed bioassay on the reference bioassay functions. The reference
bioassay functions, denoted by m, are deterministic functions designed to describe
the dynamics of the assimilated material in the body (ICRP, 2015, pg 32) They
are derived from biokinetic models, which are idealized mathematical representation
of how a material is deposited in the body, subsequently translocated to various
organs and tissues, and ultimately excreted (Boecker, 1998; Harrison, 2009). The
International Commission on Radiological Protection (ICRP) publishes biokinetic
models that are the international standard, being used to calculate intakes from
bioassay data and to calculate permissible concentrations of radionuclides in air and
water (Clarke and Valentin, 2009).
The standard method is a straightforward and quick analysis that gives point
estimates and confidence intervals of the intake, from which corresponding values
of radiation dose can be calculated. However, the standard method has two major
flaws: (i) the ICRP biokinetic model used to calculate m may not adequately describe
the biokinetics of the material in the person, which results in inaccurate estimates
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of intake; (ii) since the standard method assumes deterministic reference bioassay
functions, realistic estimates of the uncertainty in the intake can’t be calculated.
With the standard method, the reference bioassay functions do not vary by person
and thereby miss the inherent heterogeneity in ability of people to naturally remove
the radioactive material from their body. Further, to produce accurate estimates
of uncertainty around the estimated intake we must account for model uncertainty,
measurement error in the data, and uncertainty in the parameters. When using the
standard method these aspects are commonly ignored, resulting in uncertainty that
is underestimated.
Due to the above issues with the standard method, we seek to develop an approach that more effectively shares and uses the current state of knowledge about a
biokinetic model. In Chapter 3, a Bayesian hierarchical model was used to calibrate
the ICRP 134 zirconium biokinetic model shown in Figure 4.1 with the data from
a controlled study where the intakes of zirconium administered to 16 subjects were
known (Greiter et al., 2011). The end result of the Bayesian calibration was a version
of the ICRP 134 zirconium biokinetic model that incorporated prior knowledge on
the distribution of the model parameters, between person heterogeneity, and measurement error, resulting in estimated posterior distributions for the rate constants
in the zirconium biokinetic model. In this chapter, we investigate computationally
efficient methods to share and leverage the Bayesian population-level calibration results to provide point estimates and uncertainty intervals for individual level model
parameters, i.e., intake and radiation dose. The use of previous information is similar
in some respects to transfer learning, a subfield of machine learning, that allows a
population prior to be directly represented in the sampling process for an individual
(Christinaki et al., 2021).
The idea of incorporating data from previous biokinetic modeling studies into the
priors for the current study is discussed by authors like Wakefield (1996, pg 64) and
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Miller (2008, pg 394). In the context of this dissertation there are two ways of doing
this: (i) combine the data from the out-of-study subject to the data from the 16 study
subjects and repeat the population-level Bayesian analysis, or (ii) approximate the
posterior distributions from the population-level study in closed form and use them
as priors in the analysis of the out-of-study subject. The first approach is discussed
by Gelman, Carlin, et al. (2013, Section 5.1) and is referred to here as an add-one-in
analysis. This analysis requires access to all the original data used in the calibration
and to repeat the calibration process with the addition of one out-of-study subject.
The second approach of using posteriors from the population-level calibration
as priors for parameters in the out-of-sample individual-level Bayesian analysis is
referred to as posterior passing (Brand et al., 2019). Passed posteriors expressed as
custom probability density functions have been referred to in the literature as bespoke
priors 1 . Here we are using familiar distributions like a multivariate normal, so the
the passed posteriors will be referred to as canned priors. Canned priors incorporate
between-person and within-person variability in the rate constants and encapsulate
a considerable amount of prior knowledge concerning the biokinetics of a material in
a concise form hat can be easily made available to in the open literature. As will be
discussed in Section 4.4, canned priors also make it feasible to perform a relatively
fast Bayesian evaluation of bioassay data and have the potential to make a Bayesian
analysis accessible to individuals with minimal background in statistics.
The canned prior Bayesian model is evaluated using Markov Chain Monte Carlo
(MCMC) as implemented in the computer code Stan (Carpenter et al., 2017), which
provides full posterior distributions of all parameters. However, once this model
is defined point estimates of parameters can be obtained from the maxima of the
unnormalized posterior distribution. These quick and computationally inexpensive
1

The term means “made for a particular customer or user”, and in this context refers to a custom
probability distribution created for a particular purpose.
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maximum a posteriori (MAP) point estimates are superior to those obtained from the
standard method but do not provide all the information as the full Bayesian analysis,
i.e., no realistic estimates of uncertainty are provided,
A simple example of posterior passing used in an occupational internal dosimetry
evaluation was performed by James, Birchall, and Puncher (2008) when they took
the posterior distributions of 3 respiratory tract model parameters derived from the
analysis of one individual and used them as the prior distributions for the analysis
of data from another individual. On a larger scale, Puncher and Riddell (2016)
calculated the radiation doses to over 11000 radiation workers using prior distributions
for the respiratory tract model parameters derived from a previous study (Puncher,
Birchall, and Bull, 2011). The details concerning how the prior distributions were
constructed in that study are given in an internal report that is not available in the
open literature.
In this chapter, the bioassay data from two out-of-study subjects will be evaluated.
These subjects were part of the Greiter et al. (2011) study but were not included in
their final analysis and were not used in the Bayesian calibration detailed in Chapter
3. Specifically, we will compare performing an individual-level analysis using using:
(i) the standard method, (ii) the add-one-in Bayesian approach, and (iii) the canned
prior Bayesian approach. In addition, MAP estimates based on the unnormalized
posterior distribution of (iii) will be calculated. These methods are discussed along
with the methods used to calculate the canned priors. Then the final canned priors
are presented along with the intake estimates from the four methods. The chapter concludes with an assessment of the relative performance of each method and a
discussion of their pros and cons.
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4.2

ICRP 134 Zirconium Biokinetic Model

The biokinetic model for zirconium shown in Figure 4.1 is given in ICRP Publication
134 (Paquet, Leggett, et al., 2016, Page 273). This model consist of compartments
between which the movement of material is described by a system of first-order ODE.
The system of ODE can be solved to give the fraction of a unit intake of the zirconium
that is present in each compartment, or any combination of compartments at any time
after the intake.
The content of each of the nc = 16 compartments in the ICRP zirconium model
can be represented by the following system of nc ODE
dq1 (t)
= q˙1 (t) = − k11 q1 (t) + k21 q2 (t) + · · · + knc 1 qnc (t)
dt
dq2 (t)
= q˙2 (t) =k12 q1 (t) − k22 q2 (t) + · · · + knc 2 qnc (t)
dt
..
.

(4.1)
(4.2)

dqnc (t)
= qn˙ c (t) =k1nc q1 (t) + k2nc q2 (t) + · · · − knc nc qnc (t),
dt
where qi (t) describes the content of compartment i at time t,

dqi (t)
dt

describes the

rate of change in compartment i at time t, and kij describes the instantaneous rate at
which zirconium is transferred from compartment i to compartment j. Note that rate
constants for compartments with no connections are equal to 0. The rate constants
for the ICRP 134 zirconium model are given in Table 3.1.
The rate of change of the ith compartment can be expressed as
q˙i (t) =

X

kji qj (t) − kii qi (t) ,

(4.3)

j̸=i

where kii is the sum of all the rate constants that govern the transfer of material out
of compartment i by all routes, and is given by
kii = λ +

X
j̸=i
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kij ,

(4.4)

where the constant λ is added to account for removal by radioactive decay (Turner,
Downing, and Bogard, 2012, page 15; Claudio Cobelli, Foster, and Toffolo 2007,
Section 2.3). For the stable isotopes of zirconium like those used in the Greiter study
λ = 0.
The ODEs in (4.1) can be presented concisely in matrix notation as
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(4.5)

or q̇ = kq, where k is referred to as the rate matrix. The goal is to solve this
system of ODE for the quantity of zirconium qi (t) of each compartment i at time
t. There are a number of different ways to accomplish this, but here we will use the
matrix exponential which is a computationally simple and fast method for solving
linear systems of ODE that is available in the MCMC computational software (Stan
Development Team, 2021b, pg 181). The matrix exponential solution to the system
of ODE is
qt = exp (kt) q0 ,

(4.6)

where q0 is the initial contents of the compartments at t = 0, i.e., the initial conditions
needed to solve the ODE. The initial quantities q0 of zirconium in the compartments
are 1 for blood plasma-1 and 0 for the other compartments because we are assuming
an intravenous injection of a unit quantity of zirconium into blood plasma-1. Thus,
for this model the initial content of the blood plasma-1 compartment is the intake.
The collection of compartments in the biokinetic model that corresponds to what
was measured in a bioassay is referred to a reference bioassay function mj = m(tj )
at times tj (Paquet, Leggett, et al., 2016). For blood plasma, the reference bioassay
function will be the sum of blood-1 and blood-2 compartments. In practice, mj,p must
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account for the volume of the blood plasma compartment, which is incorporated via








q1 tpj + q2 tpj



mj,p ≡ mp tpj , vj =

vj



(4.7)

,

where tj is a vector of time points and vj is the volume of blood plasma, respectively,
for the jth subject (see Appendix B for more details on the calculation of blood
volume). Note that mj,p and mj,u are also a function of the rate matrix k and the
initial quantities q 0 but these parameters are suppressed for the moment to make the
notation more concise. The quantity of zirconium in an incremental urine sample has
the reference bioassay function












mj,u ≡ mu tuj , ∆tj = q12 tuj − q12 tuj − ∆tuj ,

(4.8)

where tuj is the time at which the collection of urine ended and ∆tuj is the time
interval over which the urine was collected. In practice, an individual collects an
incremental urine sample by completely voiding his bladder at time t1 . All subsequent
urine voids are collected until a later time t2 , when the individual completely voids his
bladder one last time, completing the incremental urine sample. By convention, in the
incremental urine reference bioassay function the time of the sample tj = t2 and the
collection interval ∆tuj = t2 − t1 . Collection intervals used in the Greiter zirconium




study were either 12 hours or 24 hours. The quantity variable mj = mpj , muj is a
nj × 1 vector that consists of the npj plasma reference bioassay functions stacked on
top of nuj urine reference bioassay functions.

4.3

Data

Greiter et al. (2011) performed a controlled study where known quantities of nonradioactive zirconium were injected in volunteer subjects. The zirconium in the blood
plasma and urine of the subjects was measured at various times afterwards. Subjects
Zr0101102 and Zr0102004 were participants in the Greiter study but their data were
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Figure 4.1 ICRP 134 biokinetic model for zirconium.
not used in the development of the zirconium biokinetic model discussed in Greiter
et al. (2011). The quantity of injected zirconium is normalized to be β = 1 for both
subjects and their blood plasma volumes are known, so evaluation of the bioassay
data from these out-of-study subjects allows us to compare the predictive power and
ability to accurately characterize uncertainty of the various approaches for these key
parameters. The blood plasma and urine bioassay measurements for these subjects
are shown in Figure 4.2, where the error bars are the 95% coverage intervals calculated
according to guidance given in the ISO Guide to the Expression of Uncertainty in
Measurement (GUM) (ISO, 2008).

4.4

Methods

Four different ways of calculating intake from bioassay data are discussed: standard
method, add-one-in Bayesian analysis, canned prior Bayesian analysis, and MAP
analysis. With reference to the canned prior Bayesian analysis, four different distributions are examined for fitting samples from the posterior distribution of θ in the
population model to create canned priors: multivariate Gaussian mixture (MGM),
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Figure 4.2 Concentration of zirconium in blood plasma (left column) in units of
percent of injected dose per kg of blood plasma and urinary excretion rate (right
column) of zirconium in urine with units of percent of injected dose per hour for
subject Zr0101102 (top row) and Zr0102004 (bottom row). Error bars are the 95%
GUM coverage intervals.
multivariate normal (MVN), and two multivariate Student’s t distributions – one
with 20 degrees of freedom (MVT20) and one with 4 (MVT4).

4.4.1

Standard Method

For n bioassay measurements from an individual we assume the relationship between
M and m is represented as

M (ti ) = β · m (ti ) + εi ,

i = 1...,n

(4.9)

where ε is the n × 1 vector of heteroscedastic regression error with E (ε) = 0 and
var(εi ) = σi2 . The values of the reference bioassay functions for zirconium in urine
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and blood plasma were calculated by solving a system of ODE that yields predictions
for the amount of material in various biological systems at time t as described in
Section 4.2. The system of ODE are functions of rate constants and the content of
the compartments at t = 0, i.e., the initial conditions; the ICRP models use fixed
values for the rate constants (this is relaxed in the proposed methods).
The ratio E [M (t)] /m (t) = β represents the quantity of zirconium injected into
the individual (the intake). The estimate of the intake β can be made using a weighted
linear regression of M on m, which gives a straight line with a slope equal to the
intake. The regression minimizes the weighted residual sum of squares WRSS
W RSS =

n
X

wi [M (tj ) − βm (tj )]2 ,

(4.10)

j=1

where wi are the weighting factors that are required because bioassay measurement
errors are heteroscedastic (Claudio Cobelli, Foster, and Toffolo 2007, Chapter 10;
Skrable, Chabot, et al., 1994). Commonly used weighting factors are analytical measurement uncertainties u or functions of the observed or predicted bioassay measurements (Skrable, French, et al., 2002; Wakefield, 1996; Wakefield, Aarons, and
Racine-Poon, 1999). Here, the weight w of each datum as its taken to be its squared
relative uncertainty
wi =

ui
M (ti )

!2

(4.11)

,

because the large difference in the magnitude of the urine and blood plasma measurements. The estimated intake is
n
P

β̂ =

[wi M (ti ) m (ti )]

i=1
n
P

wi [m (ti )]2

,

(4.12)

i=1

with an estimated standard error

σ̂β =

v

2
uP
n
u
wi M (ti ) − β̂m (ti )
u
u i=1
u
.
n
P
t
2

(n − 1)

wi [m (ti )]

i=1
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(4.13)





The 95% confidence interval of the intake is β̂ ± t1−α/2,n−1 σ̂b , where t1−α/2,n−1 is the
Student’s t quantile with n−1 degrees of freedom and a significance level of α = 0.05.

4.4.2

Prior for Blood Plasma Volume

The blood plasma volume used to calculate the reference bioassay functions has a
significant impact on the estimate intake. In the standard method the blood plasma
volume is assumed to be 3 liters for all individuals (see Appendix B). However, prior
distributions for blood plasma volume are needed for the add-one-in, canned prior,
and MAP analyses. When evaluating the data from an out-of-study individual whose
intake and blood plasma volume are not known, the prior for the blood plasma volume
is
v ∼ LN (µv , σv )

(4.14)

where µv = log (vr ), with vr calculated using published regression fits of blood plasma
volume to height, weight, and sex as described in Appendix B. The log standard deviation is σv = log (1.2), where geometric standard deviation of 1.2 was chosen to be
reasonably informative based on what was observed in the study population (see Figure 3.12) while allowing for relatively large deviations of the true blood plasma volume
expected when it is predicted using the published regressions. Subject Zr0101102 is
a 59 kg female with a measured blood plasma volume of 1.75 liters and an estimated
blood plasma volume of
vr = (24.0 · 59 + 872)/1000 = 2.29 liters.

(4.15)

Subjects Zr0102004 is a 78 kg female with a measured blood plasma volume of 3.13
liters and an estimated volume of
vr = (24.0 · 78 + 872)/1000 = 2.74 liters.
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(4.16)

For each subject the posterior distribution of blood plasma can be compared to the
measured value to gauge the predictive power of the model for this important parameter.

4.4.3

Add-One-In Bayesian Analysis

The calibration performed in Chapter 3 provided probability distributions for all the
parameters in the ICRP 134 zirconium biokinetic model. The most direct way to
perform a Bayesian analysis of an out-of-study subject is to add the subject’s data to
that of the 16 subjects used in the calibration and repeat the calibration, i.e., perform
an add-one-in analysis.
The add-one-in Bayesian model can be concisely expressed as
p (ψ|M ) =

p (M |ψ) p (ψ)
,
p (M )

(4.17)

where the the parameter vector ψ is
ψ = {k, θ, Π, Ω, τ, β, v}

(4.18)

and the prior
p (ψ) = p (k|θ, Π) × p (θ) × p (Π|Ω, τ ) p (Ω) p (τ ) × p (β) × p (v) .

(4.19)

The constant of proportionality is the marginal probability density of the data M
ˆ
p (M ) =

p (M |ψ) p (ψ) dψ.

(4.20)

A directed graph of this model (which describes both the add-one-in and canned prior
analyses) is shown in Figure 4.3. The bioassay M = {M1 , . . . , M16 , M17 } have the
data from the 16 study subjects used to calibrate the ICRP 134 zirconium biokinetic
model with the data from the out-of-study subject 17 appended on the end of the
vector. The only significant differences between the calibration and the add-onein calculation are: (i) the data from out-of-study subject are added to that of the
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16 study subjects, giving 17 subjects in the analysis; (ii) the out-of-study subject’s
intake is an unknown parameter to be estimated and is assumed to have a lognormal
prior with a gm = 1 and a gsd = 1.2 whereas the 16 study subjects have known
intakes β = 1, i.e., have a degenerate prior for β; (iii) the geometric mean of the
lognormal prior distribution of the blood plasma volume for the out-of-study subject
is determined as discussed in Section 4.4.2 whereas the blood plasma volume of the
calibration subjects were determined experimentally at the time of the study.
Priors and hyperpriors in biokinetic models are generally assumed to follow normal or lognormal distributions (Davidian, 2006, pg 18), and lognormal distributions
are primarily used in (4.19) because the true values of the parameters of interest are
physically constrained to be non-negative and tend to be right skewed (see Appendix
D). The hyperprior θ j describes the population level mean of the rates while the covariance matrix Πj describes the dispersion of the individual level rate parameters kj
from the population level means. The covariance matrix Πj is decomposed (Barnard,
McCulloch, and Meng, 2000) into the log of the geometric standard deviation τ and
a correlation matrix Ω, which is modeled with the same LKJ (η = 10) distribution
(Lewandowski, Kurowicka, and Joe, 2009) used for the population-level analysis. The
decomposition allows us to focus our attention on estimating the geometric standard
deviations, for which we might have some intuition, and then apply a simplified distribution to the correlations, for which we probably do not. The log of the geometric
standard deviation τ is modeled with a normal distribution truncated at 0 and the
plasma volume vj is modeled with a lognormal distribution. The reader is referred to
Chapter 3 for a more detailed description of the prior and hyperprior distributions
and Section 4.5.2 for a discussion of the how the MCMC code Stan was used used to
generate the posterior samples. The reference bioassay functions for urine and blood
plasma, mu and mp respectively, are calculated as described in Section 4.2. The
reference bioassay functions combined with the bioassay data M and their associated
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Figure 4.3 Bayesian model for evaluating bioassay data with the intent of estimating
the intake, the individual level rate matrix, and blood plasma volume (nodes in pink).
The nodes for parameter distributions are denoted by ellipses, computed parameters
by rectangles, and data by dashed rectangles. For canned prior Bayesian analysis the
nodes in blue are the canned priors.
uncertainties Σ comprise the likelihood, which is a Student’s t distribution with 4
degrees of freedom.

4.4.4

Canned Prior Bayesian Analysis

In this Section we assume that we have fitted distributions for for the population
level parameters θ and τ that can be easily sampled from, i.e., canned priors. We
will discuss how these distributions can be used to get posterior samples of the intake, blood plasma volume, and rate constants for a single subject not used in the
calibration of the model parameters.
The canned prior Bayesian model is the same as the add-one-in model defined in
equations (4.17) through (4.20) and Figure 4.3 except the parameter vector ψ has
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the canned priors p (θc ) and p (τc )
p (ψ) = p (k|θ, Π) × p (θc ) × p (Π|Ω, τc ) p (Ω) p (τc ) × p (β) × p (v) ,

(4.21)

and M = M17 , i.e., the data vector is for the out-of-study subject only. As with the
add-one-in analysis, the intake is assumed to have a lognormal prior with a gm = 1
and a gsd = 1.2. A discussion of the MCMC calculations used to generate the
posterior samples is given in Section 4.5.2.
The bioassay data for the two out-of-study subjects were analyzed using the truncated normal canned prior for log (τc ) along with the MGM and MVN canned priors
for log (θc ). Intake evaluations were not performed with the MVT4 or MVT20 canned
prior for log (θ) because of their relatively poor fit compared to the MGM and MVN
distributions. However, if longer tails are desired in the sampling distribution of θ in
a particular analysis, a useful tactic is to plug the parameters for the MVN canned
prior into a MVT sampling distribution with the desired degrees of freedom in Stan.
This is referred to as an MVT/MVN parameterisation of the MVN canned prior,
which was used in an intake evaluation to explore its relative performance. MAP
estimates of the parameters in the MVN canned prior model were calculated with
the Stan optimize function, which utilizes the LBFGS algorithm (Stan Development
Team, 2021a, Ch 10).

4.5

Computational Details

In this Section we discuss the estimation of the canned prior, which is basically an
exercise in density estimation. The results of this analysis are given in Section 4.6. In
addition, details are given on how the add-one-in and canned prior Bayesian MCMC
calculations were performed.
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4.5.1

Estimation of Canned Priors

In this Section we discuss the estimation of the canned priors using samples from
the posterior distributions θ and τ (the blue shaded nodes in Figure 4.3) from the
posterior samples obtained from the population-level analysis in Chapter 3. We want
to approximate the distributions of these parameters by fitting the samples from
the posterior with probability distributions that can be easily sampled from. These
distributions are the canned priors; in the following Section we discuss how they can
be utilized to estimate the posterior distributions of the intake β, the blood plasma
volume v, and the rate constant matrix k for an individual. Given the distributions for
these parameters the distributions for all other quantities of interest like the radiation
dose can be calculated.
We estimate the canned priors for θ and τ separately, as there was no indication
of dependence between the posterior samples of these quantities. For τ , we found that
posterior samples of log (τ ) reasonably resembled a normal distribution. This model
was fit using the fitdistr function from the MASS R package (Venables and Ripley,
2002). For θ, we considered four different multivariate distributions for log (θ) in an
effort to identify the distribution that best fit the samples. First, since the posterior
samples of log(θ) for all parameters were reasonably bell shaped, we considered a 27
dimension multivariate normal distribution (MVN)
f (log (θ)) = N (µ, Σ) ,

(4.22)

where µ is the vector of location parameters and Σ is the scale matrix. This model
can be fitted using the mvn function from the mclust package (Scrucca et al., 2016).
To allow for some potential departures from normality we tested the two component
multivariate Gaussian mixture model (MGM)
f (log (θ)) = πN (µ1 , Σ2 ) + (1 − π) N (µ2 , Σ2 ) ,
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(4.23)

where π is the mixing fraction, and {µ1 , Σ1 }and {µ2 , Σ2 } are the parameters of the
first and second multivariate normal component of the mixture, respectively. MGM
have been shown to be able to well represent a large variety of distributional forms
(Everitt, 1996; Green, 2018). This model can be fitted using the mvnormalmixEM
function from the mixtools package (Benaglia et al., 2009). Finally, we considered
the scaled, shifted and skewed multivariate Student’s t distribution
f (log (θ)) = tν (µ, Σ, λ) ,

(4.24)

where ν is the degrees of freedom, µ is the vector of location parameters, Σ is the scale
matrix, and λ the vector of skew parameters. Two different MVT distributions were
fitted, one with ν = 4 degrees of freedom and one with ν = 20 degrees of freedom
(MVT4 and MVT20, respectively), using the mstFit function from the fMultivar
package (Wuertz, Setz, and Chalabi, 2020).

4.5.2

Details of MCMC Calculations

The posterior distributions of the parameters given the data as described by (4.17)
reflect all the information contained in the data given the prior distributions. All
inferences are made with the posterior distributions of the parameters. In particular,
the mean of each posterior distribution is commonly used as the point estimate of the
parameter and the width of the posterior distribution is a measure of the uncertainty
in the parameter estimate (Hack, 2006, pg 245). The statistical model for zirconium is
too complex to obtain analytical solutions to the posterior distributions, so estimates
are by drawing samples directly from the posterior distributions using MCMC and
analyzing these samples (Gelman, Carlin, et al., 2013).
The “No U-Turn Sampler” (NUTS) variant of Hamiltonian Monte Carlo (Lambert,
2018, Ch 15; Monnahan, Thorson, and Branch, 2017; Kruschke, 2015, Ch 14) as implemented in the the computer code Stan (Carpenter et al., 2017) is used to generate
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the samples from the posterior distributions. NUTS is essentially the MetropolisHastings sampler where the proposal step incorporates information about the local
geometry of the log posterior distribution based on the motion of a particle on the
surface of the log posterior. This information allows NUTS to make good proposals
with a high acceptance rate, which results in efficient exploration of the complex parameter space. NUTS is somewhat unique in that it provides feedback on whether
the sampler is working properly, as discussed below. The Stan MCMC calculations
discussed in this dissertation were performed with cmdstan 27.1 interface (Stan Development Team, 2021a) using the codes and bash scripts discussed in Chapter 5.
The two computers used had Intel Core i7-7820X and Intel Core i9-10900X CPUs,
both with 128 GB of memory running the Linux Mint 20.2 operating system. Calculations were performed with one chain per core. Data preparation and analysis were
performed with R 4.1.1 (R Core Team, 2021).
For the add-one-in MCMC analysis, 1 chain consisting of 3000 iterations for warm
up (to tune sampling parameters of NUTS) and 10000 iterations was calculated for
each subject. For the analysis using the MVN canned priors, 3 chains were calculated
for each subject, with 4000 iterations for warm up and 15000 iterations for sampling
in each. For the analysis using the MGM canned priors, 2 chains were calculated
for each subject, with 4000 iterations for warm up and 15000 iterations for sampling
in each. Finally, for the MVN/MVT parameterization of the MVN canned priors, 1
chain was calculated for each subject, with 4000 iterations for warm up and 15000
iterations for sampling in each. The number of chains and samples obtained for a
particular canned prior reflects the level of interest in that canned prior, with the
MVN being of most interest.
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Table 4.1 Comparison of fits to the samples from the posterior distribution of θ,
where loglik is the log likelihood, k is the number of parameters in the model, and
BIC is the Bayesian Information Criterion.
Model
MGM
MVN
MVT20
MVT4
4.6

loglik
−1.025952 × 106
−1.044802 × 106
−1.062339 × 106
−1.113732 × 106

k
758
378
405
405

BIC
2.060702 × 106
2.093992 × 106
2.12938 × 106
2.232166 × 106

Results

The results of the fits of the 4 different canned prior distributions to the populationlevel posterior samples of θ are presented. Next, results of the evaluations of the
two out-of-study subjects using the 4 different methods described in Section 4.4 are
presented: a summary of the intakes and 95% intervals given in Table 4.2; the M
versus m scatter plots in Figure 4.4; density plots of the blood plasma posterior
distributions in Figure 4.6.

4.6.1

Canned Posterior Distributions

The canned prior τc is the truncated normal distribution
log (τc ) ∼ T N (log (1.991) , log (1.061) , 0) .

(4.25)

Samples from the posterior distribution of θ where fit with four different distributions. The results are summarized in Table 4.1 with details of the calculations given
Appendix H. The models, in order of lowest to highest BIC – best to worst are:
M GM < M V N < M V T 20 < M V T 4.
The skew of the Student’s t distributions were essentially 0, i.e., the fitted distributions were symmetric scaled and shifted t distributions. The comparison of BIC for
the 4 models indicates that the data are fit better with distributions having normal
tails than with distributions having longer tails (i.e., the Student’s t distribution with
4 degrees of freedom). Both the MVN and MGM canned priors were used in the eval81

uation of the data from the two out-of-study subjects and it was observed that: the
calculations take approximately twice as long with the MGM canned prior versus the
MVN canned prior; the MCMC using the MGM prior is less efficient than with the
MVN prior, i.e., the effective sample sizes are 10 to 100 times smaller for the MGM
prior for a given number of iterations; the distributions of intakes are essentially the
same for both priors (see Table 4.2).

4.6.2

MCMC Diagnostics

Stan did not report divergences for any of the add-one-in or canned prior Bayesian
MCMC calculations, which is an indication that there are no overt signs of nonconvergence. MCMC diagnostics were performed with the R package posterior (Vehtari et al., 2021). The effective sample size (ESS), which an indication of the degree
to which the MCMC samples are autocorrelated, was > 400 in all cases. R̂, which is
an indication of non-convergence of the MCMC chains, was < 1.01 for all parameters.
The relative Monte Carlo standard error of the mean versus the absolute value of the
mean is below 10% for all parameters. Additional details on these diagnostics are
presented in Appendix I.

4.6.3

Results of Evaluations Using Different Methods

The results for the standard method analysis of the bioassay from the two out-ofstudy subjects are shown in the scatter plots of M versus m in Figure 4.4. The
estimated intake β̂ and standard error of the intake σ̂ are shown on each plot, with
the β̂ and their 95% confidence intervals given in Table 4.2.
The add-one-in analysis took ∼ 30 days for each subject whereas the canned prior
Bayesian analysis with the MVN prior took ∼ 7 hours. For these two analyses: the
scatter plots of M versus m for both subjects are shown in Figure 4.4; in Figure
4.5 posterior intake distributions from the add-one-in analyses, the standard method,
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Table 4.2 Summary of intake estimates for subjects Zr0101102 and Zr0102004 calculated using: the standard method (Standard); MGM, MVN, and MVT/MVN canned
Bayesian analysis; add-on-in Bayesian analysis (Bayes AOI), and maximum a posteriori (MAP) analysis. Uncertainties for MAP are not reported by Stan. The true
value of the intake is β = 1 for both subjects.

Subject
Zr0101102
Zr0101102
Zr0101102
Zr0101102
Zr0101102
Zr0101102
Zr0102004
Zr0102004
Zr0102004
Zr0102004
Zr0102004
Zr0102004

Method
MGM
MVN
MVT/MVN
Standard
Bayes AOI
MAP
MGM
MVN
MVT/MVN
Standard
Bayes AOI
MAP

0.025
0.7826
0.778
0.7823
1.148
0.8504
0.7538
0.7546
0.7527
0.7686
0.7498

Quantiles
0.5
0.975
1.008
1.3
1.007
1.304
1.009
1.31
1.263
1.378
1.05
1.309
1.031
0.9692
1.247
0.9706
1.254
0.9658
1.246
0.8549
0.9412
0.9129
1.122
0.9249

and the canned prior analysis are compared; the intake estimate and its 95% credible
interval are given in Table 4.2; in Figure 4.6 the posterior distributions of the blood
plasma volumes for both subjects are compared to the true values. The scatter plots
of M versus m for both subjects using the MAP analysis of the MVN canned prior
posterior distribution are given in Figure 4.4 and the intake estimate in Table 4.2.
The canned prior Bayesian analysis performed with the MGM prior took ∼ 15
hours and the intake evaluation using MVT/MVN parameterization of the MVN
prior took ∼ 7 hours. The intakes and credible intervals obtained from evaluations of
bioassay data preformed with the MGM and MVT/MVN evaluations are shown in
Table 4.2 and the scatter plots of M versus m for both subjects are shown in Figure
4.4.
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Figure 4.4 Comparison of results for Subject Zr0101102 (left column) and Subject
Zr0102004 (right column) using, from top to bottom: standard method, add-one-in,
MVN canned prior, MAP.
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Figure 4.5 The posterior distribution of β̂ calculated for Zr0101102 (left) and
Zr0102004 (right) with standard method (blue), add-one-in Bayesian analysis (black),
and MVN canned prior Bayesian analysis (red). The true value of the intake is β = 1
for both subjects. The vertical lines on the distribution of β in denote the 95%
confidence or credible interval.

Figure 4.6 Posterior distribution of blood plasma volume for subjects Zr010102 (left)
and Zr0102004 (right) from MVN canned prior analysis (red) and add-one-in analysis
(black) . The vertical dashed lines on the distributions of denote the 95% credible
interval and the vertical dashed line is the true blood plasma volume.
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4.7

Discussion

In this chapter we addressed the problem of evaluating bioassay data from a specific
individual who has been exposed to radioactive materials. The bioassay data from
out-of-study subjects Zr0101102 and Zr0102004 shown in Figure 4.2 were analyzed
using four methods: (i) the standard method that consists of a linear regression of
M on m, where m is calculated from the unmodified ICRP 134 zirconium biokinetic
model; (ii) the add-one-in Bayesian analysis where data from the out-of-study subject
is combined with the data from the 16 study subjects and the calibration described in
Chapter 3 repeated; (iii) the canned prior Bayesian analysis where familiar distributions are fit to posterior samples from the calibration are used as priors in a Bayesian
analysis of a single subject; (iv) MAP analysis of the posterior distribution from the
canned prior Bayesian analysis. In the development of the canned priors, 4 different
multivariate distributions were fit to the log of the posterior samples from θ in an
effort to identify the distribution that best fit the samples.
The canned Bayesian analysis and comparison of it with the standard method is
of primary interest, and most of this discussion will focus on that comparison. The
add-one-in Bayesian analysis is included primarily to highlight the advantages of the
canned prior Bayesian analysis over the add-one-in. The MAP analysis illustrates an
inexpensive and potentially useful way to calculate intakes if estimates of uncertainty
are not needed.
The relative performance of each method is judged by its ability to recover the true
values of the intake and blood plasma volume. In other words, are the true values
of these parameters in the 95% intervals? The analyses are also compared on the
agreement between the predicted and observed bioassay, i.e., is there lack-of-fit? For
the standard method only the intake and lack-of-fit checks are performed, and with
MAP analysis only the lack-of-fit check is performed. Finally, the time required to
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perform each analysis is an important metric in practice that will be used to compare
the performance of the methods.

4.7.1

Analysis with the Standard Method

The standard method of regressing M on m is a simple and quick analysis used in
occupational internal dosimetry to give estimates of the intake (IAEA, 2004; Skrable,
Chabot, et al., 1994). This method was used on the bioassay data for the two outof-study subjects, the results of which can be seen in the M versus m scatter plots
in the first row of Figure 4.4. Outliers are seen in the bioassay data for both out-ofstudy subjects. Subject Zr0101102 has 3 urine samples and Zr1012004 has 4 blood
plasma results that do not fall near the regression line. This is likely the result of a
combination of measurement error in those bioassay results that is not accounted for
in their stated uncertainties and the biokinetics of zirconium in the individuals being
different than the biokinetics specified by the ICRP 134 zirconium model, i.e., model
misspecification.
In the linear regression the sum of the weighted squared difference between the
observed and predicted bioassay results are minimized. As clearly shown by (4.13),
the confidence intervals on the slopes shown in the plots are a function of this difference and the the measurement uncertainty. The uncertainty in the intake does
not consider the uncertainty in the reference bioassay functions, which are treated
as known constants. This means that the 95% confidence intervals on the intake are
too narrow because they do not account for the uncertainty in the reference bioassay
functions. Nevertheless, since the 95% confidence intervals on the intakes for both
subjects do not contain the true value of the intakes from these plots we conclude
that the intake estimates are inaccurate because of misspecification of the biokinetic
model.
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In most practical applications, the shortcomings of the standard method can be
safely ignored because the radiation doses are usually much lower than the applicable
regulatory limits and don’t warrant further refinements. However there are cases
where radiation doses exceed regulatory limits and steps should be taken to reduce
model misspecification and to estimate realistic uncertainties (NCRP, 2010, pg 2),
which is the motivation behind the Bayesian analyses.

4.7.2

Add-One-In Bayesian Analysis

If a Bayesian analysis has been performed on a given dataset and then additional
data are obtained, one can update the analysis by adding the new data to the existing
dataset and repeating the analysis (Gelman, Carlin, et al., 2013, Section 5.1). Thus,
the Bayesian analysis of an out-of-study subject can be performed by adding the
that subject to the 16 calibration study subjects and performing the population level
Bayesian analysis described in Chapter 3, which is referred to here as an add-one-in
analysis. Overall, the results of the add-one-in analysis are similar to those obtained
from the MVN canned Bayesian analysis discussed in the next section, but take much
longer than the canned prior Bayes analysis to run (weeks versus hours).
The intakes and blood plasma volumes of the two out-of-study subjects are known
because they were part of the study by Greiter et al. (2011), but they were not used
by Greiter and were not part of the calibration in Chapter 3. To test the predictive power of the add-in-in analysis the intakes of these two out-of-study subjects
are treated as unknown parameters to be estimated and their blood plasma volumes
are estimated using published regressions. Treating the intake of one subject as an
unknown parameter and the others as known constants required a minor change in
the Stan code used for the calibration. The plots of M versus m in the second row
of Figure 4.4 show that the true value of the slope, i.e., β = 1, is in the 95% credible
interval for the estimated slope for both subjects. Comparisons of the intake distri-
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butions calculated with the standard methods are compared to intake distributions
calculated using add-one-in Bayesian analysis in the first row of Figure 4.5. Estimated intakes and associated 95% credible intervals are given in Table 4.2. The true
value of the intakes are in the 95% credible intervals of the intakes calculated with
the add-on-in Bayesian method, which is not the case for the intakes calculated with
the standard method.
The distribution of blood plasma volumes calculated in the add-one-in analysis
were compared to the true blood blood plasma volumes determined experimentally.
The true value of the blood plasma volume is in the 95% credible interval of blood
plasma volume calculated for subject Zr0102004 but not for subject Zr0101102 (see
Figure 4.6). The blood plasma volume has a direct influence on the calculation of
the reference bioassay function for blood plasma. Thus uncertainty in the blood
plasma volume can be a significant contributor to the uncertainty in many parameter
estimates.

4.7.3

Canned Priors

The main problems with the add-one-in Bayesian analysis are: in practice the internal dosimetrist will not have access to the data used to calibrate the ICRP biokinetic
model, and it is expensive in terms of time and resources to repeat the calibration
procedure in order to get results for one subject. Rather than repeating the calibration we can summarize the posterior distributions of key parameters probability
distributions that are easily sampled and use them as priors for the out-of-subject
analysis. The procedures used to create these canned priors for the rate matrix θ
and dispersion parameter τ (the purple colored nodes in Figure 4.3) are described in
Section 4.6.1.
The distribution of samples from the posterior of log (τ ) are fit well with a normal
distribution given in (4.25). The fits of four different multivariate distributions to the
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posterior samples of log (θ) were considered: multivariate Gaussian mixture (MGM)
with 2 components, multivariate normal distribution (MVN), skewed t distribution
with 20 degrees of freedom (MVT20), and a skewed t distribution with 4 degrees
of freedom (MVT4). The distributions with normal tails (MGM and MVN) fit the
data better than the distributions with long tails (MVT4 and MVT20) using the
Bayesian Information Criterion to measure the goodness of fit. The canned prior
constructed with MVN has essentially the same means and standard deviations as
the posterior samples from the population-level model for all parameters, indicating
a good fit was achieved. The MVN and MGM canned priors produced estimates of
intake and predicted bioassay distributions (see Table 4.2) that were essentially the
same, but models using the MVN canned priors were sampled much more efficiently
by Stan than models using the MGM canned priors and ran twice as fast. Thus,
most of the discussion in this chapter focuses on the MVN canned priors because of
their relative simplicity and resulting ease of presentation. However, MGM canned
priors will be considered in the future for use with biokinetic models for materials
other than zirconium (e.g., plutonium) where the addition flexibility of the MGM
distribution might be advantageous.

4.7.4

Canned Prior Bayesian Analysis

The individual-level canned Bayesian analyses were considerably less complex than
the add-on-in Bayesian analysis performed. Stan efficiently generated samples from
the posterior distributions in a matter of hours that resulted in precise parameter
estimates. The results of the canned Bayesian intake analysis can be seen in the M
versus m scatter plots in the third row of Figure 4.4 show that the true value of the
slope, i.e., β = 1, is in the 95% credible interval for the estimated slope for both
subjects. This is made even more obvious in Figure 4.5, where the probability distributions of the intakes calculated by the canned Bayesian analysis are compared to the
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intake distribution of intakes calculated with the standard method. The 95% credible
intervals of the canned prior Bayesian analysis are wider than the 95% confidence intervals produced by the standard method because they incorporate the uncertainty in
the biokinetic model and the data model and are thus more realistic representations
of the true uncertainty in the intake estimates.
The main cause of the inaccurate estimate of intake for Zr0102004 calculated by
the standard method is the 4 blood plasma outliers. This can be seen by comparing
the plots in the first row of of Figure 4.4 (standard method) with those in the third
row (canned Bayesian method). The 4 blood plasma outliers in the standard method
plot are shifted to the left in the canned Bayesian analysis plot, resulting in a better
overall fit to the data. This horizontal shifting is the result of the rate constants in
the zirconium biokinetic model being modified during the Bayesian analysis in order
to achieve a better fit to the data. This disciplined modification is possible because
the rate constants in the biokinetic model have a probability distribution rather than
being constants and informative priors are used. Outliers like these are commonly
observed in bioassay data and can be caused by some combination of measurement
errors and systematic differences between the biokinetics of the individual and the
biokinetics of the ICRP model. The choice of the data model can also be related
to whether data are considered outliers, so a Student’s t distribution was chosen
for the data model (likelihood) rather than a normal distribution in order to better
accommodate outliers.
The inaccurate intake estimated by the standard method for Zr0101102 is caused
primarily by her small blood plasma volume compared to that used by the ICRP
134 biokinetic model. This can be seen in the second row of Figure 4.6 where the
posterior distributions of blood plasma volume for both subjects are compared to
their true blood plasma volume. The posterior distribution of blood plasma volume
for subject Zr0102004 estimated in the canned Bayesian analysis has a median of
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∼ 3.1 liters, which is quite close to her true blood plasma volume of 3.13 liters and
the 3 liters assumed in the ICRP 134 biokinetic model. On the other hand, the
posterior distribution of blood plasma volume of subject Zr0101102 has a median of
∼ 2.2 liters and a true value of 1.75 liters, which are significantly different than the
3 liters assumed in the ICRP 134 zirconium biokinetic model model.
Overall, the canned Bayesian analysis and add-one-in Bayesian analysis give comparable results that are equivalent for all practical intents and purposes. The canned
Bayesian analysis and add-one-in Bayesian analysis produce similar distributions of
intakes as can be seen in the third row of Figure 4.5, with the true value of the intake
falling within the 95% credible intervals for both methods. The plots in Figure 4.6
show that the true blood plasma volume was recovered in the canned Bayesian analysis, i.e., the true value of the blood plasma volume is in the 95% credible interval. The
plots for the add-one-in analysis in Figure 4.6 show that the blood plasma volume
for Zr0101102 was not recovered, whereas the blood plasma volume for both subjects
was recovered in the canned Bayesian analysis.

4.7.5

MAP Estimates

One drawback of the Bayesian analyses discussed here is that they take much longer
to complete than the standard method, with the canned prior Bayesian evaluation of
each subject taking ∼ 7 hours while the standard method is essentially instantaneous.
A maximum a posteriori (MAP) analysis consists of finding the maxima of the unnormalized posterior distribution formed by the product of the canned priors and the
likelihood. As can be seen in Figure 4.4, MAP evaluations give some of the benefits
of a full Bayesian analysis with the speed of the standard method while requiring no
additional coding in Stan. In particular, MAP estimates incorporate customization
of the blood plasma volume to the individual much like the full Bayesian analysis,
which results in intake estimates that more closely align with the true values.
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4.8

Summary

In Chapter 3, a proof-of-principle example was given that showed how one can define
informative priors for the distribution of rate constants in the ICRP 134 zirconium
biokinetic model and perform a population-level Bayesian calibration of the model
using bioassay data from a controlled study. In principle, a similar calibration can be
performed with any biokinetic model using different types of bioassay data including
that from controlled experiments, occupational exposures, and autopsy (Avtandilashvili, Brey, and Birchall, 2013). The end products of this calibration are the
MCMC samples of the posterior distributions of key population-level parameters. In
this chapter, fits of familiar probability distributions to these posterior samples compactly encapsulate all available information about the parameters into canned priors,
which can then be used as priors in the Bayesian analysis of bioassay data from a
new subject.
The canned prior Bayesian analysis was illustrated using two out-of-study subjects, contrasting its results with those obtained with 3 other methods: standard
method, add-in-in Bayesian analysis, and MAP analysis of the canned prior Bayesian
model. A summary of the intakes calculated by all 4 methods for both subjects is
given in Table 4.2. The intake evaluations for these 2 subjects highlight the main
advantages of the Bayesian method using canned priors over the standard method,
specifically: meaningful uncertainties can be estimated for quantities of interest, and
parameters of the biokinetic model can be customized to an individual in a disciplined fashion that avoids physiologically implausible or impossible parameters. This
adjustment of parameters in the biokinetic model can lead to better agreement between the observed and predicted bioassay results, giving increased accuracy in intake
estimates, and more realistic estimates of uncertainties. The add-one-in and canned
Bayesian approaches yield similar results. However, the canned Bayesian approach is
much faster and offers the advantage using canned priors that can be disseminated
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along with the biokinetic models when they are published. The MAP estimates of
intake are essentially as fast as the standard method and come at no cost once the
canned prior Bayesian model is specified, but are not true Bayesian estimates and
therefore do not provide meaningful estimates of uncertainty. The canned Bayesian
analysis would not be practical for evaluating a large number of cases as described
by Puncher and Riddell (2016) and Poudel et al. (2018), but would be ideal for evaluating bioassay from a small number of individuals who had significant exposures to
radioactive materials like those described by Carbaugh and LaBone (2003).
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Chapter 5
The Details
5.1

Introduction

All of the data preparation and calculations in this dissertation were performed with R
scripts and cmdstan code run from bash scripts. While completely reproducible, this
body of work is complex and difficult to communicate to others concisely. Therefore,
to provide additional details on the calculations presented in Chapters 3 and 4 here
multiple sets of simulated bioassay data for 16 hypothetical subjects are generated.
The simulated data from some subset of the 16 subjects (e.g., 5 subjects to speed
up the calculations) will then be used as the input data for the population model
calculations discussed in Chapter 3. The canned priors calculated from the simulated
population data will then be used to evaluate the simulated bioassay data from a
couple of individuals not used in development of the canned priors, which is akin
to the calculations performed in Chapter 4. Finally, a description of the codes and
procedures are put on GitHub along with key Stan and R codes. The goal is to
allow interested individuals to download and run the codes, which will facilitate them
reproducing and expanding on what was done in this dissertation.

5.2

Simulated Data

Simulated bioassay data were calculated starting with the sex, weight, t, ∆t, u,
n, nu , and np from the 16 subjects as defined in Chapter 3. For each subject 100
prior predictive distributions were generated using the canned priors for θ and τ from
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Table 5.1 Simulated bioassay data for Subject Zr_01 from run 50.
run

subject

sex

weight

vol

t

∆t

M

u

50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50

Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01
Zr_01

m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m

81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81

4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956
4.956

0.0034722
0.013889
0.020139
0.030556
0.040972
0.073611
0.091667
0.12639
0.16944
0.25972
0.33681
0.4625
0.54653
1.0035
1.1771
1.3375
0.5
1
1.375

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.5
0.5
0.375

0.1981
0.18535
0.19931
0.19551
0.17867
0.20219
0.17114
0.15155
0.1416
0.14022
0.1152
0.10957
0.10568
0.088244
0.087258
0.082417
0.0043563
0.0049678
0.003174

0.018209
0.0092612
0.0085196
0.0083008
0.0082824
0.0085674
0.0072409
0.0067768
0.0064528
0.0059817
0.0052956
0.0048248
0.0052279
0.0039411
0.0041543
0.0036531
0.00079519
0.00098987
0.00071988

Chapter 4 and the blood plasma volume posterior distributions from Chapter 3. After
the simulated blood plasma data were generated the blood plasma volume for each
subject was calculated using the methods described in Appendix B. For example, the
bioassay data for Subject Zr_01 from run 50 of the simulation are shown in Table 5.1
and spaghetti plots of the data from all 16 subjects for run 50 are shown in Figure
5.1. Data with ∆t = 0 are blood plasma samples and those with ∆t ̸= 0 are urine
samples The units of the blood plasma bioassay are the fraction of a unit quantity of
injected zirconium per liter of blood plasma and the units of the incremental urine
bioassay are fraction of a unit quantity of injected zirconium present in the urine
sample collected from t − ∆t to t. Weight has units of kg, vol liters, t days, and ∆t
days. These data are in the file ZrSimData-612.csv.
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Figure 5.1 Simulated zirconium urine and blood plasma data for 16 subjects from
run 50 of the simulation.
The R script ZrDataSim.R reads in the data from a specified run of the simulated
data, the 50th run in this example, and creates a data file Zr612-50.data.R and an
init file Zr612-50.init.R that are readable by the cmdstan code zircon-all.stan.

5.3

Computing Environment

The calculations in this chapter were performed on two computers running Linux
Mint 20.2 having 128Gb of RAM, one of which had an i7-7820x CPU and the other
an i9-10900X CPU. The statistical computing software R1 was run in the integrated
development environment RStudio2 that was used to prepare datasets for and analyze
the output from the program cmdstan3 that did the MCMC calculations. Bash scripts
were used to execute the cmdstan code as a batch file running in the background of the
Linux operating system. I tried disabling hyper threading to speed up the calculations
but found that the calculations ran faster with hyper threading on.
Although Stan was used in this dissertation, the MCMC software package NIMBLE (Valpine et al., 2017) was also considered. NIMBLE is very promising but it
1

Version 4.1 available from https://cran.r-project.org/

2

Version 1.4.1717 available from https://www.rstudio.com/products/rstudio/

3

Version V2.27 available from https://mc-stan.org/users/interfaces/cmdstan
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did not offer methods for solving the system of differential equations, i.e., the matrix
exponential function was not available. NIMBLE did offer eigenvalue decomposition,
which can also be used to solve the systems of differential equations, but it tended
to return imaginary numbers for rate matrices (which is not physically possible) and
was therefore impractical to use. NIMBLE is designed to be extensible, and my
future plans include implementing the matrix exponential and eigenvalue decomposition method so that its performance can be compared to Stan’s. Stan did not offer an
eigenvalue decomposition method for non-symmetric matrices like those encountered
with biokinetic models, and I also plan on extending Stan to handle these calculations.

5.4

Overview

The following steps give instructions on how to assemble simulated bioassay datasets
for populations and individuals, analyze them with Stan using the cmdstan interface,
and evaluate the posterior distributions with R code.
1. Run ZrDataSim.R to generate cmdstan input data files for the 16 individuals
from run 50 of the simulated dataset and cmdstan input data files for the first 5
of these individuals who are designated as the study population in this example.
2. Run cmdstan program zircon-all.stan from the bash script Zr-all-50.sh.
3. Run Zranal-Sim.R to analyze Stan output and create canned prior dataset.
4. Run the first part of Zrind-Sim.R to prepare the cmdstan data file for subject
10 from run 50 of the simulated data and to perform a standard regression of
the reference bioassay functions on the simulated bioassay data for this subject.
5. Run cmdstan program zircon-ind.stan from the bash script Zr_10.sh.
6. Run the second half of Zrind-Sim.R to analyze the Stan output.
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The three R scripts are in the main level of the GitHub directory and are not discussed
any further because they are only used to prepare and analyze cmdstan output data.
The sub directories of GitHub are
• cmdstan-home: bash scripts (and when you run it, cmdstan)
– Zr: cmdstan code
• data: input data
• diag: MCMC diagnostic plots
• plots: output plots
• subjects: datasets for individuals from run 50 of the simulated data.
The cmdstan code and bash scripts are discussed in more detail in the following
sections.

5.5

Bash script for Population Model

The bash script Zr-all-50.sh shown below runs the cmdstan code with 3000 samples
for the warm up followed by 10000 samples from the posterior distribution. The
biokinetic model parameters, prior distributions, and bioassay data are read from
Zr612-50.data.R and the starting values for the parameters from Zr612-50.init.R.
Note that if a starting value is not defined for a given parameter Stan uses a randomly
drawn value. The posterior samples for each parameter are written to Zr612-50.csv.
This script assumes that it and the folder Zr reside in the default cmdstan-home folder
as described in the documentation for cmdstan (Stan Development Team, 2021a).
#!/ bin / bash
Zr / zircon - all \
sample num_warmup =3000 num_samples =10000 \
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data file = Zr / Zr612 -50. data . R \
init = Zr / Zr612 -50. init . R \
output file = Zr / Zr612 -50. csv

The command used to submit the bash script as a background job is
nohup ./ Zr - all -50. sh > Zr -50. out &

where the warnings, errors, and progress information are written to Zr-50.out.

5.6

Stan Code for Population Model

Cmdstan code resembles a mix of C++ and R, and consists of the following sections:
• Functions - user defined functions.
• Data - anything that has a fixed value and is not subject to stochastic variation.
• Parameters - anything that is assigned a probability distribution in the Model
section.
• Transformed Parameters - anything that takes a parameter and performs a
calculation with it before drawing a sample from the posterior distribution.
Transformed parameter affect the sampling of the posterior.
• Model - the declaration of the probability distributions of the parameters.
• Generated Quantities - anything that takes a parameter and performs a calculation with it after drawing a sample from the posterior distribution. Generated
quantities do not affect the sampling of the posterior.
The cmdstan code zircon-all.stan for the zirconium population model discussed in
this section must be compiled as described in the cmdstan documentation before use.
Note that all data structures used in cmdstan code must be declared before use.
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5.6.1

Functions

The code in the Function section is broken down into two parts, the first giving
functions used to solve the system of ordinary differential equations and the second
to track and assign data and parameters to each of the 16 individuals. The key
function in the first part is q_c, which calculates reference bioassay functions given
the compartment number comp, times x, rate matrix kt, adjacency matrix H, number of compartments nc, and, number of non-zero rate constants nt that are read
from Zr612-50.data.R. The adjacency matrix concisely represents how the nodes in
a digraph like the one in Figure 3.4 are connected (Birchall and James, 1989).
functions {

// Calculate total removal rate constants in matrix K
matrix trrc ( matrix k , real lambda ) {
real Ksum ;
matrix [ rows ( k ) , rows ( k )] K ;
K = k;
for ( i in 1: rows ( K )) {
Ksum = 0;
for ( j in 1: rows ( K )){
Ksum = Ksum + k [i , j ];
}
K [i , i ] = - Ksum - lambda ;
}
return K ;
}

// calculate compartment content using the matrix exponential method
vector q_me ( int c , vector x , vector q0 , matrix k ) {
matrix [ rows ( k ) , rows ( k )] a ;
vector [ rows ( x )] q ;
q = rep_vector (0 , rows ( x ));
for ( i in 1: rows ( x )) {
a = matrix_exp ( k * x [ i ]);
for ( j in 1: rows ( k )) {
q [ i ] = q [ i ] + a [j , c ]* q0 [ j ];
}
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}
return q ;
}

// calculate content at times x and rate constants kt
vector q_c ( int comp , vector x , vector kt , int [ ,] H , int nc , int nt ) {
vector [ nc ] q0 ;
matrix [ nc , nc ] k ;
vector [ rows ( x )] content ;
q0 = rep_vector (0 , nc );
q0 [1] = 1.0;
k = rep_matrix (0 , nc , nc );
for ( i in 1: nt ) {
k [ H [i ,1] , H [i ,2]] = kt [ i ];
}
k = trrc (k ,0);
content = q_me ( comp ,x , q0 , k );
return content ;
}

The bioassay results for all subjects are arranged in one data vector and there
is another vector that contains a number from 1 to 16 that indicates the subject to
whom each bioassay result belongs. The following functions parse the data vector
into blood plasma and urine data for a given subject. The data were arranged this
way because each subject can have a different number of bioassay results and Stan
does not support ragged matrices.
// gives the number of bioassay results for a given subject
int count_sub ( int [] sub , int index ) {
int count ;
count = 0;
for ( i in 1: num_elements ( sub )) {
if ( sub [ i ] == index ) {
count = count + 1;
}
}
return ( count );
}
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// gives the number of blood plasma results for a given subject
int count_bld ( int [] sub , vector dT , int index ) {
int count ;
count = 0;
for ( i in 1: num_elements ( sub )) {
if ( sub [ i ] == index ) {
if ( dT [ i ] == 0.0) {
count = count + 1;
}
}
}
return ( count );
}

// gives the number of urine results for a given subject
int count_urn ( int [] sub , vector dT , int index ) {
int count ;
count = 0;
for ( i in 1: num_elements ( sub )) {
if ( sub [ i ] == index ) {
if ( dT [ i ] > 0.0) {
count = count + 1;
}
}
}
return ( count );
}

// returns the indices for all results for a given subject
int [] inds ( int [] sub , int index ) {
int res [ count_sub ( sub , index )];
int ci ;
ci = 1;
for ( i in 1: num_elements ( sub )) {
if ( sub [ i ] == index ) {
res [ ci ] = i ;
ci = ci + 1;
}
}
return ( res );
}
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// returns the indices for urine results for a given subject
int [] indu ( int [] sub , vector dT , int index ) {
int res [ count_urn ( sub , dT , index )];
int ci ;
ci = 1;
for ( i in 1: num_elements ( sub )) {
if ( sub [ i ]== index ) {
if ( dT [ i ] > 0.0) {
res [ ci ] = i ;
ci = ci + 1;
}
}
}
return ( res );
}

// returns the indices for urine results for a given subject
int [] indb ( int [] sub , vector dT , int index ) {
int res [ count_bld ( sub , dT , index )];
int ci ;
ci = 1;
for ( i in 1: num_elements ( sub )) {
if ( sub [ i ]== index ) {
if ( dT [ i ] == 0.0) {
res [ ci ] = i ;
ci = ci + 1;
}
}
}
return ( res );
}}

5.6.2

Data

The biokinetic model and bioassay data are read into the cmdstan code from Zr61250.data.R.
data {
int ntot ;

// total number of bioassay results
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int N ;

// number of individuals

int n [ N ];

// number of results for each individual

int sub [ ntot ];

// the subject number for each bioassay result

vector [ ntot ] T ;

// the time of each bioassay result

vector [ ntot ] dT ;

// the delta t for each bioassay result

vector [ ntot ] M ;

// the bioassay results

vector [ ntot ] u ;

// the measurement uncertainties

int nt ;

// the number of transfer rate constants

int nc ;

// the number of compratments

int H [ nt ,2];

// the adjacency matrix

vector [ N ] mu_v ;

// the log mean of the plasma volume

vector [ N ] sigma_v ;

// the log sd of the plasma volume

vector [ nt ] mu_theta ;

// log means of theta

matrix [ nt , nt ] sigma_theta ; // log covariance matrix of theta
real mu_tau ;

// log mean of tau

real sigma_tau ;

// log sd of tau

real Eta ;

// Eta for LKJ distribution

real df ;

// degrees of freedom for Student t

}

5.6.3

Parameters

Parameters have probability density models that are defined in the Model section.
parameters {
vector [ N ] V ;
matrix [ nt , N ] Kt ;
corr _ matrix [ nt ] Omega ;
real tau ;
vector [ nt ] theta ;
}

5.6.4

Transformed Parameters

In the Transformed Parameter section values of the parameters drawn in the Model
section are manipulated to give variables that are a function of one or more parameters. The data functions are first used in this section. For example, T[indb(sub,dT,i)]
retrieves the times of all blood plasma measurements for the ith subject.
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transformed parameters {
cov_matrix [ nt ] Pi ;
vector [ nt ] Tau ;
vector [ nt ] kt ;
real v ;
vector [ ntot ] m ;
Tau = rep_vector ( tau , nt );
Pi = quad_ form_dia g ( Omega , Tau );
for ( i in 1: N ) {
kt = exp ( Kt [1: nt , i ]);
v = exp ( V [ i ]);
m [ indb ( sub , dT , i )] = (
q_c (1 , T [ indb ( sub , dT , i )] , kt , H , nc , nt ) +
q_c (2 , T [ indb ( sub , dT , i )] , kt , H , nc , nt )) / v ;
m [ indu ( sub , dT , i )] = q_c (15 , T [ indu ( sub , dT , i )] , kt , H , nc , nt ) q_c (15 , T [ indu ( sub , dT , i )] - dT [ indu ( sub , dT , i )] , kt , H , nc , nt );
}
}

5.6.5

Models

The Model section is where probability distributions are assigned.
model {
Omega ~ lkj_corr ( Eta );
theta ~ multi_normal ( mu_theta , sigma_theta );
tau ~ normal ( mu_tau , sigma_tau );
for ( i in 1: N ) {
Kt [1: nt , i ] ~ multi_normal ( theta , Pi );
V[i] ~

normal ( mu_v [ i ] , sigma_v [ i ]);

M [ inds ( sub , i )] ~ student_t ( df , m [ inds ( sub , i )] , u [ inds ( sub , i )]);
}
}

5.6.6

Generated Quantities.

In the Generated Quantities section the current sample of the posterior distributions
of the parameters are used to generate the predicted bioassay results for the posterior
predictive plot and the log likelihood in case one wants to compare different models.

106

generated quantities {
real M_hat [ ntot ];
real log_lik [ ntot ];
for ( i in 1: N ) {
M_hat [ inds ( sub , i )] =

student_t_rng ( df , m [ inds ( sub , i )] , u [ inds ( sub , i )]);

for ( j in inds ( sub , i )) {
log_lik [ j ] = s tudent_t _lpdf ( M [ j ] | df , m [ j ] , u [ j ]);
}
}
}

5.7

Bash script for Individual Model

The bash script Zr_10.sh shown below contains the sample command that is used
to calculate the posterior distributions of the parameters in the individual model
(analogous to the bash script for the population model) and the optimize command
that is used to generate MAP estimates of the parameters. One nice thing about
Stan is that the same code is used for both calculations, i.e., we don’t have to write
any new code to get the MAP estimates.
Zr / zircon - ind \
sample num_warmup =4000 num_samples =15000 \
data file = Zr / Zr_10 . data . R \
init = Zr / Zr_10 . init . R \
output file = Zr / Zr_10 . csv

Zr / zircon - ind \
optimize \
data file = Zr / Zr_10 . data . R \
init = Zr / Zr_10 . init . R \
output file = Zr / Zr_10opt . csv

5.8

Stan Code for Individual Model

The Stan code for the individual model is somewhat simpler than the code for the
population model because it deals with a single individual, which means that the 6
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functions in Section 5.6.1 used to parse the bioassay data for multiple subjects are
not needed and there are no loops in the Model and Transformed Parameters sections
of the code.

5.8.1

Functions

The functions to solve the system of ordinary differential equations are the same as
those in the first part of Section 5.6.1.
functions {

// Calculate total removal rate constants in matrix K
matrix trrc ( matrix k , real lambda ) {
real Ksum ;
matrix [ rows ( k ) , rows ( k )] K ;
K = k;
for ( i in 1: rows ( K )) {
Ksum = 0;
for ( j in 1: rows ( K )){
Ksum = Ksum + k [i , j ];
}
K [i , i ] = - Ksum - lambda ;
}
return K ;
}

// calculate compartment content using the matrix exponential method
vector q_me ( int c , vector x , vector q0 , matrix k ) {
matrix [ rows ( k ) , rows ( k )] a ;
vector [ rows ( x )] q ;
q = rep_vector (0 , rows ( x ));
for ( i in 1: rows ( x )) {
a = matrix_exp ( k * x [ i ]);
for ( j in 1: rows ( k )) {
q [ i ] = q [ i ] + a [j , c ]* q0 [ j ];
}
}
return q ;
}
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// calculate content at times x and rate constants kt
vector q_c ( int comp , vector x , vector kt , int [ ,] H , int nc , int nt ) {
vector [ nc ] q0 ;
matrix [ nc , nc ] k ;
vector [ rows ( x )] content ;
q0 = rep_vector (0 , nc );
q0 [1] = 1.0;
k = rep_matrix (0 , nc , nc );
for ( i in 1: nt ) {
k [ H [i ,1] , H [i ,2]] = kt [ i ];
}
k = trrc (k ,0);
content = q_me ( comp ,x , q0 , k );
return content ;
}}

5.8.2

Data

The data are for one subject, but otherwise are essentially the same as in the Data
section of the population code.
data {
int < lower =1 > np ;
int < lower =1 > nu ;
int < lower =1 > n ;
vector [ n ] M ;
vector [ n ] u ;
vector [ n ] ru ;
vector [ n ] T ;
vector [ n ] dT ;
int < lower =1 > nt ;
int < lower =1 > nc ;
int H [ nt ,2];
vector [ nt ] mu_theta ;
matrix [ nt , nt ] sigma_theta ;
real mu_tau ;
real sigma_tau ;
real mu_beta ;
real sigma_beta ;
real mu_v ;
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real sigma_v ;
real Eta ;
real df ;
}

5.8.3

Parameters

The intake β for an individual subject is a parameter to estimate unlike in the population model where it is a known constant.
parameters {
real beta ;
corr_matrix [ nt ] Omega ;
vector [ nt ] theta ;
real < lower =0 > tau ;
real v ;
vector [ nt ] Kt ;
}

5.8.4

Transformed Parameters

transformed parameters {
vector [ np ] m_p ;
vector [ nu ] m_u ;
vector [ n ] m ;
vector [ nt ] kt ;
real Beta ;
real V ;
cov_matrix [ nt ] Pi ;
vector [ nt ] Tau ;
vector [ n ] mu ;
vector [ n ] sigma ;
Tau = rep_vector ( tau , nt );
Pi = quad_ form_dia g ( Omega , Tau );
kt = exp ( Kt );
Beta = exp ( beta );
V = exp ( v );
m_p = ( q_c (1 , T [1: np ] , kt ,H , nc , nt ) + q_c (2 , T [1: np ] , kt ,H , nc , nt ) ) / V ;
m_u = q_c (15 , T [( np +1): n ] , kt ,H , nc , nt ) - q_c (15 , T [( np +1): n ] - dT [( np +1): n ] , kt ,H , nc , nt );
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m = append_row ( m_p , m_u );
sigma = u ;
mu = Beta * m ;
}

5.8.5

Model

The all the subjects in the population model had known quantities of zirconium
injected that were normalized to β = 1 in order to facilitate comparisons of bioassay
data from subject to subject. When the data from an individual are modeled the
quantity injected β is an unknown parameter to be estimated. Having the intake and
blood plasma volume as parameters to estimate is a significant source of uncertainty
in the final parameter estimates for a out-of-sample subject.
model {
Omega ~ lkj_corr ( Eta );
theta ~ multi_normal ( mu_theta , sigma_theta );
tau ~ normal ( mu_tau , sigma_tau );
v ~

normal ( mu_v , sigma_v );

Kt ~ multi_normal ( theta , Pi );
beta ~ normal ( mu_beta , sigma_beta );
M ~ student_t ( df , mu , sigma );
}

5.8.6

Generated Quantities

The main difference between the Generated Quantities sections for the population
versus the individual model is that σ for the t distribution is estimated from the
product of the predicted bioassay measurement Beta*m[i] times the relative uncertainty in the observed bioassay measurement ru[i] = u[i]/M[i].
generated quantities {
vector [ n ] M_hat ;
for ( i in 1: n ) {
M_hat [ i ] = student_t_rng ( df , Beta * m [ i ] , Beta * m [ i ]* ru [ i ]);
}
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}

5.9

Procedure

To run the population model:
1. Compile zircon-all.stan, noting that it is assumed to be in the cmdstan-home/Zr
directory.
2. Place Zr612-50.data.R and Zr612-50.init.R. in the Zr directory.
3. Place Zr-all-50.sh in the cmdstan-home directory, set its permissions, and submit it as a background job using
a) chmod 700 Zr-all-50.sh
b) nohup ./Zr-all-50.sh > Zr-all-50.out &
4. Note that the output goes to the text file Zr-all-50.out and it takes about 4
days for the example to run using the first 5 subjects as the population. In
comparison, analyzing all 16 subjects takes about 25 days.
5. Run the R code Zranal-Sim.R to perform diagnostics and generate canned priors.
To run the individual model:
1. Compile zircon-ind.stan, noting that it is assumed to be in the cmdstan-home/Zr
directory.
2. Run the first part of the R code Zrind-Sim.R, which reads in the canned priors
from Zrcan-50.R and the bioassay data for the 10th subject from Zr_10.R.
3. Place Zr_10.data.R and Zr_10.init.R. in the Zr directory.
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4. Place Zr-ind-10.sh in the cmdstan-home directory, set its permissions, and submit it as a background job using
a) chmod 700 Zr-ind-10.sh
b) nohup ./Zr-ind-10.sh > Zr-ind-10.out &
5. Note that the output goes to the text file Zr-ind-10.out and it takes about 3
hours for the example to run.
6. Run the second part of the R code Zrind-Sim.R to perform diagnostics and
generate output.

5.10

GitHub

The code and instructions discussed here are available in the GitHub repository
ZrStan in the tomlabone account.
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Chapter 6
Summary
6.1

Essential Background

Radioactive materials spontaneously emit ionizing radiation, which has been shown
to increase the risk of an exposed individual developing cancer. In order to limit the
risk of detrimental health effects in individuals, regulatory limits are placed on the
radiation dose an individual can receive from radioactive materials taken into the
body. The quantity of material taken into the body is referred to as an intake, which
can occur through various pathways such as inhalation, ingestion, and absorption
through intact skin. It is not possible in practice to measure an intake directly, so
the intake is inferred from measurements of the quantity of the radioactive material
present in various regions of the body or in excreta at various times after the intake.
Such measurements are referred to bioassay. Once an intake is estimated the radiation
dose to the organ of interest is can be calculated. Radiation dose is the amount of
ionizing radiation absorbed in tissues and organs and is used as an index of harm
(e.g., the risk of developing cancer).
The process of using bioassay to calculate an intake requires a biokinetic model
that provides a mathematical relationship between the intake and the bioassay. Thus,
a biokinetic model is an idealized mathematical representation of how a material is
deposited in the body, subsequently translocated to various organs and tissues, and ultimately excreted. The International Commission on Radiological Protection (ICRP)
is an international non-governmental organization that publishes biokinetic models
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that relate measurements M of radioactive material in the body and excreta to the
amount β of the material taken into the body. These biokinetic models are used
world-wide as the common basis for internal dosimetry calculations. As discussed
in Chapter 2, the ICRP approximates the biokinetics of radioactive materials in the
body with compartmental models (like the one for the element zirconium shown in
Figure6.2) expressed mathematically as a system of ordinary differential equations
(ODE), for which they provide point estimates for the rate constants. The ODE are
solved to give the proportion m of an intake that is in a group of biokinetic model
compartments that corresponds to what the bioassay is measuring. This proportion
is called a reference bioassay function. If the biokinetics of the individual perfectly
match the biokinetics of the ICRP biokinetic model and the bioassay has no measurement error, the intake is given by the ratio of the bioassay to its corresponding
reference bioassay function.

6.2

Concise Statement of the Problem

In practice the biokinetics of an individual will diverge to some (possibly large) extent
from the biokinetics of the ICRP model and the bioassay will have measurement
errors, resulting in inaccurate estimates of intake and radiation dose. In addition,
the ICRP models are deterministic and don’t allow for the estimation of realistic
uncertainties in the intakes and radiation doses, which may be needed for cases where
the regulatory limits are exceeded. To address these limitations one must (i) define
physiologically realistic probability distributions for the rate constants in the ICRP
model, and (ii) provide a way to use the enhanced ICRP biokinetic model in the
evaluation of bioassay from an individual.
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6.3

Proposed Solution

In Chapter 3 (see Figure 6.1) a proof-of-principle example is given showing how the
ICRP Publication 134 zirconium biokinetic model in Figure 6.2 can be calibrated
with bioassay data from 16 subjects who participated in the Greiter et al. (2011) experimental study (Figure 6.3) using Bayesian hierarchical methods and informative
priors. Samples from the posterior distributions of the hierarchical model shown in
Figure 6.4 were obtained using Markov Chain Monte Carlo (MCMC) implemented in
the computer code Stan, with the calculations requiring weeks of run time on capable
computers. The posterior distributions from which these samples were drawn incorporate all the prior knowledge from the ICRP model and the variation in biokinetics
observed in the study population.
In Chapter 4, probability distributions like a multivariate lognormal and a multivariate lognormal mixture were fit to the samples from the posterior distributions in
the calibrated biokinetic model. These fitted posterior distributions are referred to as
canned priors and are used for posterior passing, i.e., using the posterior distributions
from one study as the priors in another. In the end, a multivariate lognormal distribution was chosen for the canned prior for θ and a truncated lognormal distribution
for τ (the blue shaded nodes in Figure 6.4). These canned priors can be used in the
Bayesian analysis of an individual, which permits the disciplined modification of the
rate constants in the ICRP 134 biokinetic model to better match the biokinetics of
the individual, increasing the accuracy of the estimated intake and radiation doses. In
addition, expressing the rate constants in the ICRP biokinetic model as distributions
facilitates the estimation of realistic uncertainties in the intake and radiation doses.
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Figure 6.1 Outline of Chapter 3 and Chapter 4.

Figure 6.2 ICRP 134 biokinetic model for zirconium.

Figure 6.3 Urine and blood plasma data for 16 subjects from the Greiter zirconium
study used in the population model and 2 subjects (in red) that were not used in the
model. These two out-of-sample individuals are discussed in Chapter 4.
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Figure 6.4 Bayesian population model for evaluating cases with the intent of estimating the posterior distributions of the hyper priors in the blue shaded nodes. The
nodes for parameter distributions are denoted by ellipses, computed parameters by
rectangles, and data by dashed rectangles..
6.4

Key Results

The end result of Chapter 3 is somewhat abstract — 110000 samples from the posterior distribution of the Bayesian hierarchical model. Things becomes a little more
concrete in Chapter 4 when probability distributions are fit to these posterior samples
to create canned priors. Then, at the end of Chapter 4 the purpose behind the process
becomes clear with examples of the canned prior Bayesian analyses of bioassay performed on two out-of-study subjects (designated Zr0101102 and Zr0102004) from the
Greiter study. The results of these canned prior Bayesian analyses are compared to
the known values of intake and the results obtained by 3 other methods: (i) regression
of M on m, where m is calculated with the standard ICRP 134 zirconium model
(i.e., the standard method); (ii) Bayesian analysis where the out-of-study subject is
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added to the 16 study subjects and the Bayesian calibration repeated (i.e., an addone-in analysis); (iii) the MAP analysis using the unnormalized posterior distribution
of the canned prior Bayesian model.
Of primary interest are the results of the standard method versus the results of
the canned prior Bayesian analysis. In Figures 6.5 and 6.6 the plots of M versus m
are given for each subject. In these plots the slope of the regression line is the intake
β of zirconium and the uncertainty in the slope is the uncertainty in the intake. For
both subjects the standard method gives inaccurate estimates of the intake, which
is known to be β = 1, whereas the canned Bayesian analysis gives more accurate
estimates of the intake. The uncertainty in the intake estimate for the standard
method is smaller than the uncertainty estimated with the canned Bayesian method
because the standard method does not account for the uncertainty in the biokinetic
model whereas the canned Bayesian analysis does. The intake distributions calculated
with the two methods are directly compared in Figure 6.7 where the inaccuracy of
the intake and underestimated uncertainty in the standard method are clearly seen.
The add-one-in Bayesian analysis was performed to see how how it compared to
the canned prior Bayesian analysis. The add-one-in analysis took weeks to calculate
and required the data from the 16 subjects used to calibrate the biokinetic model.
Contrast this with the canned prior Bayesian analysis, which gave comparable results
in hours without needing the calibration dataset. The advantages of the canned
prior approach are obvious. The MAP analysis gave some of the benefits of the
Bayesian analysis with the speed of the standard method, and could be useful as an
alternative to the canned Bayesian analysis if uncertainties in estimated quantities
are not needed.
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Figure 6.5 Comparison of standard method (right) to canned prior Bayesian analysis
(right) for Subject Zr0101102. The grey lines denote the 95% confidence interval and
95% credible interval, respectively, on the regression lines, which correspond to the
95% intervals on the intakes. The error bars denote the 95% coverage interval on the
measurements.

Figure 6.6 Comparison of standard method (right) to canned prior Bayesian analysis
(right) for Subject Zr0102004. The grey lines denote the 95% confidence interval and
95% credible interval, respectively, on the regression lines,which correspond to the
95% intervals on the intakes. The error bars denote the 95% coverage interval on the
measurements.
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Figure 6.7 The posterior distribution of β̂ calculated for Zr0101102 (left) and
Zr0102004 (right) with standard method (blue), add-one-in Bayesian analysis (black),
and MVN canned prior Bayesian analysis (red). The true value of the intake is β = 1
for both subjects. The vertical lines on the distribution of β in denote the 95%
confidence or credible interval.
6.5

Significance of Research

This dissertation provides a proof-of-principle exercise that shows how hierarchical
Bayesian models can be used to incorporate experimental data into an ICRP biokinetic model and generate realistic probability distributions for all parameters of the
model. I am proposing is a fundamental change in the level of information provided
by the ICRP in their published models, which is a prerequisite for increasing the
accuracy in estimated quantities like intake and making meaningful estimates of uncertainty in these quantities. Further, I have given examples of how this additional
information can be summarized in canned priors that can be published by the ICRP
and used in subsequent Bayesian evaluations of bioassay data from an individual.
Finally, I have shown that the canned prior Bayesian analysis can provide intake and
radiation dose estimates that have higher accuracy and more realistic uncertainties
than those obtained from the standard method. The presentation of this information
in one coherent package is novel and in my opinion can be of great practical significance to the community of scientists who develop and apply biokinetic models in the
field of internal dosimetry.
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6.6

Future Research

My future research will focus on making the MCMC calculations faster by: exploring
the use of samplers other than HMC (e.g, use NIMBLE rather than Stan); using
eigenvalues/eigenvectors to solve the system of differential equations rather than the
matrix exponential; running each MCMC chain on multiple computer cores (currently
each chain is run on a single core); trying different parameterisations of the priors
and hyperpriors (the nodes in Figure 6.4), which can have a significant impact on
the speed of the calculation. Further, I want to collaborate with expert biokinetic
modelers to see what we can do with a more complicated biokinetic model with
more data, like the one for plutonium. Finally, I want to work on making a user
interface for the canned Bayesian analysis that makes the calculation more accessible
to individuals with a modest background in statistics and computer programming.
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Appendix A
The Inverse Problem and Identifiability of the
Biokinetic Model
In theory, the maxima of the likelihood for the Riggs iodine models give the maximum
likelihood estimates of the intake and rate constants, but as discussed in Chapter 2
there are significant problems encountered if we try to do this. In the Inverse Problem
a given biokinetic model is said to be identifiable if all the unknown rate constants
in the model can be uniquely determined from the available bioassay measurements
(Bonate, 2011, page 29; Jacquez, 1985, Section 14.3; Claudio Cobelli, Foster, and
Toffolo, 2007, Ch 5; Carson, Finkelstein, and C. Cobelli, 1983, Ch 7&8). A biokinetic model that is not identifiable because one or more parameters in the biokinetic
model can’t be uniquely determined is referred to as an unidentifiable model. Biokinetic models that are unidentifiable given an infinite amount of error-free bioassay
measurements are referred to as being structurally unidentifiable. For example, the
Riggs model is unidentifiable given an infinite amount of error-free thyroid bioassay measurements (Norton, 1982, Model 6). To make the Riggs model structurally
identifiable either bioassay measurements of the blood compartment or the Other
compartment must be provided in addition to the thyroid bioassay. Looking in more
detail, given only the thyroid bioassay measurements the rate constant is k34 = koth,f ec
is unidentifiable, which causes the whole biokinetic model to be unidentifiable. Note
that it is quite difficult to determine analytically whether a biokinetic model with
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more than 2 or 3 compartments is structurally identifiable (Claudio Cobelli, Foster,
and Toffolo, 2007, pg 110).
Those who are unaware of the structural unidentifiability in the Riggs model may
proceed to feed the likelihood function for model and the thyroid bioassay measurements into an optimizer program (e.g., mle2 from the bbmle package in R) to obtain
estimates of all the rate constants in the model. We are lucky if the the optimizer fails
(i.e., does not converge to a solution). More problematic is the case when estimates
of the rate constants including koth,f ec are generated. In this case the error in the
estimate of koth,f ec will be noticeably much larger than the error in the estimates of
the other rate constants. In practice this can go unnoticed because
• the Hessian matrix used to calculate the errors in not invertable and errors are
not reported, or
• the errors may be calculated using a generalized inverse of an uninvertable
Hessian (Gill and King, 2004), which can produce error estimates that are
difficult to interpret1 .
Structural identifiability is a necessary but not sufficient property for a biokinetic
model to have because even if a biokinetic model is structurally identifiable – it may
not be practically identifiable because of insufficient quantity or inadequate quality
of data. One way to check for unidentifiability in a biokinetic model is a parametric
bootstrap analysis similar to the one discussed by (Roosa and Chowell, 2019), which
goes something like this:
1. Generate a large number of simulated error-free data using the biokinetic model.
2. Add N (0, εM ) distributed error to each datum, where ε is the relative uncertainty in each datum M .
1

Note that mle2 does this.
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3. Determine the rate constants a number of times to estimate the variation in
their estimates.
4. Repeat steps 2-3, increasing the value of ε.
This parametric bootstrap analysis was performed on the Riggs iodine model with
ε = {0.001, 0.002, 0.005, 0.007, 0.01} and 30 iterations at each relative uncertainty.
The results in Figure A.1 show that the error in the estimates of koth,f ec is over 100
times the measurement error in the content of the thyroid compartment – essentially
imperceptible measurement errors result in large errors in the parameter estimate.
The variation in koth,bld is somewhat smaller, but the variation in the estimates of
the other three rate constants is much smaller and fairly constant. This analysis
shows that the Riggs iodine model is for all practical intents and purposes unidentifiable. This conclusion will be extended to all realistic ICRP biokinetic models (like
zirconium) without proof, i.e., all ICRP biokinetic models will be assumed to be
unidentifiable.

Figure A.1 Bootstrap estimate of parameter uncertainty for a maximum likelihood
(ML) estimate of the rate constants in the Riggs iodine model as a function of measurement error in the thyroid bioassay.
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Appendix B
Volume of Blood Plasma
B.1

Blood Volume Calculated by Isotopic Dilution

In the study by Greiter et al. (2011) measurements of zirconium in the blood are made
by drawing 10 mL of blood at specified times after the iv injection of zirconium.
The measured content Mbld (t) of the blood plasma compartment is calculated by
multiplying the measured concentration Cbld (t) by the volume V of the blood plasma
compartment. The volume of the blood plasma compartment was calculated by
fitting a two exponential function to the zirconium concentration as a function of
time (Figure B.1)
Cbld (t) = A1 e−B1 t + A2 e−B2 t

(B.1)

For example, using the non-linear regression function nls in R, the fitted function for
subject Zr0602615 is
Cbld (t) = 11.515580e−0.491357t + 17.126996e−0.009952t

(B.2)

Cbld (0) = 11.515580 + 17.126996 = 28.64258

(B.3)

which at t = 0 is

both having units of percent of the injected intake per kg of plasma. Thus, 0.2864258
of the injected zirconium is present in a kg of plasma at time t = 0. Assuming the
plasma has a density of 1.027 kg/L, the volume of the is plasma compartment in units
of L is
V =

1
= 3.399519
(1.027) (0.2864258)
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(B.4)

This is same volume calculated in Greiter (2008, Section 6.3.2).

Figure B.1 Blood plasma volume in liters of subject Zr0602615 determined by calculating the concentration of zirconium in the blood at t = 0 days after the injection
intake.

B.2

Blood Plasma Volume

The dilution method used by Greiter to calculate the volume of the blood plasma
compartment is applicable only if the intake is known, which will not be the case in
practice. When the intake is not known the volume of the blood plasma compartment
for an individual can be estimated using one of the following equations (Retzlaff et al.,
1969) based sex, height H in meters, and weight W in kg:
Male blood plasma volume in mL:
• Vm = 14.5W + 2035 (when only weight is known).
• Vm = 30.2H + 2119 (when only height is known).
• Vm = 23.7H + 9W − 1709 (when height and weight are known).
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Female blood plasma volume in mL:
• Vf = 24.0W + 872 (when only weight is known).
• Vf = 48.1H + 5550 (when only height is known).
• Vf = 40.5H + 8.4W − 4811 (when height and weight are known).
The geometric mean of a lognormal blood plasma volume prior distribution for an
individual is set equal to the appropriate value calculated above. The geometric
standard deviation of the blood volume prior is set equal to 1.2, resulting in 95%
of the prior values being within a factor of ∼ 1.3 of the geometric mean. Although
ICRP Publication 89 (Valentin, 2002, pg 138) gives a blood plasma volume of 3.0 L
for males and 2.4 L for females, the volume of 3.0 L should be used when evaluating
bioassay data with the unmodified ICRP 134 zirconium biokinetic model because the
model is based primarily on data from males1 .

1

Personal communication with Dr. Richard Leggett via email on 7/8/2021.
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Appendix C
Variability, Uncertainty, and Error
Some key terms used in the dissertation are (BIPM et al., 2012;National Research
Council, 2009, pg 91):
• The measurand in metrology (the science of measurement) is the thing we are
measuring in an effort to estimate its true value. We will seldom know the true
value of the measurand, i.e., for all applications of interest it is unknown and
unknowable.
• Variability refers to the inherent heterogeneity of the true values of the measurand in a sample or population. Variability is a property of the sample or
population that cannot be reduced or eliminated but whose characterization
can be improved.
• An error is the distance between the value of the measurement and the true
value of the measurand. The distance is usually expressed as an absolute or
relative difference between the measurement and the true value. Note that
because the true value is not knowable the error is also not knowable.
• A residual is the distance between the measurement and an estimate of the
true value of the measurand, usually expressed as an absolute or relative difference. The residual is not the error, but nevertheless is knowable and gives us
information about the error.
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• Uncertainty refers to our lack of knowledge concerning the true value of the
measurand. Sources of uncertainty are measurement errors, sampling errors,
and misspecified statistical models. Steps can be taken to improve our understanding and reduce uncertainty, e.g., collect additional data or use a better
model.
In conversation, error and uncertainty are often used interchangeably, but strictly
speaking they are very different. For example, we often talk of measurement error,
which is an unknowable quantity that is of little practical use. On the other hand,
measurement uncertainty is a knowable quantity that provides our current state of
knowledge about the measurand and should be reported with every measurement. In
metrology, uncertainty is formally defined (JCGM, 2008) as a “parameter, associated
with the result of a measurement, that characterizes the dispersion of the values that
could reasonably be attributed to the measurand.” They are referring specifically
to the combined standard uncertainty u in a measurement, which can be thought
of as the variation in repeated observations as described by the standard deviation
plus all of the variation that we know is being generated by other sources. Thus, u
incorporates the effects of all known sources of uncertainty. Note that when we refer
to the uncertainty of a measurement in this report we are referring to the combined
standard uncertainty.
The uncertainty in a measurement can be reported as a point estimate ±u. For
example, the mass of a cube of tungsten might be reported as 10.0 ± 0.1 grams, where
u = 0.1 grams. The uncertainty can also be multiplied by an expansion factor like
2 to expand the uncertainty to a given probability level, e.g., we are 95% confident
that the mass of the cube is 10.0 ± 0.2 grams. This uncertainty can also be expressed
as the 95% coverage interval (9.8, 10.2). These expressions of uncertainty are the
metrology equivalents how we report a mean and its standard error in statistics.
Statements of GUM measurement uncertainty intervals appear to be interpreted like
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Bayesian credible intervals (see Kacker, 2015) and the definitions of coverage interval
and coverage probability in BIPM et al. (2012) even if the uncertainty intervals were
calculated with frequentist methods. This means that the true value of the measurand
is said to have a given probability of being in the uncertainty interval even if it is a
frequentist confidence interval.
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Appendix D
Lognormal Distribution
The lognormal distribution is used extensively as the prior distribution for many
parameters in biokinetic models, so it is appropriate to review some of the basic
properties of this important distribution.

D.1

Probability Density Functions

The probability density function for the normal distribution is
fX (x) =

2
1
1
2
√ e− 2 (x−µx ) /σx ,
σx 2π

(D.1)

where −∞ < µx < ∞ is the mean, σx > 0 the standard deviation, and −∞ < x < ∞
is the support. Note that while µx and σx are the parameters of the normal pdf
they are also the mean and standard deviation of X. The random variable X is
normally distributed, but we can also entertain the situation where it is the log of
another random variable Y, i.e., X = log (Y ) . The random variable Y has a lognormal
distribution , which has the pdf
fY (y) =

2
1
1
2
√ e− 2 (log(y)−µx ) /σx ,
yσx 2π

(D.2)

where 0 < y < ∞ is the support. In contrast to the normal distribution, note that µx
and σx are the parameters of the lognormal pdf but are not the mean and standard
deviation of Y, which will be derived in the next section.
To show how we transform X to Y, let’s first define the transform function g(x)
and inverse transform function g −1 (y):
g (x) = y = ex , −∞ < x < ∞,
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(D.3)

g −1 (y) = x = log (y) , 0 < y.

(D.4)

These functions are depicted in Figure D.11 , where the lines for x = log(7) = 1.94591
and y = 7 are shown for reference. The mean µx of the normal distribution X
is related to the geometric mean µg of the lognormal distribution Y by the same
transform functions:
µx = log (µg )

(D.5)

µg = exp (µx ) .

(D.6)

and

The same applies to the standard deviation σx of the normal distribution and the
geometric standard deviation σg of the lognormal distribution:
σx = log (σg )

(D.7)

σg = exp (σx ) .

(D.8)

and

Note that 0 < µg < ∞ and 1 < σg < ∞. Substituting the transform and inverse
transform functions in the following probability statements








P (Y ≤ y) = P g −1 (Y ) ≤ g −1 (y) = P X ≤ g −1 (y)

(D.9)

gives us




P (Y ≤ y) = P X ≤ g −1 (y) ,

(D.10)

which can be expressed as cumulative distribution functions (cdf):
−1 (y)
gˆ





FY (y) = FX g −1 (y) =
−∞

1
√

σx 2π

1

e− 2 (x−µx )

2

/σx2

dx

(D.11)

1
These three plots make what I call a DESY plot, which clearly illustrates the relationship
among g(x), fX (x), and fY (y). DESY is a particle physics research center in Germany. Gerhard
Bohm and Günter Zech from DESY wrote the book Introduction to Statistics and Data Analysis
for Physicists, where I first saw this type of plot. The book can be downloaded at http://wwwlibrary.desy.de/preparch/books/vstatmp_engl.pdf.
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The pdf of the lognormal distribution is derived by differentiating the cdf:
"

#



h

i d
d
d
fY (y) = FY (y) = FX g −1 (y) = fX g −1 (y)
g −1 (y) ,
dy
dy
dy

#

"

d
log (y) ,
fY (y) = [fX (log (y))]
dy

"

fY (y) =

1
√

σx 2π

− 21 (log(y)−µx )2 /σx2

(D.12)

(D.13)

#" #

2
1
1
1
2
√ e− 2 (log(y)−µx ) /σx , 0 < y. (D.14)
=
y
σx y 2π

e

Let’s assign values to the parameters and look at some plots. The pdf in bottom right of Figure D.1 is a N (µ = log (5) , σ = log (2.5)). The area A under the
curve at FX (log (7) = 1.94591) is shaded. The pdf in the top left of Figure D.1 is a
LN (µ = log (5) , σ = log (2.5)). The area B under the curve at FY (exp (1.94591) = 7)
is shaded. The significance of (D.9) is that area A and area B are equal.
The method that we just used to find the distribution of a lognormal random
variable is referred to as the Distribution Function Method (Wackerly, Mendenhall,
and Scheaffer, 2014). Another way of doing this is to say that fY (y) is the height
of the density curve and dy is a tiny width – so tiny that fY (y) is constant over dy.
Under these conditions fY (y) dy can be loosely thought of as probability. This sets
up the following equality between two probabilities:
h



i h

[fY (y)] [dy] = fX g −1 (y)

i

dg −1 (y) .

(D.15)

Bringing the differential dy over to the rhs gives us the relationship we ended up with
previously in (D.12):
h



fY (y) = fX g

−1

i

(y)

"

#


 d
d −1
g (y) = fX g −1 (y)
g −1 (y) .
dy
dy

(D.16)

Although it is not relevant for this transform, in general the absolute value of the
derivative is used because the pdf must be non-negative. At this point the transform
is completed as shown above. This is referred to as the Method of Transformations
(Wackerly, Mendenhall, and Scheaffer, 2014).
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D.2

Expectation and Variance of a Lognormal RV

Start with the definition of expectation
ˆ∞

!

1 log(y)−µx 2
y
√
e− 2 ( σx ) dy.
σx y 2π

E (Y ) =
0

(D.17)

Make the following substitutions:
z=

log (y) − µx
,
σx

(D.18)

y = eσx z+µx ,

(D.19)

dy = σx eσx z+µx dz,

(D.20)

ˆ∞
µx

E (Y ) = e

−∞

!

1 2
1
√
e− 2 z +σx z dz.
2π

(D.21)

The lower limit on the integral with respect to y is 0, so the lower limit with respect
to z is −∞. Finally, complete the square in the exponent
ˆ∞
E (Y ) = e

µx
−∞

!

2 1 2
1
1
√
e− 2 (z−σx ) + 2 σx dz,
2π

(D.22)

and evaluate the integral, whose integrand is a normal pdf, to give the desired result
E (Y ) = e

ˆ∞

µx + 12 σx2

−∞

!

2
1
1 2
1
√
e− 2 (z−σx ) dz = eµx + 2 σx .
2π

(D.23)

Do the same trick for the second moment. Take Equation (21) and put y = eσx z+µx
in the integrand:
ˆ∞


E Y

2



µx

=e

−∞

!

1 2
1
√
eσx z+µx e− 2 z +σx z dz,
2π

ˆ∞


E Y

2



=e

2µx
−∞

(D.24)

!

1 2
1
√
e− 2 z +2σx z dz.
2π
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(D.25)

Complete the square in the exponent
−


1 2
1
z − 4σx z + 4σx − 4σx = − (z − 2σx )2 + 2σx ,
2
2

(D.26)

which, with a bit of coaxing, leads us to the second moment:
ˆ∞




2µx +2σx2

E Y2 =e

−∞

!

2
1
1
2
√
e− 2 (z−2σx ) dz = e2µx +2σx .
2π

(D.27)

Recall that the variance of Y is given by




var (Y ) = E Y 2 − E (Y )2 ,

(D.28)

so
1



2

var (Y ) = e2µx +2σx − eµ+ 2 σ

2

2

2

,

2

var (Y ) = e2µx +2σx − e2µx +σx ,

(D.29)

(D.30)

and finally


var (Y ) = e2µx +σx

D.3



2



eσx + 1 .

(D.31)

Say it Again Simply

If Z is a standard normal random variable then X is a normally distributed random
variable
X = µx + σx Z,

(D.32)

where µx is the mean of X (the mean log parameter) and σx the standard deviation
of X (the standard deviation log parameter). If Y is given by
Y = eX = eµx +σx Z ,

(D.33)

then Y is a lognormally distributed random variable. The geometric mean (the
median) of Y occurs when Z = 0, which is
µg = eµx .
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(D.34)

The standard deviation of X = µx + σx (1) − µx = σx , so the geometric standard
deviation of Y is
σg = eµx +σx (1)−µx = eσx .

(D.35)

√ 2
σ g = e σx

(D.36)

Note that

where σx2 is the variance of X. The arithmetic mean of Y is
1

2

µy = eµx + 2 σx

(D.37)

and the arithmetic standard deviation


σy = e2µx +σx



2



eσx + 1 .

(D.38)

Note that the geometric parameters are always smaller than the arithmetic parameters
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Figure D.1 DESY plot. Starting in the lower right hand corner and going counterclockwise: pdf of the normally distributed random variable X, the transform function
g(x), and the pdf of the lognormally distributed random variable Y.
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Appendix E
LKJ Distribution
The approach recommended by Barnard, McCulloch, and Meng (2000) and Stan
Development Team (2021b, pg 34) for defining a prior on a covariance matrix Π is
to decompose it into a correlation matrix Ω and a diagonal matrix of the standard
deviations σ
Π = σ · Ω · σ.

(E.1)

This decomposition allows the modeler to think in terms of the standard deviation of
the parameters and a correlation matrix, which is usually easier than thinking about
a covariance matrix. The Lewandowski–Kurowicka–Joe (LKJ) distribution is used
to model the distribution of Ω. The LKJ distribution has one argument η, and it
places a shifted beta distribution with a support of −1 to 1 on each of the off-diagonal
elements of the correlation matrix.
To illustrate, let’s generate m = 104 n × n random correlation matrices using the
LKJ distribution as implemented in the rethinking R package with η = 1 and n = 3.
These random correlation matrices are stored in the 3-dimenional array Omega.
Omega <- rlkjcorr(1e4,K=3,eta=1)

dim(Omega)
## [1] 10000

3

3

The first index of Omega gives the ith 3 × 3 correlation matrix where i = 1, 2, . . . , m.
For example, setting the first index to 1 gives the first of 104 random correlation
matrices,
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Omega[1,,]
##

[,1]

[,2]

[,3]

## [1,]

1.000000000 0.3022829 -0.007865985

## [2,]

0.302282874 1.0000000

0.801085116

## [3,] -0.007865985 0.8010851

1.000000000

and setting it equal to 2 gives the second of 104 .
Omega[2,,]
##

[,1]

## [1,]

[,2]

[,3]

1.0000000 -0.4419927 -0.5949270

## [2,] -0.4419927

1.0000000 -0.2047289

## [3,] -0.5949270 -0.2047289

1.0000000

The second index gives the jth row of the ith correlation matrix where j = 1, 2, . . . , n.
For example, the first row of the first correlation matrix is
Omega[1,1,]
## [1]

1.000000000

0.302282874 -0.007865985

Finally, the third index gives the element in the kth column of the ith correlation
matrix where k = 1, 2, . . . , n. For example the second element in the first row of the
first correlation matrix is
Omega[1,1,2]
## [1] 0.3022829

This allows us to look at the density plots of the three off-diagonal elements of the
104 correlation matrices with η = 1.
plot(density(Omega[,1,2]),
main="Eta = 1",xlab="Correlation Coefficient",
xlim=c(-1,1)
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)
lines(density(Omega[,1,3]),col="red")
lines(density(Omega[,2,3]),col="blue")
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Setting η = 0.5 gives distributions that look more or less uniform.
Omega <- rlkjcorr(1e4,K=3,eta=0.5)

plot(density(Omega[,1,2]),
main="Eta = 0.5",xlab="Correlation Coefficient",
xlim=c(-1,1)
)
lines(density(Omega[,1,3]),col="red")
lines(density(Omega[,2,3]),col="blue")
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0.3
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Setting η = 4 concentrates the density more to the middle of the distributions, giving
something that looks Gaussian.
Omega <- rlkjcorr(1e4,K=3,eta=4)

plot(density(Omega[,1,2]),
main="Eta = 4",xlab="Correlation Coefficient",
xlim=c(-1,1)
)
lines(density(Omega[,1,3]),col="red")
lines(density(Omega[,2,3]),col="blue")
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Setting η = 10 results in a tighter distribution ...
Omega <- rlkjcorr(1e4,K=3,eta=10)

plot(density(Omega[,1,2]),
main="Eta = 10",xlab="Correlation Coefficient",
xlim=c(-1,1)
)
lines(density(Omega[,1,3]),col="red")
lines(density(Omega[,2,3]),col="blue")
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... and setting η = 100 gives essentially no correlation.
Omega <- rlkjcorr(1e4,K=3,eta=100)

plot(density(Omega[,1,2]),
main="Eta = 100",xlab="Correlation Coefficient",
xlim=c(-1,1)
)
lines(density(Omega[,1,3]),col="red")
lines(density(Omega[,2,3]),col="blue")
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If all the elements of σ are equal, σ is a scalar and equation (E.1) can be simplified
as

Π = σ 2 ·Ω .
The standard deviation is referred to as τ = σ elsewhere in this dissertation.
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(E.2)

Appendix F
ICRP 134 Zirconium Model
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Table F.1 Names of the compartments in the ICRP 134 zirconium model (Paquet,
Leggett, et al., 2016, page 274). Note that ST0 and ST1 are soft tissue compartments,
SI is the small intestines, and trabecular and cortical refer to parts of skeletal bone.
Index

From

Symbol

Comp

To

Symbol

Comp

1

Blood 1

bld1

1

Blood 2

bld2

2

2

Blood 1

bld1

1

Liver 0

liv0

3

3

Blood 1

bld1

1

Kidneys

kid

5

4

Blood 1

bld1

1

ST0

ST0

6

5

Blood 1

bld1

1

ST1

ST1

7

6

Blood 1

bld1

1

Urinary bladder cont

ubc

12

7

Blood 1

bld1

1

SI contents

SI

13

8

Blood 1

bld1

1

Trabecular surface

ts

8

9

Blood 1

bld1

1

Cortical surface

cs

10

10

Blood 2

bld2

2

Blood 1

bld1

1

11

Liver 0

liv0

3

SI contents

SI

13

12

Liver 0

liv0

3

Blood 1

bld1

1

13

Liver 0

liv0

3

Liver 1

liv1

4

14

Liver 1

liv1

4

Blood 1

bld1

1

15

Kidneys

kid

5

Blood 1

bld1

1

16

ST0

ST0

6

Blood 1

bld1

1

17

ST1

ST1

7

Blood 1

bld1

1

18

Trabecular surface

ts

8

Blood 1

bld1

1

19

Trabecular surface

ts

8

Trabecular volume

tv

9

20

Trabecular volume

tv

9

Blood 1

bld1

1

21

Cortical surface

cs

10

Blood 1

bld1

1

22

Cortical surface

cs

10

Cortical volume

cv

11

23

Cortical volume

cv

11

Blood 1

bld1

1

24

Urinary bladder cont

ubc

12

Urine

urn

15

25

SI contents

SI

13

Colon contents

col

14

26

Colon contents

col

14

Feces

fec

16

27

SI contents

SI

13

Blood 1

bld1

1
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Appendix G
Likelihood and Bayes Rule
To clarify the notation used in Bayes Rule, let’s look at an example where the probability of observing k successes in n trials for a binomial data generating process
having a probability θ of success:






n 

P (K = k|θ) = 


k

 θ k (1 − θ)n−k ,


k = {0, 1, 2, . . . , n} , 0 ≤ θ ≤ 1.

(G.1)

Note that the data K are random and the probability of success θ is constant. This
is a proper probability mass function since
i=n
X

P (i|θ) = 1.

(G.2)

i=0

If we want to calculate the probability that a random probability of success Θ equals
θ for a given value of k we need to use Bayes Rule
P (Θ = θ|k) =
where

P (k|θ) P (θ)
,
P (k)

(G.3)

ˆ
P (k) =

P (k|θ) P (θ) dθ

(G.4)

θ

Note that in Equation (G.3) we have






n 

P (k|θ) = 


k

 θ k (1 − θ)n−k ,


(G.5)

the rhs of which looks just like the rhs of Equation (G.1). However, in Equation (G.5)
the data k are fixed and the probability of success θ is random. Equation (G.5) is
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not a proper probability density function since
ˆθ=1
P (k|θ) dθ ̸= 1.

(G.6)

θ=0

To make the difference between Equation (G.1) and Equation (G.5) clear, Equation
(G.5) is referred to as the likelihood of θ given the data k






n 

L (θ|k) = L (θ) = P (k|θ) = 


k

 θ k (1 − θ)n−k .


(G.7)

So, sometimes we see Bayes Rule expressed like

P (Θ = θ|k) =

L (θ) P (θ)
,
P (k)

(G.8)

which is a bit confusing in my opinion.
When we are working with continuous data X rather than discrete data, the
probability of observing X = x is 0. If the data are measured with good precision
the appropriate probability density function is used as the likelihood (Pawitan, 2001,
page 23). For example, if the data come from a normal data generating process
and have good precision, the normal pdf is used as the likelihood in Equation (3).
Examples of data that do not have good precision are censored data and binned data.
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Appendix H
Fits to Samples from the Posterior
Distribution of Theta
In the population-level Bayesian calibration in Chapter 3, 110000 posterior samples
are generated from the rate matrix hyper prior θ. A familiar distribution must be fit
to these samples to make canned priors that are used for an out-of-sample evaluation
in Chapter 4. Here, four different distributions are fit to the posterior samples: multivariate normal (MVN), multivariate skewed t with 4 degrees of freedom (MVT4),
multivariate skewed t with 20 degrees of freedom (MVT20), and a multivariate Gaussian mixture (MGM). AIC and BIC are used to compare the models. To begin, let’s
read in the posterior samples.
theta <- read.csv("data/theta.csv")
dim(theta)
## [1] 110000

27

n <- nrow(theta)

Fit the samples with a multivariate normal distribution. The number of parameters
estimated is 27 for the means plus (272 − 27)/2 for the covariance matrix.
library(mclust)

fit.mvn <- mvn("Ellipsoidal", data = theta)
Mu <- as.numeric(fit.mvn$parameters$mean)
Sigma <- fit.mvn$parameters$variance$Sigma
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loglik.mvn <- fit.mvn$loglik
k.mvn <- 27 + (27^2 - 27)/2
AIC.mvn <- 2*k.mvn - 2*loglik.mvn
BIC.mvn <- k.mvn*log(n) - 2*loglik.mvn

loglik.mvn
## [1] -1044802
k.mvn
## [1] 378
AIC.mvn
## [1] 2090361
BIC.mvn
## [1] 2093992

Now try a multivariate skew t with df = 4. This is a shifted and scaled t distribution
that can be non-symmetric. Alpha is the skew parameter, which can be in the range
of −1 to 1. Here Alpha is essentially 0, which means the t distributions are symmetric,
i.e., they are standard t distributions.
library(fMultivar)
library(sn)

fit.mvt <- mstFit(theta, fixed.nu=4)
Beta <- fit.mvt@fit$dp$beta
Omega <- fit.mvt@fit$dp$Omega
Alpha <- fit.mvt@fit$dp$alpha
Alpha
##

theta.1

theta.2

## -1.932956e-06

3.550768e-05

##

theta.5

3.172413e-07 -6.052230e-07

1.721517e-05
theta.10

## -7.904359e-07 -2.205950e-06 -3.415253e-05 -1.144856e-05

4.809289e-08

theta.11

theta.7

theta.4

theta.9

##

theta.6

theta.3

theta.12

theta.8

theta.13

161

theta.14

theta.15

##

2.573121e-06 -6.984653e-07 -2.047055e-06

##

theta.16

## -2.253202e-06
##

theta.21

## -1.908804e-06

3.795500e-06

3.505281e-06

theta.18

theta.19

theta.20

7.319625e-07 -1.287202e-04

1.509607e-06

2.789305e-07

theta.24

theta.25

theta.17

theta.22

theta.23

1.944516e-06 -2.546741e-07

##

theta.26

theta.27

##

2.454062e-06

2.093020e-07

4.334784e-06 -1.359099e-06

tmp <- apply(theta,1,dmst,xi=Beta,Omega=Omega,alpha=Alpha, nu=4,log=TRUE)
loglik.mvt4 <- sum(tmp)
k.mvt4 <- 27 + (27^2 - 27)/2 + 27
AIC.mvt4 <- 2*k.mvt4 - 2*loglik.mvt4
BIC.mvt4 <- k.mvt4*log(n) - 2*loglik.mvt4

loglik.mvt4
## [1] -1113547
k.mvt4
## [1] 405
AIC.mvt4
## [1] 2227903
BIC.mvt4
## [1] 2231795

Now let’s look at a multivariate skew t with df = 20.
fit.mvt <- mstFit(theta, fixed.nu=20)
Beta <- fit.mvt@fit$dp$beta
Omega <- fit.mvt@fit$dp$Omega
Alpha <- fit.mvt@fit$dp$alpha
Alpha
##

theta.1

theta.2

## -4.175385e-06

7.269093e-05

theta.3

theta.4

theta.5

1.021783e-06 -1.274062e-06

3.526286e-05
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##

theta.6

theta.9

theta.10

## -1.695614e-06 -4.252899e-06 -7.042894e-05 -2.302558e-05

1.306991e-07

##
##

theta.11

theta.7

theta.13

theta.14

theta.15

4.491104e-06 -1.750862e-06 -3.220527e-06

7.588377e-06

6.883004e-06

theta.18

theta.19

theta.20

9.130683e-07 -2.623345e-04

3.448467e-06

3.995365e-07

theta.24

theta.25

##

theta.16

## -3.946342e-06
##

theta.21

## -3.631377e-06

theta.12

theta.8

theta.17

theta.22

theta.23

3.807114e-06 -5.545758e-07

##

theta.26

theta.27

##

5.006424e-06

4.630544e-07

9.237500e-06 -2.663658e-06

tmp <- apply(theta,1,dmst,xi=Beta,Omega=Omega,alpha=Alpha, nu=20,log=TRUE)
loglik.mvt20 <- sum(tmp)
k.mvt20 <- 27 + (27^2 - 27)/2 + 27
AIC.mvt20 <- 2*k.mvt20 - 2*loglik.mvt20
BIC.mvt20 <- k.mvt20*log(n) - 2*loglik.mvt20

loglik.mvt20
## [1] -1062657
k.mvt20
## [1] 405
AIC.mvt20
## [1] 2126123
BIC.mvt20
## [1] 2130015

Finally, let’s try fitting a 2 component multivariate Gaussian mixture model. The
number of parameters estimated is 2 times the number of parameters for the multivariate normal plus 2 for the mixing fractions. Note that this takes a couple of hours
to run with 110000 samples.
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library(mixtools)

fit.mgm <- mvnormalmixEM(theta, lambda = c(0.5,0.5))

loglik.mgm <- fit.mgm$loglik
k.mgm <- 2*(27 + (27^2 - 27)/2) + 2
AIC.mgm <- 2*k.mgm - 2*loglik.mgm
BIC.mgm <- k.mgm*log(n) - 2*loglik.mgm

loglik.mgm
## [1] -1025952
k.mgm
## [1] 758
AIC.mgm
## [1] 2053419
BIC.mgm
## [1] 2060702

Here are the mixing fractions ...
fit.mgm$lambda
## [1] 0.381987 0.618013

... and the means.
fit.mgm$mu
## [[1]]
##

[1]

1.1587667

-2.3449260

-4.4660132

0.9553475

-3.2217875

-2.6374344

##

[7]

-3.8139564

-1.4153139

-1.4761301

-0.1329207

-2.2608834

-2.1553302

## [13]

-0.6771897

-4.6067532

-4.6176883

-0.5562580

-3.9300067

-7.4190567

## [19]

-8.3163004

-7.6139695

-9.4441286 -10.0954131

-9.4090838

0.7609981

## [25]

0.4118240

0.4188153

-5.8091308

##
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## [[2]]
##

[1]

1.2011352

-2.8199514

-4.5079234

0.9367942

-3.4748857

-2.5542416

##

[7]

-3.8044409

-0.9671406

-1.4834241

-0.2122716

-2.1665035

-2.0904156

## [13]

-0.8256816

-4.6447395

-4.6362342

-0.6643702

-3.8780702

-6.7139352

## [19]

-8.3655028

-7.6149308

-9.4615370 -10.0960571

-9.4056106

0.6691862

## [25]

0.4023371

0.4071487

-5.8065572

The models, in order of both AIC and BIC (lowest to highest – best to worst) are
M GM < M V N < M V T 20 < M V T 4.
Table H.1 Comparison of fits to the samples from the posterior distribution of θ.
Model
MGM
MVN
MVT20
MVT4

loglik
−1.0259516 × 106
−1.0448023 × 106
−1.0626567 × 106
−1.1135466 × 106

k
758
378
405
405

AIC
2.0534192 × 106
2.0903605 × 106
2.1261235 × 106
2.2279032 × 106
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BIC
2.0607023 × 106
2.0939924 × 106
2.1300148 × 106
2.2317946 × 106

Appendix I
Chapter 4 Addendum
Additional plots of interest from Chapter 4 are presented in this appendix.

I.1

Canned Priors

The multivariate normal distribution fit to the log of the posterior distribution of the
rate matrix θ gives the canned prior θ c . The gm and gsd of the marginal distributions
of the rate constants in θc are given in Table I.1 along with the ICRP 134 rate
constants for comparison. Comparing the medians of the posterior distribution of θ
in Table 3.1 with the geometric means of the MVN canned prior θ c in Table I.1 we can
see that the MVN canned prior θ c captures the essence of the posterior distribution
of θ very well. The marginal distributions of the canned prior θ c are shown in Figure
I.1. The distributions of most of the individual rate constants in θ c strongly resemble
their priors (those whose peak density is ∼ 1 in the plot), which means that those
parameters are more or less non-identifiable given the bioassay data available in the
study. However, the distributions of the 7 rate constants associated with the blood
plasma and urine (distributions in red in the plots in Figure I.1 are clearly influenced
by the data. The reduction in the gsd of rate constants influenced by the data can
be seen in Figure I.3. The correlation plot of θ c in Figure I.2 shows that there are
strong correlations between some rate constants in the zirconium biokinetic model
that are accounted for in the canned prior. Such correlations are important when
making modifications to the zirconium biokinetic model to better fit the data from
an individual.
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Figure I.1 Plot of the marginal distributions of the canned prior for the rate constants θc .
I.2

Evaluation of Out-of-Study Subjects

Stan MCMC diagnostic plots for the canned Bayesian analysis of bioassay from the
subjects are shown in Figure I.4. An R̂ < 1.01 for all parameters indicates that the
MCMC chains converged while the large number of effective samples ESS allow for
precise parameter estimates as indicated by the relative Monte Carlo standard errors
being less than 10%. No divergences were reported by Stan and there are no overt
signs of non-convergence.
The plot of the geometric standard deviations for each rate constant in the rate
matrix k are given in Figure I.7 for Zr0101102 and Figure I.10 for subject Zr0102004.
The correlation plots for k are given in Figure I.6 and Figure I.8 show that the
correlations in the rate matrices k for the two subjects are dissimilar as are the
medians of the rate constants whose posterior is influenced by the data (Table 3.1,
Figures I.7 and I.10). This indicates that the ICRP 134 zirconium biokinetic model
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Figure I.2 Correlation plot for canned prior of θc .
was customized in the Bayesian analysis in order to accommodate peculiarities in
each subject’s the bioassay data (which are discussed below). Of particular interest is
subject Zr0101102’s rate constant k[ubc,urn] for the urinary bladder to urine pathway.
All the posterior distributions of her rate constants (and those of Zr0102004 in Figure
I.9) were more or less lognormally distributed except for this one, which can be seen in
Figure I.5. The k[ubc,urn] rate constant for Zr0101102 is highly left skewed, almost
looking bimodal, which results in a relatively large empirical geometric standard
deviation as shown in Figure I.7. This behavior is attributed to the urine bioassay
data for Zr0101102 having outliers, which results in significant changes to this rate
constant in the Bayesian analysis.
Scatter plots of M versus m on log-log scales in Figures I.11 more clearly show
the influence of the urine data on the fits. Posterior predictive distribution plots
give an idea of how future bioassay datasets might compare to the bioassay actually
observed and hence how well our biokinetic model agrees with the observed data.
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Figure I.3 Plot of θc geometric standard deviations for canned prior distributions
of rate constants. Rate constants associated with each parameter index are given in
Table I.1.
In the plots in Figure I.12 the x-axis value for each of the points is a reference
bioassay function m calculated from a draw of biokinetic model parameters from
their posterior distributions. These reference bioassay functions and draws from the
posterior distribution of the intake are inserted in the data sampling distribution
(the likelihood) to generate predicted bioassay result M̂ that is the y-axis value. The
line through the origin in each plot is formed by plotting the means of the values
of each m versus the means of corresponding values of M̂ , and the slope of this
line is the estimated quantity β̂ of zirconium injected into the subject. The error
bars are the 95% credible interval of the model predictions. The amount of scatter
in the plots is impressive, and gives us an idea of the true level of uncertainty in
the biokinetic models. The greater degree of scatter observed with the canned prior
analysis compared to the add-one-in analysis is attributed to the greater number of
MCMC iterations in the canned prior analysis.
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Figure I.4 Bulk ESS versus R̂ for the posterior distributions of all parameters for
Zr0101102 (top left) and Zr0102004 (top right). Relative Monte Carlo standard error
of the mean versus the absolute value of the mean for Zr0101102 (bottom left) and
Zr0102004 (bottom right). The standard error plots do not include the correlation
matrix Π and covariance matrix Ω
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Table I.1 Transfer rate constants in units of day −1 for the ICRP 134 zirconium
compartmental model (Paquet, Leggett, et al., 2016), the MVN canned priors, and
the posterior distributions for the out-of-study subjects. The geometric standard
deviation for each calculated rate constant is given.
ICRP 134

Canned

Canned

Zr0101102

Zr0101102

Zr0102004

Zr0102004

From

To

rate const

gm

gsd

gm

gsd

gm

gsd

bld1

bld2

2

3.276

1.04758

6.343

1.41264

1.163

1.38985

bld1

liv0

0.075

0.07181

1.26506

0.07203

2.4639

0.07411

2.41873

bld1

kid

0.0125

0.01123

1.16798

0.01116

2.31675

0.01133

2.25106

bld1

ST0

2

2.571

1.03511

4.982

1.53694

6.497

1.14656

bld1

ST1

0.0375

0.03388

1.22335

0.03468

2.40423

0.03438

2.33268

bld1

ubc

0.1

0.07532

1.05236

0.03132

1.65294

0.1461

1.37253

bld1

SI

0.025

0.02221

1.16146

0.02238

2.29202

0.02245

2.25601

bld1

ts

0.375

0.3217

1.1638

0.4069

2.60368

0.3707

2.26753

bld1

cs

0.375

0.2263

1.11338

0.2621

2.38575

0.2529

2.22777

bld2

bld1

0.462

0.8345

1.05357

0.6688

1.74955

0.4174

1.77419

liv0

SI

0.116

0.1107

1.17522

0.1112

2.29696

0.1108

2.23692

liv0

bld1

0.116

0.121

1.18291

0.1201

2.31078

0.1208

2.24973

liv0

liv1

0.462

0.4626

1.18772

0.4586

2.33802

0.4648

2.2652

liv1

bld1

0.01

0.009729

1.17553

0.009782

2.30123

0.009722

2.28468

kid

bld1

0.01

0.009726

1.18391

0.009842

2.29646

0.009755

2.26171

ST0

bld1

0.462

0.5356

1.07516

0.2879

2.01261

0.7429

1.57119

ST1

bld1

0.02

0.02034

1.19453

0.0204

2.32891

0.02003

2.27056

ts

bld1

0.000493

0.0009293

1.27893

0.0009473

2.4306

0.0009385

2.37207

ts

tv

0.000247

0.0002375

1.17311

0.0002349

2.30528

0.0002359

2.25652

tv

bld1

0.000493

0.0004923

1.18091

0.0004933

2.30262

0.0004947

2.25616

cs

bld1

8.21E-05

7.753e-05

1.16484

7.868e-05

2.28167

7.81e-05

2.24287

cs

cv

4.11E-05

4.127e-05

1.17966

4.168e-05

2.32836

4.158e-05

2.26758

cv

bld1

8.21E-05

8.154e-05

1.17827

8.112e-05

2.31484

8.28e-05

2.28499

ubc

urn

12

2.027

1.07966

4.555

3.06541

1.978

1.61825

SI

col

1.5

1.502

1.17878

1.502

2.33164

1.515

2.26836

col

fec

1.5

1.515

1.18028

1.501

2.31636

1.513

2.25847

SI

bld1

0.0030

0.002999

1.18063

0.00296

2.30146

0.003013

2.25914
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Figure I.5 Marginal posterior distributions for individual-specific rate matrix k for
subject Zr0101102. Density curves for rate constants with distributions having a
log standard deviation less than the one prescribed in the prior are in red and are
identified by name.

Figure I.6 Correlation plot for posterior of rate matrix k for subject Zr0101102.
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Figure I.7 Plot of geometric standard deviations for posterior distributions of rate
constants k for subject Zr0101102.

Figure I.8 Correlation plot for posterior of rate matrix k for subject Zr0102004.
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Figure I.9 Marginal posterior distributions for individual-specific rate matrix k for
subject Zr0102004. Density curves for rate constants with distributions having a
log standard deviation less than the one prescribed in the prior are in red and are
identified by name.

Figure I.10 Plot of geometric standard deviations for posterior distributions of rate
constants k for subject Zr0102004.
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Figure I.11 Fits on a log-log scale to more clearly show the urine bioassay results:
standard method top row, add-one-in Bayesian analysis middle row, and canned prior
Bayesian analysis bottom row. The grey lines denote the 95% intervals for the intake.
The error bars denote the 95% coverage interval on the measurements.

175

Figure I.12 Posterior predictive distributions from add-one-in analysis for Subject
Zr0101102 (left top) and Zr0102004 (right top) and from MVN canned prior analysis
for Subject Zr0101102 (left bottom) and Zr0102004 (right bottom). The error bars
denote the 95% credible intervals on the posterior predictive distribution.
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Appendix J
Urinary Bladder Model
The urinary bladder was assigned an explicit tissue tissue weighted factor in ICRP
1990 (Thorne, 1992), which prompted the ICRP to define a biokinetic model for the
urinary bladder of an adult worker in ICRP Publication 67 (ICRP, 1993, pg 3). In
this model the bladder has a fixed volume of 115 mL, which represents the average
volume between voids. The number of voids per day is taken to be 6 for a worker,
with 2 × 115 mL = 230 mL per void. This gives 6 × 230 mL = 1380 mL excreted per
day, which matches the 1400 mL for Reference Man in ICRP Publication 23 (ICRP,
1975). The first order rate constant for the bladder to urine pathway is therefore
defined as
kubc,urn =

1380 mL/d
= 12 d−1
115 mL

as given in ICRP Publication 67, ICRP Publication 68 (ICRP, 1995, pg 13), and
ICRP Publication 130 (ICRP, 2015, pg 85). In Chapter 3, a LN (log (12) , log (1.5))
prior was used for kubc,urn whereas Schmidl et al. (2012) used a T (6, 8, 24) and Li,
Greiter, et al. (2011a) a T (6, 12, 24). A lognormal was used in the dissertation to
facilitate making a multivariate normal canned prior and because the authors of Stan
advise us to avoid prior distributions like the triangular that have “kinks”.
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